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Abstract
Gene therapy has the potential to cure thousands of diseases caused by genetic
abnormalities, provide novel combination therapies for cancers and viral infections, and
offer a new and effective platform for next generation vaccines. However, after more than
three decades of research and development efforts, clinical success has yet to be realized.
Successful delivery of DNA is a crucial first step in attaining safe and effective gene
therapeutics. While vectors based upon recombinant viruses have shown high delivery and
transfection efficiencies, they may also pose certain health risks to patients, can be difficult
to target to cell or tissue types of interest, and present difficulties for large-scale
manufacturing. Non-viral vectors look to offer a safer alternative and can be engineered to
more effectively treat a specific cell type, tissue, or pathology, but these vectors are still
plagued with low transfection levels and cannot provide adequate and sustained levels of
gene expression. Continued efforts focus on producing next generation non-viral vectors
that safely deliver therapeutic transgenes with the efficiency of their viral counterparts.
Many barriers exist in the successful trafficking of these non-viral complexes to the
nucleus. Current evaluations of non-viral gene delivery treatments in more clinical settings
often focus on a single barrier at a time, and as a result, may not lead to an overall
improvement in gene delivery. Concurrently, more quantitative or systematic in vitro
experiments may not correlate well with in vivo data. Our combined approach of quantitative
vector trafficking and expression experiments coupled with computational simulation of
vector specific mathematical models that describe every step of the gene delivery process has
shown that a systems level approach can glean insight into the most rate-limiting steps for a
given vector and generate hypotheses for future vector development and improvement.
These studies have been extended to primary liver cultures, coupled with device
development to attain a more clinically relevant model system and more spatial resolution to
study intracellular vector trafficking and localization. A larger perfused 3-D liver bioreactor
has been built that allows for long-term culture of primary hepatocytes that more closely
mimic hepatic phenotype than in conventional 2-D cultures and for multiplexed quantitative
measurement that is not possible in animal models. A newly constructed density gradient
electrophoresis device can separate vesicular organelles and track vector dynamics
throughout the cell. These systems have provided more comprehensive data sets which
show that vectors behave differently in different culture systems and that different vectors
show unique cell trafficking dynamics. These results lend insight for future vector screening
methodologies and provide vector specific mathematical models for primary cell transfection
that can lead to further optimization of the polymer vectors studied in this work, which can
contribute to the development of more efficient next generation in divo delivery agents.
Advisors: Linda Griffith and Douglas Lauffenburger
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Chapter 1
Introduction and Background
1.1 Gene Therapy
Gene therapy can be broadly defined as a therapeutic approach that seeks to treat or
prevent diseases by adding, correcting, or replacing genes [1]. Through the delivery of DNA
or RNA to desired cell types, this strategy has the potential to treat a number of disorders by
leading to the expression of wild-type or recombinant proteins that have a curative effect [2] or
by modulating RNA expression levels to remedy aberrant gene expression [3, 4].
Some of the most obvious benefactors of this form of treatment are single gene
inherited disorders such as sickle cell anemia, hemophilia, acquired immune disorders, familial
hypercholesterolemia, muscular dystrophy and cystic fibrosis [5-12], where transfection and
expression of an appropriate transgene without the deleterious mutation could effectively cure
the disease. Gene therapy may also be used to develop recombinant therapies for diseases that
involve many genes. For instance, unwanted gene expression profiles may be altered in cancer
cells, cancer cells can be targeted and altered to illicit an anti-tumor immune response, or
cytokines may be expressed that make it easier for targeted cells to be treated with a pro-drug
[13-16]. Recombinant multi-gene therapies could also be adapted for heart disease and
diabetes along the same lines where intervention may be required at multiple checkpoints to
achieve the desired remediation of cell or tissue phenotype [9, 17, 18]. Chronic infectious
diseases, including HIV, herpes and hepatitis, also stand to benefit from gene therapy [19-23].
Delivery of DNA vaccines could prevent the onset of infection altogether [24, 25], while the
expression of small RNA fragments and recombinant proteins could shut down viral gene
expression or enzyme function to slow disease progression in already infected patients and
allow parallel treatment strategies to work more effectively [21, 26-29]. DNA vaccines also
offer the potential to attain safer and more stable methods of storing, distributing and
expressing antigens that could allow for robust and affordable prophylactics for third world
countries and more efficient distribution during impending large scale epidemics that would
not be possible with traditional attenuated viruses and protein based vaccines [30].
After the inception of gene therapy in the early 1970's, research in the field greatly
accelerated in the 1980's with the discovery of restriction endonucleases and the arrival of PCR
amplification methods [2, 31]. With progress in the following decade and eventual completion
of the human genome project at the turn of the century, more and more information has
become available for gene therapy approaches to exploit. Additionally, greater understanding
of small RNA based regulation of gene expression in recent years continues to offer increased
flexibility and application for gene therapy platforms. However, after more than thirty years of
research and nearly two decades of clinical trials, long-term clinical success has yet to be
attained [32-34]. To date, no clinical trials have received full approval, with only a handful of
restricted approvals issued for orphan drugs in the U.S. and Europe [35-38], and the few
Indications Addressed by Gene Therapy Clinical Trials
Cancer diseases 67% (n=797)
* Vascular diseases 8.9% (n=106)
* Monogeneic diseases 8.6% (n=102)
* Infectious diseases 6.5% (n=78)
* Other diseases 3.4% (n=40)
Gene marking 4.2% (n=50)
.sik k1--- h.L- ...... l-·- |.P .... i / , __ln\
H ealt y voiunteers 1.6%s (n=19)
Gene T~ypes Transferred in Gene Therapy Clinical Trials \}:`
Cytokine 26% {n=312)
* Antigen 16% (n=189)
* Tumor supressor 12% (n=139)
* Suicide 79% (n=94)
* Deficiency 6.0%, (n=72)
* Drug resistance 4.7% (n=56)
Replication inhibitor 3.8% (n=45)
O Receptor 3.7% (n=44)
* Others 17% (n=203)
* Unknown 3.2% (n=38)
The Journa Af Gene Medicn. r, 2006 John Wle ad Sons LtJ www.0w :ley.c: .dL.qdred/c ial
Figurel.1: Overall breakdown of disease indications and gene types used in all documented gene
therapy clinical trials to date, worldwide [34].
recent early successes have resulted in tragic consequences such as development of leukemia
[39-41]. Very few gene therapy trials have been able to progress into Phase III studies, and
due to many of these setbacks and adverse complications, the number of approved trials has
decreased significantly in recent years from the peak at the turn of the century.
Phases of Gene Therapy Clinical Trials 1 4-.
Phase i 62% (n=743)
* Phase I/11 20% (n=242)
* Phase 1 14% (n=169)
* Phase l/111t 1% (n=12)
* Phase III 2.2% {n=26)
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Figure 1.2: Distribution of worldwide gene therapy clinical trials by current or ending phase and byyear [34].
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1.2 Gene Therapy Strategies: Delivery Methods and Vectors
For gene therapy to be successful, a transgene or multiple transgenes must be safely
delivered to the nucleus and lead to therapeutic gene expression without any dangerous side
effects. Cells can either be transfected in vivo by administering various gene formulations to
the patient, or cells can be removed from the patient, transfected ex vivo to attain the desired
phenotypic change, and then reinserted to have their desired effect [1, 2, 42]. Either of
these strategies can be theoretically accomplished by using viral or non-viral transfection
methods.
1.2.1 Viral Vectors
Viral gene therapy utilizes modified viruses to serve as efficient vehicles for DNA
delivery [33, 43]. Specific regions of the viral genome are removed to theoretically render
the viral vectors incapable of replicating and becoming infectious, while the desired
transgenes are inserted in their place. In general, viral vectors are highly efficient in
delivering their gene payload, and normally lead to long term or even permanent gene
expression. However, viral vectors still pose potential disadvantages to patients [44].
Common viral vectors include adenovirus, which has high transfection efficiency both in
vivo and ex vivo on cells in any stage of the cell cycle, but may invoke strong immune
responses or undergo recombination and once again become infectious [43, 45]. Retrovirus
is an effective viral vector that achieves long-term gene expression in ex vivo transfections
with a relative low immune response; however, this virus is highly inefficient in vivo and is
unable to transfect non-dividing cells [43].
In addition to recombination, retroviruses can also lead to insertional mutatgenesis
and more serious complications, potentially curing one disorder but leading to another [33,
46-48]. Lentiviruses have been studied for their ability to transfect hematopoietic stem cells,
but they still have potential for infection and concerns exist regarding their
immunodeficiency virus origins [49-51]. All three of these vectors share the common
limitation that they can only carry a limited amount of gene material (usually less than 8 kb),
making some multi-gene approaches unfeasible. This setback may be addressed by herpes
virus carriers, which have a high payload capacity, although these vectors can be highly
immunogenic and potentially toxic [43, 52]. Adeno-associated vectors look to provide high
in tivo transfection efficiency and prolonged gene expression with a low immune response,
but are hampered by even smaller carrying capacity (less than 4.5 kb) and can also pose the
risk of insertional mutagenesis and infection [43, 45, 53, 54]. Although this list is not
exhaustive, it can be seen that while at first sight viral vectors may appear to be the perfectly
evolved gene delivery vehicles, each vector possesses a set of advantages and disadvantages
that makes it potentially suitable for certain applications, but not without risks.
1.2.2 Non-viral Vectors: Naked DNA and Facilitated Delivery
The simplest non-viral alternative for gene delivery is the introduction of naked
plasmid or oligomeric DNA to cells [55, 56]. DNA plasmids can carry virtually unlimited
payloads, are noninfectious, and do not pose immunogenic risks, while oligomers are also
relatively safe and are cheap to produce. However, these advantages are tempered by the
fact that delivery of naked DNA is plagued with low transfection efficiency, and the minimal
levels of gene expression that do result are normally very short-lived [57]. This transient
expression can be prolonged via "gene gun" delivery or intramuscular injection of plasmid,
which slows the rate of plasmid degradation, but these approaches are only applicable to a
limited number of disorders [58-62]. Some of the most exciting and recent progress in non-
viral gene therapy has been in the development of technologies that actively enhance the
delivery of naked DNA. Electroporation, which subjects cells and tissue to very short pulses
of a high voltage electric field, serves to reversibly permeabilize the plasma membrane,
facilitating plasmid transport to the cytoplasm and eventually the nucleus [63-66]. Although
this treatment method has shown success in a number of pre-clinical trials, the long term
effects and safety of this technique must be established before its clinical utility can be
realized. Hydrodynamic delivery of plasmids has also developed into a useful technique to
evaluate the curative potential of different plasmids in animal models. High pressure
injection to the tail vein of mice or rats can lead to long term, efficient gene expression in the
liver [66, 67], though limitations exist in completely scaling up this approach for humans, as
injection volumes would have to be on the order of liters! Catheter guided balloons may be
developed to close off portions of the liver, substantially minimizing the apparent volume
for delivery [68], but such an approach may not be very appealing for patients when other
options are available. In summary, while naked DNA delivery techniques may provide
increased safety, it is unclear as to whether these approaches will realize widespread
application in gene therapy.
1.2.3 Non-viral Vectors: Molecular Conjugates
The use of synthetic, non-viral vectors as gene carriers provides another route for
improving the transfection efficiency of RNA and plasmid and oligomeric DNA [1, 69, 70].
The first synthetic gene carriers studied in the early 1980's were traditional liposomes, which
fused to the plasma membrane and delivered their DNA cargo into the cytoplasm [71, 72].
Cationic lipids and organic polymers such as polylysine came into use shortly thereafter, with
some carriers incorporating ligands for cell specific uptake [73-75]. These carriers formed
smaller, cationic particles with the negatively charged DNA, entering the cell through
endocytosis and protecting the plasmids from degradation for more of the intracellular route
to the nucleus. However, most of these non-viral complexes were still subjected to
degradation within the lysosomal pathway, since no vesicular escape mechanism was in place
for these carriers.
With the advent of polyethylenimine (PEI), this picture began to change [76]. With
every third atom of this polymer being a protonatable nitrogen atom, PEI could serve as a
buffering agent, or "proton sponge", in the acidic late endosomes and lysosomes. While the
mechanism of endosomal or lysosomal escape remains to be definitively proven, this
property of PEI certainly contributes to more efficient trafficking of complexes into the
cytoplasm, increasing the chances for nuclear association and delivery. As a result, PEI has
become one of the most widely studied non-viral vectors [77-94]. This discovery has also
led to a new wave of synthetic vectors that seek to engineer polymer properties that increase
endosomal lysis and escape due to pH sensitive functional groups, bind nuclear import
proteins more efficiently with the incorporation of nuclear localization sequences, and
increase vector lifetime in vivo by preventing serum protein aggregation with steric stabilizing
agents such as polyethylene glycol (PEG) [95-97]. Hybrid vectors are also being designed
which incorporate targeting ligands and other recombinant or viral capsid proteins to
increase cell specific targeting and trafficking efficiency [69, 97-102]. Novel combinatorial
chemistry approaches and reengineering of traditional cationic, amine containing polymers
has also led to different classes of next generation gene delivery vehicles which are less toxic
than traditional PEI vectors, but deliver their genetic payload far more efficiently[103-111].
However, these non-viral carriers still transfect cells with much lower efficiency and
shorter expression times than their viral counterparts. It is hoped that with further
refinements to both vector and plasmid properties, novel complexes can be developed that
rival the efficiencies of viral vectors, while still remaining safe for patients and providing the
versatility to be tailored to a multitude of very specific disorders.
Vectors Used in Gene Therapy Clinical Trials
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Adenovirus 26% (n=305)
* Retrovirus 24% (n=288)
* Naked/Plasmid DNA 17% (n=206)
* Lipofection 8.3% ({n99)
* Poxvirus 6.9% (n=82)
* Vaccinia virus 6.5% (n=78)
Adeno-associated virus 3.4% (n=40)
0 Herpes simplex virus 3,4% (n=40)
i RNA transfer 1.3% (n= 15)
* Others 2.4% (n=29)
* Unknown 3.1% (n=37)
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Figure 1.3: Breakdown of gene therapy vector types used in gene therapy clinical trials to date. As can
be seen above, the vast majority of trials are focused on viral vectors, followed by roughly one quarter
of trials using more traditional first generation non-viral techniques such as lipofection and naked DNA
transfer. More progress needs to be made on next generation non-viral carriers so that they are not
only safe, but also increasingly effective and more attractive for clinical application.
Motivation and Significance of Thesis Work
1.3 Non-viral Carriers Face Multiple Extracellular and Intracellular Barriers
In order for efficient transfection to be accomplished, a non-viral vector/plasmid
complex must overcome a number of barriers on its way to the nucleus [112, 113]. First,
whether in vivo or in vitro, the complex must travel via convection or diffusion to the surface of
the cells that require treatment. The complex must be resistant to aggregation in the presence
of serum proteins, while also having low immunogenicity. These properties are essential for a
carrier to have high safety and efficacy in vivo. The complex must then bind to the cell surface
and be internalized, either through a specific ligand-receptor interaction leading to receptor
mediated endocytosis, or via non-specific interactions with cell surface proteoglycans such as
syndecans followed by fluid phase endocytosis [114, 115].
After internalization, the complex is trafficked from coated pits to early endosomes,
where it may then be recycled or shipped further down the pathway to the acidic late
endosomes and lysosomes. It is crucial that the complex have some form of vesicular escape
mechanism, so it can enter the cytoplasm before degradation occurs within these late vesicles.
The complex must then travel to the nucleus, with any prematurely unpackaged DNA being
subjected to rapid degradation rates due to the presence of cytosolic nucleases [116]. DNA
segments larger than 100 bp cannot freely diffuse through nuclear pores [117], so the complex
or plasmid alone must then bind to nuclear import proteins by utilizing a nuclear localization
sequence since most transgenes are 3 kb pairs or larger [113]. After nuclear pore complex
formation and import, gene expression can't occur unless the vector has successfully
unpackaged from the plasmid, giving transcriptional machinery access to the transgene [118].
After successful nuclear delivery, non-viral DNA can also be subject to various mechanisms of
gene silencing, which can result in highly transient gene expression [119].
Figure 1.4: Non-viral vectors face multiple barriers multiple barriers on the way the successful nuclear
delivery and transgene expression. Since non-viral complexes are usually on the order of 100 to 500
um in diameter and cannot freely diffuse across the plasma membrane, they must rely on the endocytic
pathway for cellular uptake and intracellular trafficking to the nucleus.
In general, a majority of past research on both viral and non-viral fronts has been of a
more clinical and qualitative nature. Studies would mainly focus on overcoming one barrier at
a time and merely evaluate resultant gene expression levels and duration for some dosing level
of a given viral or non-viral formulation. In the case of viral vectors, which have evolved
complex mechanisms to efficiently surpass all of these barriers, this methodology can still yield
some useful outcomes. However, in the context of non-viral vectors that must be designed
from the ground up to overcome each barrier, this approach can be detrimental and
inefficient. Changing the physical properties of a vector may be favorable for one barrier, but
actually hinder overall efficiency by making it more difficult to accomplish another step in the
delivery process. Past work has shown binding and internalization at the cell surface [120,
121], endosomal escape [122-124], transport in the cytoplasm [116, 125], nuclear import [126-
131], and vector unpackaging [118] to all be potentially rate-limiting steps in the delivery
process. The most important message to take away from these conclusions is that the rate-
limiting step and significance of other major barriers can depend heavily on the specific
vector/plasmid complex used and the particular cell type being studied.
1.4 New Experimental Approaches Can Glean Insight for Vector Design Properties
Quantitative and systematic studies of gene delivery may be advantageous to tackle this
multiple-barrier scenario. Past work in our group has shown that taking a computational
modeling approach combined with quantitative experiments for gene delivery analysis can
provide a powerful predictive tool for gene carrier development and refinement [113]. By
adjusting model parameters to fit quantitative experimental data, sensitivity analyses can be
performed to determine what steps are most rate limiting for a specific complex. Parameter
spaces can also be varied in a systematic manner in simulations that reveal how multiple vector
properties could be adjusted to give the most optimal gene expression profiles. However,
current models are experimentally limited due to the small number of subcellular fractions that
can be studied quantitatively. Many processes are lumped together, and as a result, a good deal
of mechanistic information regarding the intracellular dynamics of gene delivery is lost.
This systems level analysis was extended more recently by coupling quantitative whole
cell and nuclear trafficking data from a variety of vectors, both viral and non-viral, with a more
refined mathematical model [132]. Additional experimental data from the literature was used
to build a more comprehensive model that could more accurately describe many of the
aforementioned intracellular delivery barriers. Vector dependent parameters were fit to the
respective data sets to acquire specific models for Adenovirus, PEI25, PEI2, and a next
generation branched PEI called PEI2C12, Lipofectamine, and naked plasmid DNA.
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Figure 1.5: Schematic representation of the first order rate processes involved in intracellular
trafficking and delivery of plasmid to the nucleus via a gene delivery vector. These steps were included
in a mathematical model of ordinary differential equations, and the model was fit to experimental data
for each vector by varying rate constant values that were dependent on the vector properties.
Simulations could then be run with each vector specific model to gain mechanistic insight for that
carrier [132].
Sensitivity analyses were then run on each these vector specific models to gauge which
steps were most important for the vector to achieve successful gene delivery and maximal
transgene expression. Some of the most important conclusions from this analysis were that
different vectors did in fact have different rate limiting steps within the same cell type (in this
case, the C3A hepatocarcinoma cell line). Some of these conclusions made mechanistic sense
due to what was expected of the carrier from its structure and inherent chemical properties.
While other results were less intuitive, they did make physical sense and generated interesting
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Figure 1.6: Sensitivity analysis results for each vector specific mathematical model. Parameter
sensitivities were evaluated for delivery steps that were dependent on vector properties. A high
sensitivity value implies that a step may be potentially rate limiting in the delivery process, revealing
here that different vectors have different rate limiting steps [132].
hypotheses for further experimental study and refinement. Interestingly, overall results for
some of the vectors differed significantly from those seen in other cell types. For instance,
PEI2C12 greatly outperformed traditional PEI25 in the Cos-7 monkey kidney cell line, but this
phenomenon was not observed in the C3A cell line. This observation lends credence to the
idea that vectors should be evaluated on a cell type by cell type basis, as the intrinsic
phenotype of a cell can affect the delivery efficiency of a given carrier. Furthermore, this
supports the need for more efficient methods of quantitatively screening novel vector
performance in primary cell types and more in vivo like experimental models, since cell lines
can differ greatly from their original primary cell source.
d Dodecylated 2 kDa PEI
~,,*'64 7e
,ze A j,
I-A :s <P 4 0f\
I.A
1.5 Experimental Goals for Improved Gene Delivery Analysis
To further improve on these findings and build more accurate and predictive
mathematical models, increased subcellular resolution must be obtained to more accurately
identify potentially important barriers and gain additional understanding of the gene delivery
process for specific non-viral complexes. Progress has also been made in systematically
producing and screening novel non-viral vectors in a more high-throughput manner,
increasing the chances for the discovery of new chemical moieties that have desirable
properties for gene therapy [133, 134]. While this work is significant, improvements in
screening are needed that will be able to determine why novel vectors show increased
transfection efficiencies. Comparing gene expression levels in conventional two-dimensional
cell line cultures will identify the best performing vectors in that cell line, but likely won't
correlate with vector performance in vivo in animal models and patients. While animal models
and clinical studies can reveal overall vector safety or efficacy, it can be very difficult to acquire
quantitative, mechanistic data, and therefore, it is once again difficult to understand why or
why not a gene therapy vector was successful or how it could be further improved. The
knowledge gained from better screening in a more in vivo like experimental system that still
allows for quantitative analysis will allow for more intelligent refinements in subsequent vector
iterations, potentially resulting in highly efficient carriers.
1.5.1 Increased Spatial Resolution for Intracellular Trafficking Experiments
A major goal of this thesis work is to develop a method to better study the intracellular
trafficking of non-viral gene delivery vectors. Different groups have attempted to track PEI
transport within the endosomes and lysosomes of single cells via different imaging and
fluorescence detection strategies [90-94]. The fact that these studies have actually brought
about conflicting observations and reopened the debate over the mechanism of PEI-mediated
gene delivery highlights the fact that a more quantitative method of analysis would be
beneficial in examining these processes. Other efforts have focused on utilizing novel
fluorescence techniques to more quantitatively track the pH environment of non-viral
complexes [135], but this approach only allows analysis of a limited portion of the overall
delivery route and leaves some uncertainty of the actual location of the complex. Conducting
a more comprehensive, and not merely quantitative, analysis could allow for the validation of
mass action kinetic models for more accurate prediction of vector behavior and insight for
improvement.
After reviewing a myriad of potential subcellular fractionation methods, it has been
concluded that an approach utilizing density gradient electrophoresis (DGE) could yield the
desired intracellular resolution, while still meeting the sensitivity demands of quantitative
downstream assays. DGE exploits differences in both the density and charge of proteins, cells
and organelles by driving electromigration of charged species through a viscous medium that
varies in density in the same dimension as the applied electrical potential [136]. As a result,
this methodology is exceptionally useful for separating and collecting different classes of
endosomes and lysosomes, which have differential surface protein expression and membrane
composition, leading to diverse and distinct density and charge properties [137-141].
traction numbe
Figure 1.7: Separation potential of density gradient electrophoresis (DGE) columns: a typical
fractionation pattern of organelles from labeled Mel Juso cells performed on an early density gradient
electrophoresis prototype. LE = Late Endosomes, L = Lysosomes, RV = Recycling Vesicles, EE =
Early Endosomes, PM = Plasma Membrane, s-Tf = soluble transferrin, s-HRP = soluble HRP.
Fraction 1 was at the top of the DGE column at the beginning of the separation run and fraction 80 at
the bottom of the column [142].
More conventional methods such as density gradient centrifugation or free flow
electrophoresis perform separations based on either density or charge differences alone [143].
As a result, these techniques cannot separate endosomal subpopulations or robustly deal with
the slight intrinsic variability of each vesicle type, while requiring multiple runs on the same
sample to achieve the same number of fractions with high resolution [143, 144]. Meanwhile,
microfluidic bioseparation devices have shown proof of principle to sort vesicular organelles,
but don't provide efficient recovery methods or enough material to support downstream
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assays [145]. A functional DGE device will be built based on the work of Ab Tulp and
coworkers at the Netherlands Cancer Institute (NKI) [142, 146-148]. Two prototypes were
constructed that performed efficient, one-step separation of vesicular organelles in a number
of cell lines, allowing all organellar fractions to be collected with high resolution from the same
sample. It is hoped that a similar device can be adapted and optimized to separate the same
organelles from primary rat hepatocytes.
1.5.2 A More In Vivo-like System to Study Vector Delivery and Expression Efficiency
While successful implementation of DGE on non-virally transfected cells can provide
a wealth of information on the intracellular mechanisms of gene delivery, there is no guarantee
that this data will lead to clinically applicable conclusions. Oftentimes, as previously
mentioned, experimental results acquired from a cell line in 2-D culture do not correlate well
with those seen in in vivo tissue or primary cells in general [149]. As a result, a requisite first
step in furthering these experimental approaches is to move experiments into the appropriate
primary cell types of interest. Optimizing DGE experiments in primary hepatocytes should
offer a number of insights into the intracellular delivery mechanisms of different vectors in a
cell type that is highly relevant in in vivo gene therapy approaches. The liver performs many
important functions in the uptake and processing of xenobiotics in the body. Additionally, it
serves as an attractive organ target for a number of gene therapy applications [150-158].
However, the two-dimensional culture formats that are optimal for throughput and sample
processing when studying vector trafficking do not reflect the complex three dimensional
tissue structure and cell type interactions that exist in native liver. When primary cells cultured
in 2-D on either adsorbed collagen monolayers or collagen gels are transfected with a gene
therapy vector, every cell in the culture has equal access to vectors in the culture medium.
These cultures are also static, and in the absence of flow, particles simply sediment on the cells
and are endocytosed.
This is not the case in in vivo liver, where a complex hierarchy of cell types and overall
tissue organization means that not every cell has equal access to a therapeutic that is large
enough that it must rely on endocytosis for cell uptake. Additionally, some of the cell types in
native liver, such as Kupffer cells, may preferentially take up the vector and degrade it before
the desired target cells, hepatocytes, have access to significant vector uptake. Furthermore,
primary hepatocytes cultured in traditional two-dimensional formats quickly dedifferentiate
and lose liver specific phenotype. Therefore, it is difficult to carry out long term gene delivery
and expression analyses in these systems to gauge primary cell success of vectors. It should be
noted that liver structure and function and the role of specific cell types is reviewed in great
detail in the thesis introductions of Anand Sivaraman and Albert ItIwa, and the reader is
referred to these documents for further background information on the liver [159, 160].
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Figure 1.8: Schematic representations of the 3-D)
structure and hierarchy of the liver. A) Cell
arrangement of the sinusoidal flow conduits in a liver
lobule. B) Vascularization of one liver portal triad unit.
C) Detailed schematic of a sinusoid cross section
highlighting the complex interaction of multiple cell
types. Cell types are as follows: H, Hiepatocytes; EC,
Endothelial Cells; SC, Stellate Cells; KC, Kupffer Cells;
P, Pit Cells. Images A and B are taken from Junqueira
and Carneiro, Basic IIlstology, a text and atlas, p. 333,
Figure 16-11. Image C is taken from Wake et al. 1997.
Images originally appeared in the thesis of Anand
Sivaraman, © Massachusetts Institute of Technology.
Ideally, the gap between cell line and animal model studies must be filled with an
experimental system that can foster cells or tissue in a manner that promotes in iwvo-like tissue
structure and phenotypic expression, while also facilitating quantitative study in greater
temporal and spatial resolution. It is hoped that studying non-viral gene delivery in a three-
dimensional, perfused liver bioreactor that has been previously developed in the Griffith lab
will generate more clinically relevant data. 'lhis bioreactor has been shown to facilitate the
reorganization of primary rat hepatocytes and hepatic spheroids into tissue with liver-like
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morphology and phenotype, and greatly prolongs the time that these primary cells can be
cultured in vitro [161, 162]. As mentioned previously, liver itself is a common target organ for
in vivo gene therapy strategies [163], so this system has the potential to provide an excellent,
controllable test bed for the improvement of non-viral vectors for a wide variety of clinical
applications. The system also utilizes serum containing perfusion medium, which can provide
an additional test for how a vector may perform in vivo. Multiple reactors can be seeded and
repeatedly form consistent tissue structures, allowing for numerous transfection runs from the
same primary cell source that can be analyzed at different time points or for multiple vectors.
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Figure 1.9: The perfused 3-D Milli-F liver bioreactor. Hepatocytes in the reactor channels are
perfused with culture medium and form tissue structures that remain viable over long term culture with
enhanced liver phenotype as compared to traditional in vitro culture formats.
By combining quantitative DGE trafficking studies in short term two-dimensional
cultures relevant to the time scales of nuclear delivery of gene therapeutics and long term
delivery efficiency and expression assays in the liver bioreactor to compare differences
between 2-I) and 3-D systems of primary cells, it is hoped that both mechanistic and clinical
level lessons can be learned about non-viral vector performance and knowledge can be gained
on design properties of these vectors that can potentially be enhanced.
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1.6 Overall Thesis Objective and Specific Aims
The overall goal of this thesis work is to develop and optimize devices and methods
for a combined experimental and modeling approach for the quantitative analysis of the
dynamics of non-viral gene delivery in primary liver cultures. Successful implementation of
this dual strategy should provide added insight and refinement in identifying the major barriers
to successful non-viral gene delivery in a more clinically relevant experimental system. To
achieve this end goal, the specific aims of this thesis are:
1. Develop an improved experimental method for subcellular fractionation to permit
higher-resolution quantitative measurement of vector dynamics in primary hepatocytes.
a. This will require the fabrication of a density gradient electrophoresis device
that exploits charge and density differences in cellular organelles, thus allowing
for more efficient post-transfection organellar separations. This fractionation
method must ideally allow for early endosomal, late endosomal/lysosomal,
nuclear and cytoplasmic fractions to be acquired from the same sample.
b. The method must be repeatable and completely preparative to allow for
reliable fraction identification and downstream quantification of DNA plasmid
and polymer carrier. The approach must allow for large enough sample sizes
for downstream assays to accurately measure vector and plasmid levels.
Separation runs and cell lysis techniques will be specifically optimized for
primary hepatocytes.
2. Perform transfection experiments with non-viral vectors and a canonical viral vector in
primary liver cultures coupled with downstream assays to quantify intracellular
trafficking and gene expression at time points of interest.
a. Characterization and improvement of the scaled-up giant reactor will be
performed in order to acquire a reliable experimental system that will provide
cell numbers which satisfy the demands of the quantitative downstream assays.
A more efficient transfection scheme will also be explored in this larger reactor
set-up, and cell recovery from the reactor chip will be optimized.
b. Employ a series of non-viral gene delivery and post-transfection assays in short
term 2-D cultures to determine vector/plasmid and plasmid levels in
intracellular fractions recovered from DGE processing. Build trafficking time
courses with increased spatial, resolution for each vector.
3. Build an improved mathematical model that accounts for vector, plasmid and
vector/plasmid complex dynamics by describing for each relevant species: Binding and
internalization at the cell surface, vesicular trafficking and escape, nuclear localization
and import, complex unpackaging, and transgene expression.
a. The degree of subcellular resolution obtained via specific aim I and the
availability of kinetic data for primary hepatocytes/related cell lines will dictate
the complexity of the overall model and its individual components.
b. Model parameters will be fit to the quantitative kinetic data acquired via
specific aims I and 2 to make vector specific models. Sensitivity analyses will
be performed on these to determine which processes are rate limiting for
successful nuclear delivery, providing insight for potential improvement of a
vector's physical properties and related efficiency. In si/co model simulations
over tractable parameter spaces could serve as a basis for optimization of
transgene expression as a function of vector properties, and generate
hypotheses for future experiments.
Chapter 2
Device Development and Optimization of Experimental Systems
2.1 Introduction
This chapter will discuss the initial development and refinement of the major
experimental systems that were used throughout this thesis. Finalized systems and
applications of the optimized experimental methods will be detailed in chapters three
through five. The major goals of this stage of the overall thesis work were to build and
optimize two devices that would make specific aims 1 and 2 experimentally feasible in
primary hepatocytes.
The first device, a density gradient electrophoresis (DGE) column, was built in
collaboration with researchers at the Netherlands Cancer Institute based on an earlier
prototype that showed potential for separating the vesicular organelles of the endocytic
pathway at the desired subcellular spatial resolution [142, 147, 148]. Modifications, which
will be discussed below, were made on a newly built device in the hopes of achieving
enhanced separation and more consistent and efficient runs. It should be mentioned that a
good deal of the assay development and optimization was performed in collaboration with
Jennifer Fang, a BE masters student whose thesis centered on testing a large matrix of cell
culture conditions, cell lysis and lysate processing techniques, and DGE run parameters to
arrive at the optimization of hepatocyte organelle separation and fraction identification. A
comprehensive summary of our joint assay development work has been described in
Jennifer's thesis, as well as a more extensive review on the selection of an appropriate
separation method from the available options. For brevity this chapter will highlight
essential work and findings only, and the reader is referred to her thesis for further details
[164].
The second device to be used in this work is a scaled up, perfused 3-D liver bioreactor
for gene delivery studies in a tissue engineered liver surrogate. Previous experiments have
been performed in the lab to examine adenovirus gene therapy and delivery efficiency in the
original, smaller liver bioreactor systems developed in the Griffith lab [161, 162]. However,
these original systems only housed on the order of 10,000 to 20,000 cells, and a very high
multiplicity of infection (usually an MOI of 1,000) was used to achieve detectable levels of
EGFP transgene expression by interrogation via two-photon microscopy. As was discussed
in the introduction, non-viral vectors typically yield transgene expression levels that are many
orders of magnitude below those of their viral counterparts. As a result, it would be very
difficult to measure transgene expression levels with enough resolution to quantitatively
compare the performance of different non-viral carriers. Additionally, an end goal of this
and future work is to develop bioreactor systems that allow for easy recovery of cells. In the
original bioreactor systems and experimental protocols, the reactor housing was optimized
for high performance in situ imaging of the liver tissue, but it was difficult to quickly recover
the cells for quantitative downstream assays. A new system with more total tissue can also
provide enough material for multiple assays from the same reactor, thereby providing a very
high-information content assay system. With enough material, cells could be recovered and
used to recover RNA, DNA and protein from the same system, or assays could be
performed at the subcellular level now that sensitivity requirements could be met.
With two viable experimental systems at hand, a last step in the assay development
phase is to ensure that the systems not only work for primary hepatocytes in general, but
also for hepatocytes transfected with gene therapy vectors. Just as important is the screening
and identification of new and interesting non-viral vectors that are able to be studied in these
systems. Moreover, the development of robust viral and non-viral transfection protocols are
needed that allow for accurate comparison of the vectors and determination of appropriate
dosage levels that are clinically applicable, allow for unbiased comparison between vectors
and between 2-D and 3-D results, and don't simply achieve high transfection levels due to
unrealistically high dosages. These considerations will be discussed at the end of each
section and the chapter as a whole.
2.2 DGE Device and Protocol Development
This section describes the newly built DGE device, device characterization, assay
development and proof of concept results showing a preparative separation method that can
be used to study the intracellular dynamics of gene delivery. Chapters 3 and 5 discuss final
applications for this device. This section will primarily discuss preliminary and end results
and the steps that were taken to optimize the overall protocol for cell lysis, lysate preparation
and loading and the DGE run. For a detailed, step by step description of the DGE
protocol, please see Appendix 4.
2.2.1 The Device: Component Descriptions and Initial Characterization
The DGE device was constructed in collaboration with the H4 Tumor Biology
Division of the NKI. The device follows the same design principles of the Tulp DGE
prototype seen below in figure 2.1, with some modifications made to improve separation
potential and efficiency. Briefly, the separation column (s) and the upper and lower
electrophoresis buffer chambers (I and II) were machined in one piece from a cylinder of
polymethylmethacrylate (PMMA). The electrode holders (n and B) are also made from
PMMA, but are removable to allow for easy cleaning and maintenance of the column and
chambers. Circular platinum and palladium electrodes (Pt, anode and P, cathode) were
machined with exactly the same diameter of the separation column to ensure a more constant
current density throughout the column, which has been shown to enhance separation
resolution in the previous prototype. A non-gassing palladium electrode is required in the
lower chamber because bubbles generated by a traditional gassing electrode would cause
hydrodynamic disturbances to the contents of the separation column. The membrane (m),
which is secured by an O-ring
(o) to the rounded bottom of
the separation column, allows
for the passage of ions and
serves to connect the column
electrically, but not
hydrodynamically, to the
lower buffer chamber.
Standard banana clips are
used to attach the electrodes
to a power supply, which
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under constant current Figure 2.1: DGE prototype and gradient mixer. Schematic
represents a cross section of the device, which is machined from
conditions at roughly 10 cylinders of PMIMA. [117]
milliamps. A multimeter is used to ensure that the current does indeed stay at 10 milliamps for
the entire run, as this is crucial for repeatable, high-resolution separations since charged species
maintain a constant electromigration velocity when driven by a constant current power supply.
Since constant current conditions maintain migration speed but can lead to temperature
increases and fluctuations, all runs must be performed in a cold room at 40C to maintain
density gradient integrity and sample band uniformity. The removable top cone (c) allows for
precise and evenly distributed sample and density gradient introduction, as well as post-
separation sample collection when outfitted with a capillary tube. A syringe pump is used to
introduce separation media into the column via a specially designed inlet (i) that causes little
disturbance to the column contents. The gradient mixer at the right of figure 2.1 consists of
PMMA columns connected by a rubber tube at (v), and the mixing rod (r) is powered by a
simple motor and variable voltage AC adaptor that can yield different mixing speeds for
different stages of the gradient layering. The mixer base is fashioned such that it firmly
interconnects with the top buffer chamber and allows for gradient introduction via the outlet
(e) directly into the top cone.
In all DGE runs, a lower gradient, usually varying from 10- 7% Ficoll, is layered in the
column, and then the cell lysate is layered onto the column in a thin band of 6% Ficoll.
Finally, a larger upper density gradient, usually varying from 5-0% Ficoll is layered over the
sample. The top cone is then replaced by the electrode after the upper chamber (I) is filled
with electrophoresis buffer. An electric potential is then applied to cause cellular organelles of
different density and surface charge to migrate away from the initial sample band to different
heights in the column. At the end of the run (usually 40-80 minutes) the upper electrode (n) is
once again replaced with the cone (c), and a syringe pump can then be used to pump 10%
Ficoll into the bottom of the chamber through the inlet (i) in order to elute the column
contents through the cone and attach capillary tube and into a multiwell plate or fraction
collector to acquire the separated organelles and assay for their location. Peristaltic perfusion
pumps were built to continuously cycle electrophoresis buffer to and from inlet and outlet
pairs for the upper (1.1 and f) and lower chambers (II.1 and II.1, one outlet occluded in view).
This is especially important for the replenishment of the non-gassing palladium electrode in
the bottom chamber. The device must also be completely level and free of vibration to yield
the best separation results, so a vibration isolation platform is used under the device to ensure
these optimal conditions.
One of the most significant changes that was made to the device was an increase in
overall size in order to make a longer separation column. In the original prototype, the
column measured 7 cm in length, but only 5 cm were actually usable since a water front co-
migrates with cations across the bottom of the anion impermeable membrane during the
course of a run. Traditionally, a 10% Ficoll cushion was left in the bottom 2 cm of the column
and the initial sample band would migrate upwards into the upper 5% to 0% Ficoll density
gradient that filled the remaining 5 cm of the column. Separation runs typically lasted 40 to 60
minutes, and the water front would remain below the 2 cm sample line during this short time.
The new DGE device was designed with a column length of 12 cm, with buffer chambers,
outlet and inlet sizes, and flow rates of buffer replenishment being scaled appropriately. This
increased size was settled on due to empirical findings made by the Tulp lab and theoretical
predictions that balanced sample band dispersion over the course of the run with overall
separation potential between organellar cohorts for a given upper gradient length and overall
separation column length [142].
Additionally, a more simple cellophane membrane that is permeable to both anions
and cations replaced the original membrane, which was exclusively permeable to cations [142,
146]. Observation has shown that this new membrane significantly slows the rate of water co-
migration into the bottom of the separation column, making for more usable column length
and much longer run times. This will benefit the longer column as well in that more sizable
density gradients can be used to potentially receive better organelle separation than that
observed with the traditional 5% to 0% gradient of only 10-12 mL in total volume.
Accordingly, a larger gradient mixer was also built, which can accommodate gradient layers of
up to 30 mL. A larger upper orifice was also be incorporated in the upper electrode cap, so
that 02 and H2 bubbles can be gently removed from the platinum electrode during operation,
making for a more uniform electric field and better separations.
Some design flaws were discovered and remedied during the very initial
characterization runs in cell lines that had been used with the previous prototype. Since the
gradient mixer was made larger to accommodate the modified device, more air was present in
the upper, unused portion of the mixing column. As a result, inserting the mixer caused a
pressure disturbance great enough to distort the sample layer. While the newly designed upper
electrode cap gave better access for the cleaning of air-bubbles during the separation run, it
also allowed the electrode to move slightly during the cleaning, leading to more harm than
good for the uniformity to the electric field. The new openings in this electrode cap also gave
the buffer in the upper chamber an alternate route of egress, and buffer merely spilled from
the top of the chamber rather than from the small outlet tube. These circumstances led to a
poor separation pattern, and the need for additional machining. To remedy the gradient
mixer, two small holes were drilled in the top portion of the mixing column to expel air when
the mixer is inserted. A groove was also cut into the motor housing and a stop pin was put on
the outer surface of the column to put the mixing shaft tip at a more exact position further
from the tube exit so the sample band would not be disturbed during upper density gradient
administration. A removable clamp was machined from PMMA to keep the upper electrode
steadfast during cleaning. The overflow problem was solved by simply boring the upper outlet
tube to a larger diameter, so that it would pose less resistance to the exit flow.
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Figure 2.2: The new DGE device is able to maintain a constant current in the appropriate range
over adequate separations times, both in the presence and absence of cell lysate. A commercially
available electrophoresis power supply capable of running in a constant current mode with mrAmp
resolution is all that is required. This is a crucial feature of the device since migration velocity
correlates directly with current, and constant organelle speeds allow for more effective and consistent
separations.
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With these modifications in place, the following run successfully recreated the
separation pattern seen in previous experiments with the Mel Juso cell line. Odd fractions
were assayed for n-Hex activity for lysosomal activity, HRP activity and total protein as can be
seen in figure 2.4A. The HRP pulse-chase routine employed allowed for visualization of both
early and late endosomal peaks. Fractionation experiments were then moved on to HepG2
cells, to evaluate the ability of the device to separate organelles in liver-like cells. Due to time
constraints, only one run was performed on the HepG2 cells. Compared to past results
obtained with the original DGE prototype, the system performed even better than expected
(see figure 2.4B). Unfortunately, the second pulse of HRP was too long to effectively label the
early endosomes, but the most surprising and positive results came from the fact that the late
endosomal and lysosomal peaks were more than ten fractions apart from each other and very
well separated from the total protein peak, which is where early endosomes normally localize
to in DGE runs, whereas in the shorter column there had been no significant separation in
HepG2 for these two subpopulations from the main peak (these runs were conducted in the
very first DGE prototype [146], with only 3 cm of usable column and 40 minute runs). This
set the grounds for further optimization in primary hepatocyte cultures.
Figure 2.3: A) DGE device with palladium electrode base and platinum electrode at top. The gradient
mixer is at the lower left and the mixing motor is at lower right. B) Peripheral components for the
device, clockwise from top left: loading tweezers and extraction tool for ultracentrifuge, platinum
electrode, top cone for sample loading and recovery, adjustable C clamp for lower waste tube between
syringe pump and column, scissor clamps for gradient mixer connection tube, metal sieve to protect
column contents during buffer addition/removal to upper chamber, clamp and screw for platinum
electrode alignment, long arm to replace clamp to hold elution tubing during sample collection.
C) Working device on vibration isolation platform and integrated with peripheral components, clockwise
from left: syringe pump for chamber filling and sample collection, power supply, ammeter, syringe pump
controller, peristaltic pumps for buffer circulation, buffer flask, and waste flask for gradient addition.
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Figure 2.4: Results of initial characterization runs on cell line cultures using the original upper gradient
length on the new column. A) Fractionation of Mel Juso cells, the most well characterized cell line on
the earlier DGE prototype. Cells were pulsed with HRP for 4 minutes, chased with unlabeled media,
pulsed again for 3 minutes to label both early and late endosomes (right and left HRP peaks). The 3-
Hex assay indicates the lysosomal peak, and the protein assay shows the main total protein peak the
organelles migrated away from. This data exactly recapitulated what was seen in the earlier prototype,
showing that the physical changes to the new device did not hinder separation with the original run
conditions. B) Fractionation of HepG2 cells to gauge the potential for separation in liver like cells.
The 4 minute, 27 minute, 7 minute pulse-chase-pulse regiment was not optimal to label the early
endosomes, but this run showed excellent separation of late endosomes and lysosomes from the total
protein peak. Note: Fraction 1 is at the top of the column and fraction 60 fraction 60 is at the bottom
of the lower gradient at the end of the run. This holds in all subsequent DGE output plots.
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2.2.2 DGE Optimization for Primary Hepatocyte Fractionation
After the initial characterization runs at the NKI and integration of new peripheral
components to complete a new DGE set-up at MIT, characterizations runs were performed
on primary rat hepatocytes to determine how the original protocol and run parameters
would fare. Unfortunately, these first separations runs did not yield a desirable output.
Fractions were assayed for P-Hex and total protein alone to simply see if a single lysosomal
peak could be separated from the total protein peak. Unfortunately, multiple lysosomal
peaks were observed at different locations in the column, and a significant portion of
lysosomes was still stuck with the total protein peak (see Fig. 2.5).
DGE Output: 6 Million Primary Rat Hepatocytes
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Figure 2.5: DGE output for an 80 minute run on 6 million hepatocytes plated on an adsorbed
collagen monolayer. The same run conditions and gradients volumes (6 mL lower, .5 mL sample
layer, 10 mL upper) were used as with the initial cell line runs.
This result suggested that both sample processing and DGE run parameters needed
to be optimized for the primary cells. The rest of this section will summarize the changes
that were made to the protocol in order to obtain acceptable resolution in the separation of
early and late vesicular organelles from hepatocytes.
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1) Cell Culture Conditions and Cell Number per Run
A modified protocol was developed for the preparation of adsorbed collagen
monolayers (see Appendix 3). Drying the monolayers after the adsorption of collagen
allowed for better cell adhesion and morphology and ultimately better DGE separations.
There had been prior evidence in the literature that dried monolayers were superior for
culturing primary cells such as hepatocytes [165-169]. This avoided the need to move
experiments to collagen gels or gel sandwiches, which would have made cell collection and
lysis far more difficult and could have potentially made time course studies for trafficking
impossible with the desired temporal resolution. Successful separations were obtained with
cultures of 24, 48 and 72 hours on these surfaces (with daily medium changes); however,
DGE runs for final characterization and data sets were only performed on hepatocytes
within 24 hours of seeding to make sure that data was obtained on cells that had undergone
as little de-differentiation as possible and maintained cuboidal morphology and other traits
of hepatic phenotype maintenance [164].
Fewer total hepatocytes were also loaded onto the column, due to the fact that
primary hepatocytes have a greater amount of total protein per cell. For Mel Juso cells, the
cell limit had been established at 10 million cells/DGE run. However, for hepatocyte runs
approaching these numbers it seemed that the organelles were not escaping from the total
protein peak efficiently and streaming effects may have been muddling the separation of the
lysosomes. Experiments were moved to 60 mm dishes seeded with 2.4 million hepatocytes.
Culture medium was also changed 4 hours post-seeding to remove debris and prevent
overcrowding. Cutting down on debris significantly improved cell lysis steps and overall
separation. Considering the wash step after seeding, washing during sample processing,
retention of a small fraction of the whole cell lysate and post-nuclear spin supernatant, DGE
runs successfully separated organelles for a column load of roughly 1-1.5 million primary
hepatocytes.
2) Cell Lysis
Since hepatocytes have a larger diameter than HepG2 and Mel Juso cells, a larger
gauge needle was settled on for cell lysis. Ultimately, a 21G x 2 inch needle was used with a
3 mL syringe. Cells were also collected in a greater volume of DGE buffer, as a more dilute
cell suspension was found to lyse far more efficiently. Cells were still allowed to swell on ice
in hypotonic DGE buffer for 20 min before 12 expulsions through the syringe. As long as
the tube was prechilled before collection, endocytosis was complete halted at the time points
of interest regardless of this swelling time and a lysate with greater than or equal to 98% pure
nuclei was consistently obtained. Cell washing and labeling steps, as well as cell collection
and lysis technique specifics are highlighted in Appendix 4.
3) Cell Lysate Processing
After the nuclei are spun out of the cell lysate, the supernatant must be trypsinized in
order to free up the different vesicular organelles from cytoskeletal filaments. The trypsin
type used and the trypsinization time are highly important and can have different effects in
different cell types [170]. After testing a number of trypsin types and digestion conditions, it
was found that using Trypsin type XII A for six minutes was optimal. It was also found that
adding cold PBS instead of DGE buffer to the supernatant after inhibition of the trypsin but
before addition of extra protease inhibitors maintained organelle integrity and yielded a
larger organelle pellet after ultracentrifugation.
4) Sample and Gradient Layering and Run Duration
One of the biggest advantages that this new DGE device provided was the flexibility
to perform runs with larger density gradients or gradients over different ranges of Ficoll
concentrations. The separation column length in the original prototype limited the lower
gradient to be no more than 6 mL (3 mL of 10% and 3 mL of 7% Ficoll in each leg of the
gradient mixer) and the upper gradient to be no more than 10 mL (5 mL of 5% Ficoll and 5
mL of DGE buffer with no Ficoll in mixer). Increased gradient lengths and run times were
tested in the hopes of attaining wider separations between the different classes of organelles.
The conditions that were found to give the best separations in primary hepatocytes were an
eighty minute run at 10.6 mAmps and 300 volts (constant current mode), with 0.5 mLs of
sample in 6% Ficoll layered between the original 6 mL 10-7% lower gradient and a much
larger 25 mL 5-0% upper gradient. An optimized protocol was also developed which took
advantage of the computer controlled syringe pump, variable rate power supply to the
mixing motor, and more pliable tubing at the lower column inlet to ensure that the sample
layering and gradient introduction resulted in an extremely flat and thin sample layer, which
greatly enhances separation potential in the device.
5) Sample Collection and Fraction Assays
A movable based was used to allow for easy collection of samples in small and large
well 96 well plates. This allowed for a higher flowrate during sample collection while still
providing careful control over fraction size to gauge what the optimal volume was to retain
resolution between organelle subpopulations but reduce the total amount of assays to map
the fractionation pattern. Assays were miniaturized so that throughput could be increased
by reading fractions in a multiwell plate reader format.
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Figure 2.6: Fractionation pattern of primary hepatocyte organelles after optimization of the overall
DGE protocol. Odd fractions were probed for HRP after a dual pulse chase pulse to label early and
late endosomes. Optimal pulse chase pulse conditions were found to be 4 minute pulse - 15 minute
chase - 3 minute pulse. Assay for J3-Hexosaminidase shows the location of lysosomes after the
DGE run. The DGE device successfully separates these three organelle types. Late pulse only and
early pulse only DGE runs only show one HRP peak in the appropriate location, giving support that
these peaks are indeed separate endosome sub-populations (see Chapter 3).
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As can be seen in figure 2.6, optimization of this large panel of sample processing
techniques and run parameters has achieved excellent separation of the organelles of interest
on primary hepatocytes. This work was then extended to better fraction identification via
various sample concentration techniques and western blotting for membrane proteins
unique to early and late endosomes. While traditional protein precipitation techniques were
not compatible with the separation buffer, the fact that DGE fractionation is completely
preparative and keeps organelles intact after the run is complete was exploited to attain a
novel concentration method. DGE runs were performed on HRP pulsed hepatocytes and
the fractions comprised the second late vesicle HRP peak were recollected in an
ultracentrifuge tube and spun down at 100,000 x G for an hour. This repelleted the
organelles in those fractions, and the pellet was resuspended in sample buffer and run on an
SDS-PAGE gel. A western blot was then performed where the late endosome fraction, the
post-nuclear spin supernatant (PNS) (which should contain all vesicles) and the post-
endosomal ultracentrifugation spin supernatant (which should only contain a small amount
of broken vesicle membranes if any) were blotted with two antibodies. One antibody, anti-
Rab9, is specific for late endosomes, while the other, anti-EEA1, is specific for early
endosomes [164]. These antibodies were previously optimized for primary hepatocyte cell
lysates [164]. In the late fractions sample, there was a strong Rab9 signal and no detection of
EEAI1 binding. This provided strong evidence that the late fraction exclusively contains late
endosomes and that there are indeed two distinct endosomal populations separated by the
D(;E device.
Figure 2.7: Western results probing for late and early endosomes in a positive control (PNS), a
negative control (PES), and in vesicles spun down from the leftmost "late endosome" peak from
HRP pulse-chase-pulse mapping of a DGE run. Rab9 is a Rab GTPase specific to late endosomes
and EEA1 or early endosome antigen one, is a protein complex specific to early endosomes.
2.2.3 Feasibility of DGE Analysis for Gene Delivery Tracking
With robust separation of organelles optimized for primary hepatocytes, the
remaining task at hand for assay development was to verify that this approach could truly be
effective in measuring non-viral vector trafficking. The biggest question that remained was
whether or not DGE would still work in the presence of cationic non-viral gene delivery
complexes, or if the separation pattern would be greatly deflected by the addition of these
dense, charged particles to the cells and organelles. Additionally, if an acceptable separation
pattern is still attainable in transfected cells, can the delivered plasmids be recovered from
the various cell fractions in a large enough amount that they could still be measured via real-
time quantitative PCR.
Figure 2.8 shows that upon gene delivery with polyethylenimine/plasmid DNA gene
delivery complexes and a standard HIRP pulse-chase-pulse labeling, the DGE fractionation
pattern results in organelle peaks that are a bit more spread out in width and shifted
downward in the column slightly. The late endosome and lysosome peaks are also less well
separated, likely due to the fact that NV complexes are building up in these vesicles and as a
result there may be less of a difference in density between them. Overall, DGE
fractionation is able to repeatedly separate a late and early vesicular fraction such as this
particular example, and as a result the approach should be able to provide increased spatial
resolution in for quantitatively studying gene delivery trafficking dynamics.
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Figure 2.8: DGE fractionation pattern for a cell sample processed 40 minutes after delivery with a
PE125 non-viral gene delivery vector complexed with plasmid DNA at an N/P ratio of 20. 10 ug of
total DNA was delivered to the cells at a concentration of 5 ug/mL of HGM.
The fact that the DGE device was able to achieve more than thirteen 380 uL
fractions of separation between the fractions containing the late and early vesicular peaks in
the presence of gene delivery vector provided an added advantage for future experiments as
well. Instead of taking these smaller volume fractions in a conventional 96 well plate, fewer
larger fractions could be taken in a deep well plate and still allow for enough resolution to
separate the two cohorts. This significantly cut down on the amount of samples that had to
be processed for DNA purification and real-time PCR.
In the end, it was determined that twenty four 1.25 mL fractions could be collected
for each run. This accounted for the entire volume of the upper and lower density gradients
and the original sample band volume, and still provided adequate separation between the late
and early peaks. As a result, DNA could be purified from each fraction instead of only
probing alternating fractions. Therefore, with a simple volume correction calculation, all
plasmids were accounted for in actual measurement and could simply be added up to
determine the total number of plasmids in each vesicle type. This method is far less error
prone than probing a few fractions and then devising an integration function to interpolate
the total number of plasmids in each vesicle, which would have been the required method if
a larger number of fractions were required to achieve the desired spatial resolution. This
higher volume also provided enough material to perform these assays in multiplicate in order
to ensure the most accurate measurements possible, while also allowing for enough material
to assay for J-Hex activity in every fraction to provide absolute certainty that the lysosomal
peak separated well in each run and that plasmids were being mapped to proper vesicle type.
A DNA purification protocol was optimized using a high-throughput 96 well plate
format to purify delivered plasmids from four full runs at once. A previously optimized
Taqman primer and probe set and protocol were then used to quantify the number of
delivered gWiz 3-Gal plasmids in each fraction by comparing the cycle threshold numbers of
each sample to a plasmid standard curve. Figure 2.9 shows two example of these
preliminary plasmid mapping experiments, which showed that DGE could be used to
quantitatively track plasmid delivery dynamics in primary hepatocytes.
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Figure 2.9: Quantitative real-time PCR measurement in larger DGE fractions to track plasmid
trafficking A) 40 minutes after and B) 2 hours after trans fection with a PEI 25 vector complexed
with gWiz B-Gal Plasmid at an N/P ratio of 20. 10 ug of plasmid DNA in 2 mL of HGM was
delivered to 2 million hepatocytes for both cases. At 40 mins post delivery, it can be seen that most
plasmids have already trafficked to the late vesicles with a small amount remaining in the early
vesicles. At 2 hours nearly all of the plasmid has built up in the late vesicles and these unescaped
complexed have caused the late fraction to shift lower in the separation column.
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2.3 Optimization of a Scaled-up 3-D Liver Bioreactor
As was discussed in the chapter introduction, the development of a larger perfused
liver bioreactor is necessary to meet the needs of a number of experiments including the
quantitative evaluation of non-viral gene delivery carriers. At the beginning of this thesis
work, a "giant" liver bioreactor was in its nascent stages of development. This new reactor,
seen below in figure 2.10, was scaled up from the previously designed Milli-F reactor using
basic design principles. The giant reactor houses one thousand 300x300x230 um square
channels in its scaffold as compared to the forty channels of the same size in the Milli-F
reactor. Combined with a removable top window to allow for easier and more efficient
seeding, this reactor has the potential to culture on the order of one million cells, which
would meet the sensitivity demands of a number of new assays and experimental strategies.
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Figure 2.10: The scaled up giant reactor next to its smaller predecessor, the original Milli-F reactor.
Design principles and microscopic design parameter considerations to recapitulate
the essential elements of the in vivo liver microenvironment in an in vitro system for the
original Milli-F reactor have been extensively covered in previous work in our lab [161, 162,
171]. Since the giant reactor employs a scaled up array of channels that remain at the same
length scale for each functional channel unit, many of these findings and work carry over to
the new system. This new reactor still utilized a dual perfusion pump system that supplied
the flow of culture medium into the upper and lower reactor chambers to control the flow
rate of the media over and through the channels of the cell containing scaffold, the middle
filter and the bottom support scaffold. Since the channels were the same size of those of the
Milli-F scaffold and there were simply more of them, oxygen and nutrient diffusion
limitations were the same within each functional unit of the reactor. Under the assumption
that the middle filter provided the main resistance to perfusion flow and therefore dictated a
uniform flow rate through every channel, flow rates were linearly scaled up to keep the per
channel flow and residence time in the upper chamber the same as that in the Milli-F.
Initial runs in the new system, however, proved problematic. The increased number
of cells in the system led to a good deal of debris in the fluidic circuit after both seeding and
reversal of crossflow. There also appeared to be recirculation of medium occurring in the
upper flow chamber. These issues compounded in the build-up of pressure in the system.
Peristaltic pumps would break down, and if they were able to continue operating, pressure
would build up enough to crack the silicon scaffolds. The traditionally used inline filters
were unable to handle the debris load after the crossflow change and usually resulted in
prematurely ended runs with no crossflow if the scaffolds didn't crack. It is universally
accepted in past work in our lab that reactors seeded with day three hepatocyte spheroids
should be cultured for an additional 4 days in the bioreactor before liver phenotype and
tissue structure and reorganization have reached a more in vivo like state suitable for
performing assays of interest. Since these new reactors could not consistently reach day
seven of culture post isolation, a number of improvements needed to be made to achieve a
viable system. imaging & spectroscopy
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Figure 2.11: General schematic for the Milli-F reactor fluidic system and reactor pocket
components [160]. Two peristaltic pumps drive the flow of culture medium over the top of and
through an upper cell holding scaffold and a lower support scaffold. A 5 um filter is sandwiched
between the two scaffolds to provide precise and uniform control over the rate of perfusion flow
through the tissue aggregates in the upper scaffold channels and to aid in the retention of cells during
initial seeding, cell attachment to the scaffold walls, and tissue reorganization. The giant reactor
follows the same general scheme with some modifications that will be described in subsequent
sections.
2.3.1 Improvements for the Giant Reactor Culture System
A number of modifications were made to the physical components of the giant
reactor, as well as to the steps of the seeding and maintenance protocols, in order to achieve
a viable scaled up liver surrogate for gene delivery studies and other applications that
required a higher cell number. These improvements are summarized in this section. For a
detailed assembly, seeding and maintenance protocol, please refer to Appendix 6.
1) Materials Changes
A number of new materials and parts were adapted for components of the fluidic
circuit and reactor pocket. One significant problem with the original set-up concerned the
scaffold material and alignment issues of the scaffolds in the reactor pocket. While silicon
wafers with etched channels provided an excellent scaffold for the smaller reactor versions,
they provided a number of problems in the giant reactor. First of all, due to the physical
area of exposure available at the MIT facilities for etching these scaffolds from a master
wafer, only two giant reactor scaffolds could be made at a time (as compared with 30-50
scaffolds at a time for the smaller reactors), making them very costly and tedious to fabricate.
In order to ensure uniform crossflow through the channels, the top, cell containing scaffold
and the bottom, support scaffold need to be perfectly aligned. To accomplish this, scaffolds
were machined with very stringent tolerances to exactly match up with the width and length
of the reactor pocket. Practically, this made it very difficult to insert the scaffolds into the
reactor pocket however. The scaffolds would not match up well with the different gasket
materials used to create a seal between the upper and middle reactor body pieces and the
lower and middle body pieces (It had been much easier to match up and peel off the gaskets
without breaking the scaffolds in the small reactor due to the much smaller aspect ratio of
the original scaffolds). This either broke the scaffolds, or significantly delayed assembly
time. If assembly was successful, the scaffolds would frequently crack due to the
aforementioned pressure buildups.
These problems were solved by moving to polycarbonate scaffolds to seed cells in a
more flexible material that could deal with initial pressure fluctuations without breaking and
also be easier to load into the reactor pocket. Drilling methods did not provide enough
precision for proper alignment, so channel fabrication was performed via laser machining.
Designs for a blocking mask were sent to a laser machining company (J.P. Sercell and
Associates), and different exposure times were tested to assess overall cost with precision. A
longer exposure time at a lower power causes less warping in the polycarbonate and
therefore more precision for alignment, but is also more tedious and costly. Scaffolds were
tested at 16, 23, and 28 minutes of exposure with the appropriate power levels to finish
etching in that span. Alignment holes were also etched in the sides of the scaffold that
would fit exactly over new alignment pins in the reactor pocket. This alignment strategy was
now possible with the more flexible polycarbonate. It was found that all 28 minute scaffolds
aligned well with at least one other scaffold in the group, and roughly half of the 23 minute
scaffolds aligned well in specific pairings. None of the 16 minute scaffolds aligned
particularly well. This approach yielded 8 pairs of usable scaffolds. The scaffolds were easy
to assemble, aligned well in the reactor pocket, and sealed up well with new silicone gaskets.
Changes were also made to the reservoir, tubing, and connectors in order to decrease
pressure buildup and recirculation of debris in the system. Larger diameter connectors were
used to decrease the chances of clogging and the required pressure drop. Similarly, larger
tubing was also used for connecting tubing and peristaltic tubes. The larger peristaltic tubes
also decreased the amount of work the pump had to expend for a given flow rate. This
decreased wear on both the pumps and the tubes. Additionally, the inlet tubes on the inside
of the reservoir cup were shortened such that they would pick up less of the unseeded cells
and debris that would build up on the reservoir floor, thus cutting down on the amount of
debris being recirculated in the system.
Figure 2.12: A) New laser machined polycarbonate scaffolds and silicone gaskets and B) larger
tubing and connectors and shorter inlet and outlet reservoir tubes helped to significantly improve the
performance of the giant reactor.
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2) Improved Flow Chamber Geometry
It was also suspected that simply proportionally scaling up the flow chamber
volumes and inlets and outlets to a lesser extent may have created non-uniform or
recirculating flow in the upper chamber. Computational fluid dynamics simulations were
performed in Femlab to investigate this suspicion. Simulations revealed that flow was
breaking down in the upper chamber and that some recirculation was occurring at the outlet
end of the chamber (see figure 2.13). As a result new geometries were tested in Femlab to
find inlet and outlet designs that would allow for uniform flow over the scaffold array over
the range of velocities that could be used in the new set-up. A new design was settled on
that showed improved uniformity in flow over the cells, quelled high velocities before the
scaffold array, and maintained straight streamlines into and out of the upper chamber (see
figure 2.14).
Figure 2.13: Femlab simulation of fluid flow velocity distribution in the first iteration of the giant
reactor. The original upper chamber geometry in the giant reactor led to recirculation of culture
medium in the upper chamber and complete breakdown of flow at high velocities.
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Figure 2.14: A) Original giant reactor inlet and outlet at left, and improved design at right.
B) Femlab CFD simulation results for the new design, CCW from top: The new geometry results 
in
uniform fluid flow over the scaffold array with high velocity quelled before the 
channel containing
area of the scaffold. Streamlines indicate that no recirculation is occurring, and 
velocity is very
uniform and non-zero just above the cell bed. Reactor body was cut in half for faster computation.
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These modifications appeared to completely resolve recirculation and flow
uniformity issues for the giant reactor. A new prototype was machined to these specs and
evaluated qualitatively using dye tracking experiments, which indicated that flow was indeed
uniform in the upper chamber with no recirculation. As a result, new reactor bodies were
machined in bulk to begin biological characterization. In addition to the inlet and outlet
changes a new top window was also machined with a thicker middle insert that decreased the
upper chamber volume and in turn decreased the residence time for the medium in the
upper chamber, which is advantageous for general culture of hepatocytes in the system as
well as for a number experimental applications for dosing and measurement sensitivity. In
general, with these combined changes, there is fully developed flow in the main chamber
such that all cells in different spatial locations in the channel array see the same conditions at
any given time in culture. The results of this second change and arrival at a final working
system are covered in more detail in Chapter 4.
3) Assembly and Seeding Protocol Modifications
Similar to the optimization for 2-D cultures during DGE characterization, it was
determined that a dried, adsorbed collagen monolayer on the upper scaffold surfaces allowed
for the best cell adhesion and tissue reorganization in hepatocyte seeded giant reactors.
Originally, silicon scaffolds were only soaked in collagen solution for 30 minutes and then
reactors were assembled. This provided adequate cell adhesion, but when the same protocol
was followed for polycarbonate scaffolds, less efficient cell adhesion was observed. The two
materials obviously have different inherent surface properties which can affect the strength
of cell adhesion and ultimately a 2 hour soaking and 2 hour drying regiment for the
polycarbonate scaffolds was found to be optimal.
In all seeding optimization experiments and the majority of future experiments, giant
reactors were seeded with day 3 spheroids to maintain consistency with past experiments in
the Milli-F reactor. For spheroid formation, 30 million primary rat hepatocytes were
cultured in 100 mL of hepatocyte growth medium (HGM, for complete recipe, please see
Appendix 2) in a spinner flask. Flasks were spun at a rate of 84 rpm at 8.5% CO 2 and 37oC
for 3 days. One important rule in giant reactor seeding is to avoid overseeding. A single
giant reactor should not be seeded with more than 2 million cells. It is difficult to count
actual cell numbers in spheroids or to accurately count spheroids themselves and thus some
estimating is necessary. If spheroids are size fractionated between 100 and 300 um in size
for seeding, the efficiency of cell recovery has been estimated to be roughly 2 0%, meaning
that for 30 million cells seeded into a spinner flask, 6 million cells will be recovered in
seedable spheroids. If the size range is extended to between 50 and 300 um in size, then
recovery is closer to 35-40%. This will ensure that roughly 10-12 million seedable cells will
be recovered. The second size range was settled on ultimately, but some initial
characterization runs were performed with the 100 to 300 um size range of spheroids being
seeded. A general rule that should be followed is to seed three reactors per spinner flask for
the 100 um cutoff and 5-6 reactors per spinner flask with the 50 um cutoff.
Seeding is also far more efficient if BSA containing media is used to prime the
system after assembly and is also used to resuspend and seed the recovered spheroids. In
albumin free medium, the spheroids aggregate considerably and reduce the number of cells
that can be pipetted into the channels. With BSA in the medium, it is completely safe to
repeatedly pipette the cell suspension up and down over the scaffold channels with moderate
downward crossflow turned on to ensure the most even seeding of the channels. Some
initial characterization runs were performed with albumin free medium to compare results
and liver phenotype in the system to previous albumin free data in the Milli-F. However,
subsequent experiments described in Chapter 4 use HGM with BSA. Additionally, a
medium and reservoir cup change 2 hours after seeding greatly helps in reducing debris and
extra cells from the system if slight overseeding has occurred. For full details on the
optimized seeding protocol, please see Appendix 6.
4) Maintenance Protocol Modifications
After 24 hours of culture in the reactor, crossflow direction is normally changed.
After seeding, a downward crossflow is maintained at a flow rate of 1 mL/min, or 1
uL/min/channel (which was the same rate used in the Milli-F). This helps to retain the cells
in the channels as they attach to the walls and begin to reorganize. After 24 hours, the
crossflow is reversed to an upward direction at the same flowrate to remove dead and
unattached cells and other debris from the channels. This reversal in cross flow means that
medium is now pumped from the reservoir into the bottom flow chamber. If the freed cells
and debris circulating in the system get pumped into the lower chamber and up against the
bottom of the filter, crossflow can get blocked. To make certain that this perfusion flow is
maintained for the duration of the culture, an in-line filter is placed on the crossflow line
before it gets to the reactor, thereby screening out debris and only sending clean medium to
the bottom chamber.
In the Milli-F reactor, a 25 mm 0.8/0.2 um dual syringe filter disc was placed in the
crossflow line. This filter could last up to 3 days before the risk of clogging arose. With the
increased amount of cells and debris circulating in the giant reactor fluidics, this filter would
sometimes clog in a matter of hours. To resolve this problem, a strategy was adopted where
three different filters of decreasing pore size were placed in sequence in the cross flow line.
A chain consisting of a 5 um filter, a 1.2 um filter, and a 0.8/0.2 um filter (now at a larger 32
mm diameter size) were place in the crossflow line upon flow reversal. Additionally, media
was changed in a new reservoir cup before adding in the filter chain. In the Milli-F, the in-
line filter was added, flow was turned on, and the filters were primed for an hour before
media was change. This was too risky for the giant reactor, so filter chains are primed with
fresh media on a separate pump before adding them to the crossflow line so that the media
can be immediately changed and less debris initially gets stuck in the filters. This new set-up
was able to maintain consistent crossflow with no clogging or leaking for up to four days.
Typically, filters were changed every three days to guarantee no adverse events. It was also
seen that with anything less than the three filters during the first three days after crossflow
reversal, leaking would occur in the crossflow line, indicating clogging and reduced or no
crossflow.
Typically, culture medium was changed just prior to seeding (after priming), at the
time of crossflow change, and every 2 days thereafter. In the case of overseeding, media
could also be changed 2 hours post seeding as was previously mentioned. In general this
equates to a lower medium/cell ratio than that achieved in the Milli-F, since there is an order
of magnitude more cells but only slightly more HGM in the giant reactor. Presently, with
the advent of the new multi-well liver bioreactor system, the giant reactor has an
intermediate medium/cell ratio since the most frequently used iteration of the multi-well
system holds between 500,000 to 800,000 cells per well with an order of magnitude less
medium. Future studies need to be performed to address potential issues that arise from
these discrepancies.
5) Recovery of Cells from the Giant Reactor
As was mentioned in the chapter introduction, another desirable feature of this new
system was to optimize the rapid recovery of cells from the reactor in order to perform
various quantitative assays of interest. Within the context of this thesis work, a major goal
was to optimize cell recovery to quantitatively measure transgene expression after gene
delivery via different vectors to compare efficiencies in 2-D vs. 3-D culture systems.
Depending on speed of recovery and temporal resolution needed for intracellular trafficking
studies, experiments could also be performed to study intracellular trafficking in 3-D as well.
For the brunt of experiments performed in the Milli-F system, either in situ imaging
was performed to probe a fluorescent reporter of interest, or metabolism or general cell
phenotype was measured by probing for molecules in the medium flowing out of the reactor
outlet. In the case that cells did need to be recovered from the reactor, the entire chip would
be removed and submerged in a lysis or recovery buffer, for instance, in the case of RNA
extraction, a scaffold could be removed, submerged in Trizol and frozen. In the case of the
giant reactor, the polycarbonate scaffolds are not compatible with Trizol and can be
damaged by multiple rounds of freezing and thawing. Therefore, it is desirable to find a
method to extract whole cells from the giant reactor channels, pellet them, and then place
them in the appropriate lysis buffer.
A number of methods were examined, including different calcium free buffers,
collagenase, and EDTA buffers. The most rapid method of recovery was obtained with
Dispase, a bacterial analog of trypsin. Reactors could be quickly disassembled with the
upper, cell-containing scaffold placed in a 10 cm Petri dish. Dispase could then be pipetted
on top of the cell array (usually 3 mL per scaffold was sufficient), the plate could be
incubated at 37TC for 5 minutes, and after this brief incubation, cells could be gently pipetted
out of the channels, collected in a centrifuge tube, and spun down (see figure 2.15).
Protocols were optimized for RNA purification and quantification of f-Gal expression via a
delivered reporter plasmid from recovered and pelleted cells.
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Figure 2.15: Incubation in Dispase allows for rapid recovery of tissue from the scaffold channels.
As can be seen at left, addition of Dispase and incubation at 370C for five minutes already loosens
tissue structures from the channel walls, and with gentle pipetting the channels are completely
cleaned.
2.3.2 Characterizing a Functional Giant Reactor System
With all of the initial design problems addressed in the giant reactor, the next step in
characterizing the system was to gauge its ability to foster 3-D liver tissue cultures with more
in vivo like phenotype than conventional 2-D culture systems. Qualitatively, tissue
reorganization and morphology over time were evaluated via light microscopy. The primary
quantitative metric that was used in this evaluation was to measure the mRNA expression
levels of transcripts indicative of liver specific phenotype via RNA purification, cDNA
generation and quantitative real-time, reverse transcriptase PCR. mRNA levels for a number
of cytochrome P450 enzymes, phase II metabolic enzymes, liver specific transcription
factors, membrane transporters and nuclear receptors were quantified in giant reactor
cultures and then compared to in vivo liver slices, isolated hepatocytes, 2-D collagen sandwich
cultures and the Milli-F reactor. Previous microarray experiments had shown this pool of
genes to be the most significantly upregulated in liver tissue versus other tissue types from in
vivo rat samples [160].
These quantitative comparisons of relative gene expression levels provided a good
deal of information. Direct comparison between the two bioreactor systems revealed
whether or not design changes from the scale up significantly affected giant reactor
performance. Comparison of giant reactor transcript levels to 2-D cultures and in vivo liver
slices also allowed a gene by gene assessment of the maintenance of hepatic phenotype in
gauging whether or not the reactor providing a more in vivo-like culture system than the
conventional collagen sandwich cultures, which serve as the current gold standard for in vitro
primary hepatocyte studies [172].
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Figure 2.16: A) Final giant reactor system with peristaltic pumps, fluidics and in-line filters in the
crossflow line feeding the lower chamber. Reactor feet are only used on the outlet end of the reactor
to prevent build-up of air bubbles in the upper flow chamber. B) In situ light microscopy image of
liver tissue structure under optimal seeding and maintenance conditions at seven days post isolation.
Tissue attachment and overall morphology is comparable to that seen in silicon scaffolds and in the
Mlilli-F reactor.
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Figure 2.17: Initial comparison of gene expression levels by relative expression of liver specific
mRNA transcripts across culture systems. All relative fold changes are first normalized the amount
of 18s ribosomal RNA in that sample and then normalized to transcript levels in in vivo liver slices.
Liver slices were submerged in Trizol and homogenized immediately after removal from the animal,
isolated hepatocytes were lysed in Trizol immediately after perfusion isolation, and collagen
sandwiches and both reactor cultures were taken down at day y after isolation and lysed in Trizol.
Please see appendices for detailed RNA purification, cDNA generation, and RT-PCR protocols.
Results for the initial gene expression comparison were promising. The giant reactor
compared fairly well with the Milli-F results, with some genes being slightly more
upregulated/less downregulated than in the Milli-F and others less upregulated/more
downregulated than in the Milli-F. Overall, the expression patterns between the two systems
were comparable, and both systems were less downregulated as compared to 2-D collagen
gel sandwiches at day 7 in culture. Further optimization in the system was now continued to
obtain more efficient seeding and to develop a viable gene delivery and detection protocol.
Further expression analysis on the final iteration of the giant reactor is discussed in Chapter
4.
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2.3.3 Optimizing Transfection Protocols in the Giant Reactor
Initial attempts to perform gene delivery and transgene expression experiments in
the giant reactor were largely unsuccessful. These poor results were traced to the in-line
filters in the crossflow line, which provided a good deal of surface area for non-viral
complexes to adsorb to. A modified protocol was developed where giant reactors were
seeded with day 3 spheroids, crossflow was reversed at 24 hours, and then the inline filter
chain was left in the crossflow line for 3 days. At day 7, the crossflow filter chain was
removed and replaced with a silastic tube. Since the crossflow line was filterless now, the
direction of crossflow was changed back to 1 mL/min downward to prevent clogging the
lower chamber during gene delivery. Non-viral complexes were then prepared following
each vector specific complexation protocol, added to 6 mLs of HGM and added to the
reactor reservoir. DNA was delivered at a concentration of 5 ug/mL to keep conditions
consistent with 2-D transfection protocols, thus allowing for unbiased comparison of 2-D
and 3-D gene delivery efficiencies for a given vector.
HGM with and without BSA was evaluated for transfections. The presence of BSA
in the medium can lead to aggregation and sedimentation of non-viral particles, while its
absence can cause increased adsorption of the particles to the surfaces of the tubing,
reservoir and reactor parts. Empty reactors were transfected with complexes in each type of
medium, and a small volume of medium was taken from the reactor outflow every hour for
the first four hours of delivery. DNA was purified from each aliquot, and the amount of
plasmid DNA copies per unit volume of medium was determined via quantitative Taqman
real-time PCR. Results of this experiment showed that depletion of complexes in the
circulating media was more a function of adsorption rather than aggregation and
sedimentation (see figure 2.18). Reactors transfected with BSA containing medium retained
relatively constant levels of plasmids in the circulating flow, while BSA free replicates all
showed a decrease in circulating plasmids over time. The fact that such a small media
volume was being mixed by inflow to the reservoir by both the outlet tube and the crossflow
line (and that the intake tubes in the reservoir being very close to the floor in these set-ups)
meant that complexes were being retained in the circulated media and didn't stay sedimented
on the floor.
As a result, all future transfection experiments were performed with BSA containing
HGM. Using the modified transfection protocol described above, reactors were transfected
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Figure 2.18: Effect of BSA on the maintenance of constant circulating concentrations of non-viral
particles. Giant reactors assembled and primed with medium with and without BSA were dosed with
PEI25/gWiz P-Gal plasmid non-viral complexes at an N/P ratio of 20. Plasmid concentration was
then measured in the reactor outflow over time via real-time PCR.
on day 7 and taken down on day 9 to measure transgene expression levels 48 hours after
delivery. Cell scaffolds were incubated in Dispase for 5 minutes, collected and pelleted,
resuspended in reporter lysis buffer, and assayed for j-Galactosidase activity levels (see
Appendix 13). Preliminary tests with PEI25 vectors showed detectable levels of gene
expression over controls, paving the way for future studies with next generation vectors (see
figure 2.19).
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Figure 2.19: 3-Galactosidase transgene expression 48 hours after gene delivery of two amounts of
total plasmid DNA. gWiz b-Gal plasmids were complexed with PEI25 at an N/P ratio of 20, added
to 6 mL of BSA containing HGM in each giant reactor reservoir. (-Gal absorbance was normalized
to total protein.
2.3.4 Extension of Polycarbonate Scaffold Machining and Processing
All remaining experiments in this thesis work are performed in the optimized
systems as described above. However one limitation of this iteration of the giant reactor
system lies in the fact the laser machined polycarbonate scaffolds are expensive and aligned
pairs are in low supply in the lab. Additionally, spheroid formation and seeding is still
relatively inefficient in terms of the number of cells that are wasted in reactor seeding. This
will become an important factor when reactor studies are moved to other cell types, such as
human hepatocytes, where cells are usually in scarce supply. Work was performed to look at
solutions for these problems.
In summary, new cooled drilling methods were adapted to successfully reduce
polycarbonate warping. Along with the use of the new alignment hole strategy in the sides
of the scaffold, this greatly reduced alignment issues. By drilling multiple scaffold blanks in a
stack, a batch of ten to twenty scaffolds could be acquired that were completely
interchangeable as top and bottom scaffolds in the giant reactor pocket. The walls of these
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new circular channels obviously had different surface properties due to the new processing
technique, but provided good cell adhesion and are currently being used in another study in
the Griffith lab.
To address the issue of variation in channel surface properties due to different
processing methods or batches, as well as explore methods of single cell seeding to increase
seeding efficiency, a collaboration with the Yannas lab was undertaken to adapt a method to
put previously developed freeze-dried collagen-gag scaffolds within these drilled channels
[173-175]. By forming a flexible and porous strut network of collagen and different
glycosaminoglycans relevant in hepatocyte binding and signaling throughout the channel,
cells could have a consistent scaffold environment to bind to and reorganize without having
to depend on the actual structure and properties of the scaffold wall, be it polycarbonate or
any other material. This could potentially allow for consistency in experiments across
scaffold materials and eliminate dependence on spheroid formation for cell seeding. These
pre-treated scaffolds would also
A method was developed to consistently form these freeze-dried scaffolds within the
drilled channels and sterilize the scaffolds without compromising their structure. Initial
experiments in the giant reactor showed promise for single cell seeding; however, more work
needs to be performed to find a consistent priming method for these scaffolds, since air can
sometimes become trapped in the freeze dried collagen structures and build up during
culture. Some of the progress from these projects is highlighted in figure 2.20.
B)
Figure 2.20: A) Freeze-dried collagen-gag scaffold structure within on the newly drilled
polycarbonate channels. The channel diameter is 300 um, so most features are on the order of 50-
100 um. B) Day 6 tissue structures formed from single cell seeding of rat hepatocytes into a drilled
array of channels with collagen-gag matrix. Cells take over the matrix during the culture and form
nodules of tissue.
A)
2.4 Selection of Vectors for Gene Delivery Studies
While unmodified polyethylenimine (PEI25) vectors served as an excellent first
vector to test for proof of concept studies in trafficking and 3-D transfection assays, they
also posed many problems in the move to primary cell systems. PEI25, the high molecular
weight version of this cationic polymer, has been well studied in in vitro gene delivery
experiments 170, 76, 77, 80, 82, 83, 93, 176], typically in cell lines. In a number of culture
systems and animal models, and even in cell lines, the toxicity of traditional PEI vectors has
been documented [177]. In the primary hepatocyte culture systems used in this thesis work,
especially in the 2-D adsorbed collagen cultures, PEI25 proved to be highly toxic and had a
pronounced effect on the membrane integrity of primary hepatocytes, as discovered by an
LDH release assay that is not typically used in general toxicity screens of gene therapy
vectors. This caused binding and uptake and trafficking experiments in primary hepatocytes
to be highly variable and largely unrepeatable with PEI25. It is important to note that a
lower N/P ratio than 20 may have results in lower toxicity effects, but if this vector were to
be used in future mechanistic studies, it was desirable to keep this ratio consistent with past
cell line studies [132] for a direct mechanistic comparison between hepatic cell lines and
primary hepatocytes. Lowering this N/P ratio would increase particle size and change a
number of the physical properties of the complexes, making mechanistic comparisons
impossible.
These PEI vectors were also highly vulnerable to the presence of BSA in the
medium when used in static 2-D transfections. Without the presence of mixing as is the
case in the reactor systems, these particles sediment onto cells and are taken up via fluid
phase endocytosis. It was seen that in the presence of BSA in static cultures, cells would
aggregate and likely become too large to be taken up into cells, making for vastly different
uptake dynamics in the different medium formulations (see figure 2.22). Displaying serum
stability in the presence of albumin and other serum proteins is a crucial first step in
demonstrating that a vector may have in vivo efficacy. As a result, finding vectors that
perform well in more in vivo like medium formulations was a goal in this work in order to
perform experiments that could study more clinically relevant therapeutics mechanistically.
These issues made it necessary to identify new vectors to use in the final quantitative
trafficking studies.
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Figure 2.21: Toxicity assays to gauge the effect of PEI25 delivery on primary hepatocytes. The LDH
release assay measures general membrane integrity and shows that PE125 is just below half as disruptive as
the addition of a strong lysis buffer for the maximum LDH release case. Total cellular ATP provides a
measure of the overall metabolic health of the hepatocytes, and PEI25 delivery cuts this metric to one third
of that for untreated cells. Cells were dosed with PEI25/gWiz 3-Gal plasmid complexes at an N/P ratio of
20 and a concentration of 5 ug DNA/mL of media.
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Figure 2.22: Plasmids uptake dynamics with a PEI25 vector are highly sensitive to the presence of serum
proteins such as BSA.
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A number of next generation polymers were screened for expression efficiency and
toxicity in primary hepatocytes. These included next generation PEI based carriers
developed in the Klibanov lab, as well as a new class of poly(p-amino ester)s from a polymer
library that was generated in the Langer lab using high throughput combinatorial chemistry
approaches [103-105, 108, 109]. All of these vectors displayed increased efficacy and
decreased toxicity when compared to PE125 in previous studies, and it was a matter of
finding carriers that displayed these desired properties in our primary cell systems as well.
These polymers were used to complex gWiz P-Gal plasmid DNA and transfect primary
hepatocytes. Three assays were performed on each sample at both 4 hours and 24 hours to
gauge toxicity. A traditional MTT' metabolic activity assay and a total cellular ATP assay
gave a metric for the overall metabolic health of the cells, and an LDH release assay gave
information on the integrity of the plasma membrane. For specific toxicity assay protocols,
please refer to Appendix 14. Gene expression was also quantitatively measured at 24 hours
to compare efficacy. Previous to the wide-scale screening, optimal N/P ratios were
determined for maximal gene expression in primary hepatocytes for the linear PEI22 and
cross-linked PEI polymers (data not shown).
Of the panel of polymers tested, the small cross-linked PEI and the poly(f-amino
ester) C32-7 (see figure 2.23) provided the best mix of membrane integrity, high expression
and maintenance of metabolic activity at the early and late time points. A summary slide of
these assay results at 24 hours can be seen in figure 2.24. It was decided that these vectors
would be good candidates to explore mechanistic trafficking differences in comparison with
one another and with adenovirus gene delivery (see chapters 3 and 5). These three vectors
are also compared to traditional vectors such as naked DNA and PEI25 in terms of gene
expression efficiency in 2-D and 3-D cultures (see chapter 4).
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Figure 2.23: Structures of the two next generation cationic polymers to be studied. Small cross-
linked PEI consists of low MW 2 kDa PEI cross-linked together with DSS [108]. C32-7, generally
referred to as C32 in the literature and the remainder of this document, results from the Michael
addition of an amine group with a hydroxylated carbon chain into an ester backbone [103]. Both
molecules contain protonatable amine group that can act as proton sponges in lysosomes and aid in
vesicular escape, but overall structural differences may lead to mechanistic differences in trafficking.
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Figure 2.24: Summary of 24 hour toxicity and gene expression results for candidate PEI based
vectors and poly(O-amino ester)s C32-7, 52, 36, and 32. Cells were dosed with 5 ug/mL at the
indicated N/P ratios for the PEIs and at a polymer/DNA mass ratio of 100:1 for the poly(P-amino
ester)s.
Interestingly, similar screens were performed in Cos-7 and HepG2 cell lines in
preparation for a high throughput uptake and expression study for a number of C32 and
other poly( 3-amino ester) variants, and these cells were largely insensitive to the toxic effects
of the different polymers. LDH release levels were three to four fold lower in these cell lines
than they were in primary hepatocytes for the same vectors and metabolic activity was fairly
constant in all cases (data not shown). Additionally, the 36 poly(p-amino ester) vector
studied above was inefficient in primary hepatocytes, yielding gene expression levels barely
above the untreated control cases, but was highly efficient in both Cos-7 and HepG2
transfections [178]. These findings reinforce the importance of moving vector screening
into primary cells and into the specific cell type of interest for analyses that can truly reveal
whether or not a vector could perform well for a clinical indication of interest.
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Chapter 3
A Density Gradient Electrophoresis Approach to Quantitatively Measure
Intracellular Trafficking of Non-viral Therapeutics
3.1 Introduction
For a gene therapy vector to be successful, a transgene must be safely delivered to
the nucleus and lead to therapeutic levels of gene expression without any dangerous side
effects. Recombinant viral vectors are the current gold standard for attaining highly efficient
gene transfer and expression, but carry along with them certain risks and limitations. While
non-viral vectors look to offer a safer alternative with enhanced versatility, these synthetic
vehicles fail to achieve levels of expression or delivery efficiency to be considered as viable
clinical options in most cases.
In order for efficient transfection to be accomplished, a non-viral vector/plasmid
complex must overcome a number of barriers on its way to the nucleus [112, 113]. In
general, a majority of past research on both viral and non-viral fronts has been of a more
clinical and qualitative nature. Quantitative or mechanistic studies would mainly focus on
overcoming one barrier at a time and merely evaluate resultant gene expression levels and
duration for some dosing level of a given viral or non-viral formulation. In the case of viral
vectors, which have evolved complex mechanisms to efficiently surpass all of these barriers,
this methodology can still yield some useful outcomes. However, in the context of non-viral
vectors that must be designed from the ground up to overcome each barrier, this approach
can be detrimental and inefficient. Changing the physical properties of a vector may be
favorable for one barrier, but actually hinder overall efficiency by making it more difficult to
accomplish another step in the delivery process. Past work has shown binding and
internalization at the cell surface [120, 121], endosomal escape [122-124], transport in the
cytoplasm [116, 125], nuclear import [126-131], and vector unpackaging [118] to all be
potentially rate-limiting steps in the delivery process. The most important message to take
away from these conclusions is that the rate-limiting step and significance of other major
barriers can depend heavily on the specific vector/plasmid complex used and the particular
cell type being studied.
Quantitative and systematic studies of gene delivery can be advantageous to tackle
this multiple-barrier scenario [113, 132, 179-182]. Past work has shown that taking a
computational modeling approach combined with quantitative experiments for gene delivery
analysis can provide a powerful predictive tool for gene carrier development and refinement
[113, 181]. Fitting mathematical models to quantitative data can allow for unbiased analysis
that can generate insights about the data that is not readily appreciated by crude inspection
of individual time courses or end point analyses. This can immediately drive new hypotheses
as to why a vector is or isn't successful, while also allowing for more intelligent design of
future investigations.
One setback that hinders these efforts is the lack of tools that can provide rich
quantitative data with the spatial and temporal resolution needed to build truly accurate and
informative models. As a result, many analyses tend to lump multiple intracellular processes
into single steps and multiple organelles into a single compartment. While model fits can
then be more accurate and or true to what little quantitative data can be acquired, overall
conclusions usually can't pinpoint what is specifically important in the overall process for a
given vector. The multiple delivery steps that occur in the endocytic vesicles and cytosol are
often a victim of these lumped approaches. Imaging can provide some information to help
in understanding intracellular trafficking and nuclear import [181, 183]. However, imaging
approaches are usually semi-quantitative at best and it is difficult to discriminate between
organelle types without sophisticated labeling techniques which hinder analysis throughput.
They also measure phenomenon on a cell by cell basis and don't always reflect what is truly
going on in the population of cells as a whole. Approaches are needed that compliment
these imaging techniques and provide quantitative data on a populational level.
We have developed a subcellular fractionation method employing an improved
density gradient electrophoresis (DGE) device based on past work that demonstrated the
ability of this approach to separate the organelles important in gene delivery uptake and
trafficking [142, 147, 148, 184]. This method is completely preparative and allows for
quantitative measurement of delivered plasmids not only in these organelles, but also in
whole cell, nuclear, and cytoplasmic fractions of the same sample, allowing for data sets with
enhanced spatial resolution. Past studies have developed rigorous methods to quantitatively
monitor vesicular trafficking, but were unable to extend measurement to other
compartments [94, 135].
DGE exploits differences in the charge and density properties of different organelles
in the same dimension, allowing for separation of organelle subpopulations while also
making for highly efficient collection and measurement of these organelles. More
conventional methods such as density gradient centrifugation or free flow electrophoresis
are either tedious or costly and perform separations based on either density or charge
differences alone [143]. As a result, these techniques cannot easily separate endosomal
subpopulations or robustly deal with the slight intrinsic variability of each vesicle type, while
requiring multiple runs on the same sample to achieve the same number of fractions with
high resolution, causing sample loss between steps and making it difficult to be truly
quantitative [143, 144]. Meanwhile, microfluidic bioseparation devices have shown proof of
principle to sort vesicular organelles with excellent resolution, but don't yet provide efficient
recovery methods or enough material to support presently available downstream assays [145,
185, 186]. DGE has the potential to handle cell numbers that satisfy the sensitivity demands
of current assays to faithfully map organelle separation patterns and measure plasmid
delivery.
Furthermore, a goal in this work is to move studies to more clinically relevant
experimental systems. Quantitative work in cell lines is more repeatable and potentially
easier to perform with greater throughput, but screening new vector chemistries in these
systems may not correlate well with results obtained in animal models, which do not lend
well to quantitative analysis, or the ultimate clinical application. Here, we show proof of
concept for this approach to separate the vesicular organelles in primary liver cells that are
important in the trafficking of gene therapy vectors. This work is then extended to a next
generation Poly(P-amino ester) non-viral vector, C32 and an enhanced polyethylenimine
vector, small cross-linked PEI. These cationic polymers have previously been shown to be
highly effective next generation synthetic vehicles [103, 105, 108], and we explore the
potential for this DGE approach to quantitatively study the dynamics of the vesicular
trafficking of these carriers in order to glean further mechanistic insight into their success as
gene delivery agents.
3.2 Materials and Methods
3.2.1 DGE Device and Peripheral Set-up
The DGE device was machined from a cylinder of poly(methyl methacrylate)
(PMMA). All peripheral components for the device such as the loading cone, electrode
holders, clamps and custom gradient mixer were also machined from PMMA. Custom
electrodes were machined from platinum and palladium to have the same diameter as the
separation column, thereby ensuring the most uniform current density. Peristaltic pumps
(Instech Laboratories, Plymouth Meeting, PA) were used to constantly replenish the upper
and lower chambers with fresh buffer. Silicone O-rings, clamps, tubing and connectors were
purchased from McMaster Carr, USA. A cellophane membrane (Amersham Biosciences,
USA) separated the lower buffer chamber from the separation column, allowing for
hydrodynamic but not electrical isolation of the column. A computer controlled syringe
pump (Harvard Apparatus, Holliston, MA) was used in tandem with the gradient mixer to
load and elute the column contents. A standard electrophoresis power supply in constant
current mode (Bio-Rad Power Pac 300, Bio-Rad, USA) was used to drive the migration with
current levels monitored by an ammeter. The column was set-up on a vibration isolation
platform (Kinetic Systems, Boston, MA) in a 4oC cold room to minimize the effects of
thermal fluctuations and vibrations in the column.
3.2.2 Primary Cell Isolation and Culture
Primary cells were isolated from male Fisher rats weighing 150-180 gm using a
modified version of the Seglen 2-step collagenase procedure as previously described [161,
162]. Blendzyme Type III (Roche, USA) was used for digestion instead of collagenase. Cells
that were released by the digestion were suspended in DAG (DMEM (Sigma-Aldrich, USA),
Albumin, Gentamycin) and spun and washed twice at 50g for 3 minutes. The final pellet
was resuspended in HGM, as described previously [161, 162, 187], to yield a 95% or greater
pure suspension of hepatocytes. The final cell viability was determined by trypan blue
exclusion, and cells were only used if viability was in the 89-95% range. Cells were seeded in
60 mm tissue culture dishes treated with a dried adsorbed collagen monolayer. Collagen type
I from rat tail (BD Biosciences, Bedford, MA) was diluted in sterile 1x PBS at a
concentration of 30 ug/mL. Plates were incubated with 3 mL of this solution for 2 hours,
then aspirated and allowed to dry in a sterile hood for two hours prior to seeding. Cells were
seeded in 3 mL of HGM at a density of 800,000 cells/mL immediately after isolation.
Medium was changed 4 hours post-seeding to eliminate dead and unattached cells and
debris, while ensuring 90-95% confluency. All experiments were performed within 24 hours
of seeding to ensure the best maintenance of hepatocyte phenotype.
3.2.3 Cell Labeling and DGE Fractionation of Primary Hepatocytes
Cells were placed on ice to halt endocytosis and washed once with cold PBS++ (1x
PBS with 1 mM MgC1, and CaC1). Pre-warmed HGM containing 2 mg/mL horseradish
peroxidase (HRP) was added to the cells and the dish was returned to 370C for 4 minutes.
Cells were returned to ice, washed again, and given unlabelled medium for 15 minutes at
37oC to chase the first HRP pulse into the late endosomes. Cells were then returned to ice,
washed, and pulsed with HRP for an additional 3 minutes to label early endosomes. Cells
were then returned to ice, washed, and scraped and collected in 3 mL of hypotonic DGE
buffer (250 mM sucrose, 10 mM acetic acid, 10 mM triethanolamine, and 1 mM Na EDTA).
Cells were placed on ice briefly and allowed to swell and were then mechanically lysed by
passing the suspension through a 21G x 2 inch needle 12 times. Lysis was evaluated to be >
98% efficient with no whole cells typically visible and nuclei left fully intact. This
mechanical lysis technique eliminated the need for detergent based lysis buffers and allowed
for rupture of the plasma membrane while keeping all other organelles of interest intact.
Nuclei were spun out of the suspension, and the supernatant was treated with trypsin for 6
min at 37oC and then returned to ice. Trypsin inhibitor and the protease inhibitors
aprotinin, leupeptin and PMSF were added to the lysate. The lysate was spun for one hour
at 100,000g to recover all organelles. The organelle pellet was resuspended in 0.5 mL of 6%
Ficoll (Amersham Biosciences, USA) in DGE buffer and was layered in the DGE column
between a lower linear density gradient of 6 mL ranging from 10% -7% Ficoll, and an upper
linear density gradient of 25 mL ranging from 5%-0% Ficoll. Migration of the organelles
was driven by an electric potential at 10.6 mAmps and 300 volts for 80 minutes in constant
current mode. The top electrode was replaced by a cone and tube to elute off the column
contents into a multiwell plate at the desired fraction volume. All reagents were purchased
from Sigma-Aldrich, USA unless otherwise noted.
3.2.4 DGE Fraction Mapping Assays and Western Blotting
Fractions were assayed in a multiwell format to determine the location of the
organelles of interest after the separation. HRP activity was determined by mixing 100 uL of
each fraction with 200 uL of an O-dianisidine substrate reagent. Samples were incubated for
1 hour at room temperature and absorbance was read at 455 nm. P-Hexosaminidase, an
endogenous enzyme in lysosomes, was assayed by adding 150 uL of a P-nitrophenyl-N-
acetyl-p-D-glucosiminide substrate reagent to 60 uL of each fraction. Samples were
incubated at 370 C for 1 hour, the reaction was stopped by adding 90 uL of a 2 M glycine
buffer at pH 10 and absorbance was read at 405 nm.
Western blots were performed by labeling and fractionating cells by DGE and
identifying the fractions which contained late endosomes and lysosomes by the HRP and [-
Hex peaks. These fractioned were pooled together and spun at 100,000g for 1 hour to re-
pellet the intact, separated organelles. The organelle pellet was resuspended in sample
buffer, run on a 7.5% SDS-PAGE gel (Bio-Rad, USA) and transferred to a Sequi-Blot
PVDF membrane. The membrane was blocked with non-fat dry milk and incubated with
primary antibodies anti-EEA-1 (Mouse IgG, BD Biosciences, Bedford, MA) or anti-Rab9A
(Goat IgG, Santa Cruz Biotechnologies, Santa Cruz, CA) overnight at 40C at a dilution of
1:250, and in the appropriate HRP-conjugated secondary antibody (Santa Cruz
Biotechnologies, Santa Cruz, CA) for 1 hour at room temp at a dilution of 1:2,500. Blots
were developed by adding 1 mL of Western Lightning reagent (Perkin Elmer, Boston, MA)
and imaging on a Kodak developer (Kodak, Rochester, NY).
3.2.5 Plasmid, Polymers, and Non-viral Complex Formation
Plasmid gWiz-3-Galactosidase (Gene Therapy Systems, San Diego, CA) encodes the
enzyme P-galactosidase controlled by the human cytomegalovirus (CMV) promoter. The
plasmid DNA was purchased purified and ready for use from a contract plasmid
manufacturing company (Aldevron, Fargo, ND). 25kD PEI was purchased from Sigma-
Aldrich (St Louis, MO). The C32 and small cross-linked PEI polymers were synthesized as
described previously [103, 104, 108].
For transfection via PEI25, polymer and DNA were diluted to the appropriate
concentrations in sterile water and combined at an N/P ratio of 20. Polymer was added to
DNA and left at room temperature for 20 minutes to allow for formation of complexes.
For C32, polymer and DNA were diluted in sterile filtered sodium acetate buffer, pH 5.4,
and combined at a polymer mass/DNA mass ratio of 100. For the cross-linked PEI,
polymer and DNA were diluted in sterile water and were mixed at room temperature for 10
minutes at an N/P ratio of 30. All complexes were added to HGM at a DNA concentration
of 5 ug/mL. Non-viral particle size was determined via dynamic light scattering using a
ZetalALS Zeta Potential Analyzer with ZetaPALS Particle Sizing Software Version 2.3
(Brookhaven Instruments Corporation, Holtzville, NY). Number averaged particle
diameters were determined over a lognormal distribution for each PEI vector/plasmid
complex. The 25kD PEI complexes measured 228.3 ± 47.6 nm in diameter, the C32
complexes were 152.0 ± 4.2 nm, and the cross-linked PEI complexes were 167.5 ± 8.2 nm
in diameter.
3.2.6 DNA Isolation and Taqman Quantitative PCR
Plasmid DNA was purified from each fraction of a given DGE run using the
DNEasy 96 Tissue Kit (Qiagen, Valencia, CA). Plasmid quantification was performed using
the MJR Chromo 4 (Bio-Rad, USA). P-Galactosidase plasmid forward and reverse primers
and probe were designed using Primer Express Software (Applied Biosystems) and yielded
sequences for forward primers, reverse primers, and dual labeled probes. Two sets of
forward and reverse primers with probe were ordered and tested for optimal efficacy, as
determined by widest spread of linear standard curve range and steepest slope of standard
curve (Applied Biosystems, Foster City, CA). The resulting primers and probe spanned an
80bp region in the P-Gal coding region of the plasmid and had sequences: forward primer
(5'-TITA CAG GGC GGC TTC GTC T-3'), reverse primer (5'-TAA GCC GAC CAC GGG
TTG-3'), and dual labeled probe (5'-6FAM-CTG GGT GGA TCA GTC GCT GAT TAA
ATA TGA TG-TAMRA-3), used at concentrations of 400nM/400nM/25nM, respectively.
PCR cycle conditions were 500C for 2 min, 950 C for 10 min, followed by 40 cycles of 950 C
for 15 s and 60 0 C for 1 min. In order to normalize samples to a per cell basis, genomic
DNA was also purified from a whole cell sample from each DGE run. Taqman primers and
probe were similarly designed to quantify the rat GAPDH gene which spanned an 80bp
region with the following sequences: forward primer (5'- TGG GAT AGC CAG TGC TCT
TA -3'), reverse primer (5'-ACA GGA GAT GGG TTG GAA CT -3'), and dual labeled
probe (5'-6FAM-TGA GCC ATC ATC ATC TCC GCT G-TAMRA-3'). The primers and
probe were used at concentrations of 900nM/900nM/225nM, respectively. PCR cycle
conditions were 500 C for 2 min, 950 C for 10 min, followed by 40 cycles of 950 C for 15 s and
54 0C for 1 min.
3.2.7 Transfection and Trafficking Assays
Cells were washed and complexes were added in 2 mL of HGM at 5 ug DNA/mL.
At the post-delivery time point of interest, plates were removed from 37oC, placed on ice to
halt endocytosis and subjected to the DGE collection, lysis prep, and separation protocol
without HRP labeling. DGE fractions were assayed for [-hexosaminidase activity to
determine the location of the late vesicles (since late endosomes and lysosomes were found
to colocalize on the column when transfected with these gene delivery vectors). Real-time
PCR was performed on each fraction, and plasmid quantities in the fractions corresponding
to the late vesicles were summed and normalized to the cell number as determined from the
rat GAPDH amplification and comparison to a standard curve. Similarly, the smaller
plasmids peaks that were measured to the right of the late vesicle peak and were negative for
P-hexosaminidase activity were summed to determine the amount of plasmids in early
endosomes for each time point. Triplicate runs were performed at each time point to build
the late and early vesicle trafficking time course. To determine nuclear localization of
plasmids, nuclei were spun down at 1000g after cell samples were lysed for DGE run
preparation. Nuclear pellets were frozen, resuspended in PBS and purified for plasmid and
genomic DNA as described above, and subjected to Taqman real-time PCR for plasmid and
cell number quantification.
3.3 Results
3.3.1 An Improved Density Gradient Electrophoresis Device
A DGE device was designed and built based on work by Tulp and coworkers that
reported an early prototype which showed the potential for high resolution separation of
cellular organelles and laid the ground work for the empirical and theoretical principles of
device design and operation [142, 147]. Figure 3.1A shows a schematic of the assembled
device, which consists of a separation column that is surrounded by an upper and lower
buffer chamber that contain custom machined platinum and palladium electrodes. Cell
lysates are layered onto the column between lower and upper linearly varying density
gradients of Ficoll. Migration of the organelles is driven by an electric potential under
constant current conditions, which ensures constant migration speeds of the various
organellar cohorts at a given position in the column and allows different organelle types to
migrate up or down the column as tight horizontal bands. Different cohorts will experience
differential acceleration as they escape from the initial sample band from buoyancy effects
and electromigration due to the fact that different organelle types have different density and
charge characteristics [142]. After an electrophoresis run of 40-80 minutes, multiple
organelle bands separate to different vertical locations in the column. Since separation is
performed in only one dimension, organelles can be easily collected by eluting the column
contents into fractions of a given volume, which is dictated by the desired resolution.
Therefore, this approach is completely preparative and allows for multiple assays to be
performed on intact organelles in the collected fractions.
The device body and peripherals were machined following the same design principles
as the earlier device (see figure 3.1B for a detailed description of components). In order to
obtain potentially higher resolution separations, the new device was designed to be 70%
larger overall with significantly more usable column length than its predecessor. A limitation
to the old device lied in the fact that there was only 6 cm of usable length in the separation
column. While other improvements had allowed for longer runs in the range of 60-100
minutes in this prototype, large density gradients could not be layered to take advantage of
this and achieve better separations. Our new prototype has a usable column length of over
11 cm, which can potentially maximize the potential for differential acceleration and overall
separation distance between different organelles, while also being within suitable size limits
such that band broadening of organelle cohorts over time does not significantly affect
resolution [142]. A custom gradient mixer was also built that allows for linear density
gradients of up to 35 mL to be carefully layered onto the separation column. This provides
more freedom in optimizing gradient lengths and concentrations as well as run parameters to
achieve the best possible separations for the organelle and cell types of interest, in this case,
endosomes and lysosomes in primary rat hepatocytes. New device peripherals such as a
computer controlled syringe pump and a vibration isolation platform were also integrated in
the current set-up to allow for more consistent results with the best possible resolution for
the given run conditions.
3.3.2 Subcellular Fractionation of Primary Hepatocytes
A large panel of gradient lengths and ranges, run conditions, and cell collection and
lysis steps were examined in order to find the optimal set of conditions for endosome and
lysosome fractionation for primary rat hepatocytes. The best results were obtained when
500 uL of the processed organelle suspension was layered between a lower Ficoll density
gradient of 6 mL varying from 10-7% Ficoll and an upper gradient of 25 mL from 5-0%.
Organelle migration was driven for 80 minutes at a constant current of 10.6 mAmps, and 85
fractions were collected in 380 uL increments and assayed for organelle distribution (see
figure 3.2). Prior to lysis and fractionation, hepatocytes were subjected to a pulse chase pulse
routine with horseradish peroxidase (HRP) to label both early and late endosomes. An
endogenous marker enzyme for lysosomes, j-hexosaminidase (P-Hex), provided an assay
target for these vesicles. The late endosomes (leftmost HRP peak) and lysosomes migrate
significantly further up the column than early endosomes, with the late endosomes localizing
to fractions 21-47 and the primary lysosomal peak at fractions 37-49. The lower shoulder on
the left side of the lysosomal peak has been shown to be maturing P-Hex with lower levels
of activity in late endosomes and endoplasmic reticulum compartments [142, 170]. Both of
these cohorts are significantly separated from early endosomes, which localize in fractions
63-71. This separation pattern has been found to be repeatable for cell loads of up to 1 mg
of lysate total protein, allowing for fractionation of up to 4 million primary hepatocytes.
To confirm that the HRP peaks did in fact represent two homogeneous endosomal
subpopulations, fractions 21-47 were pooled together and subjected to ultracentrifugation to
repellet the separated organelles. The organelle pellet was resuspended in sample buffer and
subjected to western blotting with primary antibodies specific to late (anti-Rab9 GTPase)
and early endosomes (EEA-1, early endosome antigen 1). The pelleted organelles gave a
strong Rab9 signal and no EEA-1 signal, denoting a pure population of late endosomes in
these fractions (see figure 3.3). To reinforce these findings, cells were also labeled with a
single HRP pulse followed by a chase with unlabeled medium or with a single short pulse
with no chase to label only late or early endosomes, respectively. In both cases, a single
HRP peak resulted in the appropriate location (see Figure 3.4).
With excellent separation between late and early vesicles and the ability to separate
late endosomes and lysosomes further if desired by optimizing runs with slightly longer
gradients or run times and smaller fractions, it remained to be seen if the introduction of
charged gene delivery complexes would significantly deflect the fractionation pattern. To
explore this question, primary hepatocytes were transfected with cationic polymer/plasmid
complexes and simultaneously labeled with HRP as previously described with the same
concentration of non-viral complexes in the pulse and chase media. While there was a small
degree of broadening of the peaks overall, and the build-up of complexes in late endosomes
and lysosomes caused these vesicles to co-localize more significantly and shift slightly
downward in the column, DGE fractionation still provided excellent separation of late and
early vesicles (see figure 3.5). Since DGE fractionation resulted in over 11 380 uL fractions
of separation between early and late vesicles, much larger fractions could be taken with the
desired resolution still achieved in future trafficking studies.
3.3.3 Quantitative Non-viral Trafficking Studies
To quantitatively evaluate the vesicular trafficking dynamics of the C32 poly(P-amino
ester) and small cross-linked PEI vectors, multiple DGE runs were performed on
transfected hepatocytes at different time points after administration of the complexes.
Hepatocytes were placed on ice to halt endocytosis, lysed and fractionated at 10, 20, 40, and
60 minutes after transfection. Separated organelles were collected in 24 fractions of 1.25
mL. DNA was purified from each fraction, and the amount of delivered plasmids per
fraction was determined using Taqman real-time PCR. Plasmid numbers were then
normalized to a per cell basis by performing Taqman real-time PCR for rat GAPDH
genomic DNA copies from a whole cell aliquot from each replicate. Data was then
compared to P-Hex mapping of the fractions (Figure 3.6), and the appropriate late vesicle
containing fractions were summed to acquire the total number of plasmids present in late
endosomes and lysosomes.
Figure 3.6A shows representative per cell plasmid distributions over the collected
DGE fractions at each time point for the C32 vector. Plasmids have already trafficked to the
late vesicles within 10 minutes of delivery and build up significantly at 20 and 40 minutes.
With each ensuing time point up to 40 minutes it can be seen that the vesicles become
denser due to the build-up of complexes in these vesicles and the late vesicle localized
plasmids shift slightly lower in the column. By 60 minutes after transfection, significantly
fewer plasmids are detected and the peak localizes back to a higher position in the column.
A clearer picture of the quantitative trafficking time course in early and late vesicles
can be seen when late vesicle negative and positive fractions are summed for each replicate
and averaged together (see figure 3.7). Both vectors show a similar trend in early vesicle
dynamics, though more plasmids seem to be delivered or accumulated in these
compartments for the PEI vector. The C32 vector shows dynamic entry and exit of
plasmids in the late vesicles with nearly 1,000 plasmids per cell trafficked into these
compartments by 10 minutes, and a peak of over 1,500 plasmids per cell in these vesicles is
reached by 20 minutes. After this point, processes such as endosomal and lysosomal escape
as well as degradation can lead to the decreasing trend that is seen in the data. Conversely,
the cross-linked PEI vector demonstrates a more linear trafficking profile in the late vesicles,
and steadily builds up to nearly 12,000 plasmids per cell at 1 hour post delivery, suggesting
potentially different uptake and escape kinetics at these delivery steps.
While these vectors demonstrate different vesicular kinetics for the same dose of
plasmid DNA, they do ultimate result in nearly identical delivery of plasmids to the nucleus.
Each carrier achieves greater than 100,000 plasmids per cell at or in the nucleus at 1 hour
post transfection (Figure 3.8). Once again, the C32 vector appears to deliver its DNA
payload faster than the cross-linked PEI vector, which shows a more gradual nuclear delivery
but achieves the same degree of overall efficiency over the time span studied in this work.
3.4 Discussion and Conclusions
Quantitative and systematic approaches to studying non-viral gene carriers can offer
a good deal of insight into why vectors are efficient or inefficient at a mechanistic level.
Monitoring dynamic uptake and intracellular delivery processes in various quantitative and
semi-quantitative experimental formats can answer many questions regarding these physical
steps. However, in this complex multi-step delivery process, coupling systems level analysis
with these approaches can result in additional information and conclusions not apparent
from experimental observation alone. Fitting mathematical models to quantitative data sets
is particularly useful in this context. Models can reveal delivery steps that are not intuitively
rate limiting by visual inspection, but actually play a crucial role in successful nuclear delivery
and transgene expression for a specific vector chemistry in the cell type of interest. Model
analyses and simulations can drive mechanism based development of next generation
carriers by generating new hypotheses for the intelligent design of vectors, and can also
account for the effects that a potential change could have on all or many delivery steps and
the ensuing degree of overall success.
However, for a model to be instructive, it must be trained with the right information
and with accurate information. One of the major current limitations to these systems level
approaches is the lack of tools that can provide rich, quantitative data sets at the intracellular
level. We have developed a density gradient electrophoresis (DGE) approach that allows for
the quantitative analysis of intracellular trafficking in primary liver cells. The liver plays a
number of highly important roles in systemic in vivo gene therapy [151, 152, 154, 156, 158],
and it hoped that with assay development in primary hepatocytes, quantitative data can be
generated which will contribute to future models that can better reflect how a vector will
perform in clinical application.
We have developed an improved DGE device that allows for the separation and
recovery of the cellular organelles important in gene delivery (Figure 3.1). This device was
based on past work that showed excellent proof of principle for high resolution organelle
fractionation in a human melanoma cell line [142]. DGE provides a number of advantages
over other currently available approaches. Other widely used subcellular fractionation
techniques are unable to perform one step separation of endosomal subtypes, and usually
require centrifugation or flow routines that can last on the order of 12 to 24 hours and result
in sample loss. By exploiting both charge and density differences in the same dimension, our
device is able to separate organelles from cell lysates in 80 minutes while allowing for easy
sample collection in less than 10 minutes. Other approaches that utilize two modes of
separation usually do so in two dimensions, which complicates sample collection for
quantitative assays, and these methods usually use substrates that make it impossible to
separate large intact organelles. Buffers and reagents used in this DGE method are
completely compatible with downstream techniques such as DNA purification and western
blotting, and this device is able to process cell quantities that meet the sensitivity demands of
currently available assays such as real-time PCR. Additionally, the sequential processing
steps in our approach allow whole cell, nuclear, and cytoplasmic fractions to be collected in
addition to the vesicular organelles from the same sample. This allows for quantitative
measurement of the comprehensive cellular distribution of delivered plasmids.
Modifications made in our new device have allowed for more flexibility in optimizing
separations for different cell types and for increased precision, repeatability, and overall ease
of use. Cell lysis, lysate processing, and DGE run conditions have been optimized for
primary rat hepatocytes to achieve excellent separation of late and early vesicles involved in
non-viral complex uptake and trafficking. Cell labeling techniques and western blotting were
performed to confirm repeatability of the fractionation pattern and separation of specific
endosomal subtypes (Figures 3.2, 3.3, and 3.4). Late endosomes migrate upward in the
column (towards the positive anode) slightly faster than lysosomes and both organelle types
separate significantly from early endosomes.
Characterization of the device was extended to gauge separation ability for non-
virally transfected cells. Cationic complexes have the potential to change both the charge
and density characteristics of organelles and could therefore significantly alter the
distribution of organelles in the column. Delivery of cationic PEI25 complexes decreased
the upward migration of the late endosomes and caused minor broadening of the organelle
peaks (Figure 3.5). However, excellent separation was still attained between late and early
vesicles. Intensity of the late vesicle HRP peak relative to the early peak was diminished.
This was most likely due to the fact that the PEI complexes were escaping from these
vesicles and causing leakage of HRP into the cytosol.
For the particular application of separating and collecting late vesicles to measure
vector trafficking, the DGE device provided more than enough resolution with the
previously optimized conditions, such that fraction size could be significantly increased.
Early and late vesicles could still be separated and collected, but with significantly fewer total
samples to assay. This made quantification of delivered plasmids in a given organelle
fraction more experimentally feasible for multiple vectors and time points. DNA
purification and real-time PCR, as well as organelle mapping, could be performed on every
fraction due to the increased amount of material in each fraction and decreased number of
overall samples. Simply summing the relevant fractions for a total vesicular plasmid amount
could now be performed, rather than relying on integration methods that estimated total
plasmid amounts from a subset of fraction measurements or by mixing adjacent fractions,
which would have introduced more uncertainty and error into the quantitative
measurements. This proof of concept paved the way for more in depth studies of vector
trafficking for next generation non-viral therapeutics.
C32 is a next generation cationic vector that has been shown to be the most efficient
non-viral delivery agent from a new combinatorial chemistry library of polyP3-amino ester)s
[106]. Small cross-linked PEI has also demostrated enhanced transfection ability over
traditional PEI vectors while offering lower overall toxicity [108]. In our primary hepatocyte
culture systems, these vectors yielded highly efficient transfection levels and reduced toxicity
as compared to more traditional vectors such as PEI25 (data not shown). We extended a
more in depth analysis utilizing DGE fractionation and DNA quantification via Taqman
real-time PCR to study the dynamic trafficking of plasmids in late vesicles via C32
transfection. Hepatocytes were transfected with C32 complexes and were lysed and
fractionated at 10, 20, 40 and 60 minutes after transfection. Larger 1.25 mL fractions were
collected from the DGE column after the run, making it possible to purify DNA from every
sample and perform triplicate real-time PCR to accurately quantify the amount of plasmid in
each fraction of every replicate.
Representative DGE column distributions at each time point already give some hint
to the trafficking dynamics of the vectors, as is detailed for a series of C32 replicates (Figure
3.5). Plasmids are rapidly trafficked into the cell, with a significant of amount of plasmids
already detected in the fractions specific to late vesicles. Plasmids build up in these late
compartments significantly at 20 and 40 minutes, and due to this accumulation, cause the
prominent late vesicle peaks in the DGE column to shift downward slightly. This is most
likely due to an increase in organelle density from the presence of the particles, though the
positive zeta potential of the particles can lessen the overall negative charge of the organelles
and lessen electromigration towards the anode. However, it is thought that the lipid bilayer
of the organelles buffers the charge effects of the particles and that a change in peak location
is mainly caused by density effects. By 60 minutes post delivery, a decrease of peak height is
seen and the peak shifts upward in the column. Endosomal and lysosomal escape of C32
complexes is the most plausible explanation for this combined decrease in magnitude and
upward shift and lends merit to the hypothesis that increased density caused this shift more
than a change in zeta potential. If a decrease and shift is seen, it is thought that the decrease
in magnitude in late vesicle plasmids is more due to endosomal escape for this vector and
less to vesicular degradation, since significant degradation and minimal escape would have
retained similar contents and overall charge inside the vesicles and should have resulted in
similar column distribution. Additionally, the tighter fraction distribution of the plasmid
peaks at 40 and 60 minutes potentially suggests vesicles with a more homogeneous
distribution of complexes within the vesicles or a more pure population of a given late
vesicle subtype, denoting that some vesicles were more likely to allow escape earlier on and
others required more build-up of complexes before escape could be possible. Since the C32
polymer is thought to utilize the proton sponge mechanism for escape from late endosomes
and lysosomes, this makes mechanistic sense. For instance, more acidic lysosomes may
allow for faster vesicle swelling and rupture due to increased activity of ion pumps and water
channels, leaving behind less acidic late endosomes that require a higher build-up of polymer
before vesicle escape can occur. Conversely, complexes may build up to level significant for
escape sooner in late endosomes than in lysosomes, allowing for some early rupture of late
endosomes before fusion and progression to lysosomes. Future studies that identify run
conditions that provide greater resolution between these vesicle subtypes could help in
answering these questions, as well as coupling this quantitative approach with systematic data
analysis or qualitative imaging data.
While examining this raw data can generate interesting mechanistic hypotheses, it is
difficult to pinpoint a correct explanation due to the multiple barriers and events that exist at
this stage of the gene delivery process. Averaging the summed late vesicle distributions over
time can yield a quantitative time course that can be potentially more useful and accurate to
this end in future analyses and also give a clearer overall picture for generating hypotheses
and making polymer to polymer comparisons (figure 3.7). For the C32 vector, total late
vesicular plasmids peak at 20 minutes and begin to decrease, supporting the plausibility of
early escape from some of these compartments, and showing substantial decreases by 60
minutes. This gives direct quantitative evidence that rapid vesicular trafficking and escape
could contribute to this polymer being such an efficient carrier, however, it should be
acknowledged that complex unpackaging and plasmid degradation can also contribute to this
decrease. Although this vector does rely to some extent at least on the proton sponge
mechanism, its slightly more hydrophobic character than traditional vectors such as PEI may
lend to faster disruption of vesicle membranes or more efficient binding and uptake at the
cell surface for enhanced early trafficking. The small cross-linked PEI has a more linear
profile for late vesicle trafficking and shows significantly more build-up in these
compartments than the C32 vector. However, the fact that this vector ultimately achieves
the same number of nuclear plasmids suggests that vesicle escape may not be ultimately be a
rate limiting step for this vector, suggesting that other steps may require attention to further
optimize this carrier.
These individual contributions can be parsed out by using these quantitative
trafficking data sets to fit mathematical model parameters that describe these individual
steps. Future work will focus on generating quantitative vesicle trafficking sets for a number
of vectors to compare mechanistic differences in these delivery steps that are difficult to
extract from the data without this higher level analysis. Furthermore, since this DGE device
and experimental approach also allows for the recovery of whole cell, cytoplasmic, and
nuclear fractions, comprehensive quantitative data sets can be built following these same
principles. These high information content data sets can be used to constrain parameter fits
to the experimentally measured total cellular distribution of plasmids and not just the early or
late vesicle trafficking data sets alone. This preliminary characterization and proof of
principle work has shown our approach to be robust in attaining quantitative trafficking data
from primary hepatocytes from multiple animals. Extension of these methods should
provide more rigorous and accurate mechanistic data and models that can drive the
improvement of next generation non-viral therapeutics.
~·g.
I. f. J.
C.
e.d.
.e.
... .... .. - h
Figure 3.1: A) Schematic of the assembled density gradient electrophoresis device. B) Mid-plane
view of the device. The separation column (a) is situated within the outer device cylinder with makes
up the lower (b) and upper (c) buffer chambers. An inlet (d) connects to a computer controlled
syringe pump for control over loading steps and eluting fractions out of the top of the column at the
end of the run. A cellophane membrane (e) is held over the bottom of the separation column with
an O-ring and makes up the floor of the column, connecting it electrically but not hydrodynamically
to the lower buffer chamber. A removable cone attachment (f) allows for uniform gradient and
sample layering and is reincorporated with a capillary tube connected to it at the end of the run for
precise control of fraction collection. The platinum anode (g) locked onto the top chamber during
the separation run, and the palladium cathode (h) is seated in a removable based that allows for
cleaning of the device and seals off the lower chamber with an O-ring. Ports (i) and (j) (second set of
port occluded by view, allow for peristaltic tubes to add and remove electrophoresis buffer during
runs to keep the buffer fresh and make separation runs more consistent.
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Figure 3.2: Optimized DGE fractionation pattern of endosomes and lysosomes in primary rat
hepatocytes. 380 uL fractions were eluted off of the column and collected in a 96 well plate after an
80 min separation run, with fraction 1 being at the top of the column and fraction 85 being at the
bottom of the lower density gradient. Prior to lysis and fractionation, cells were subjected to a dual
pulse chase pulse of horse radish peroxidase (HRP) to label early and late endosomes. Odd fractions
were assayed for IJRP to determine the location of these endosomes after the DGE run, and an
assay for f-hexosaminidase shows the location of lysosomes. The DGE device successfully
separates these three organelle types.
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Figure 3.3: Western blot results probing for late and early endosomes in a positive control (PNS,
post nuclear supernatant after 1000xg spin of lysate, which should contain all endosomes), a negative
control (PES, post endosomal supernatant after 100,000xg spin of lysate), and in vesicles spun down
at 100,000xg from fractions comprising the leftmost late endosome peak in figure 3.2 A). Rab9 is a
Rab GTPase specific to late endosomes and EEA1, or early endosome antigen one, is a protein
complex specific to early endosomes. It should be noted that there is a faint signal in the negative
control due to a small fraction of broken endosomal membranes that remain in the supernatant after
ultracentrifugation.
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Figure 3.4: Pulse chase characterization of DGE fractionation of primary hepatocytes. Primary
hepatocytes were subjected to a single short early HRP pulse immediately followed by lysis or a pulse
of HRP followed by an unlabelled media chase to label only late vesicles before lysis. DGE runs
yielded unique peaks for the two labelling approaches.
100
a)
0
L-
S60
E
E 40
e- 200
100
- Beta-Hexosaminidase
4) -- Horse Radish PeroxidaseO
C 80
0
60
S40 -
0
0 20
0 10 20 30 40 50 60 70
Fraction Number (380 uL)
Figure 3.5: Effect of non-viral gene delivery via cationic polyplexes on the DGE fractionation
pattern. Primary hepatocytes were simultaneously HRP labeled and transfected with a
polyethylenimine non-viral vector (PEI25) complexed with gWiz 3-Gal plasmids at an N/P ratio of
20 were lysed 40 minutes after delivery. Organelles were separated by an 80 minute DGE run and
380 uL fractions were collected in a 96 well plate. Gene delivery broadens peaks and causes the late
vesicles to shift downward slightly in the column, but this approach still provides excellent separation
between late and early vesicles.
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Figure 3.6A: Plasmid mapping of vector trafficking via DGE.
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Figure 3.6: A) Plasmid mapping of vector trafficking via DGE. Primary hepatocytes were
transfected with C32 complexes at a plasmid to cell ratio of 5e5 plasmids per cell. At the indicated
time points after administration of the complexes, cells were collected on ice, lysed and fractionated
in an 80 minute run on the DGE column. 24 fractions of 1.25 mL were collected, with fraction 1
representing the top of the column at the end of the run and fraction 24 representing the bottom
portion of the lower density gradient. DNA was purified from each fraction, and quantified on a per
cell basis using Taqman real-time PCR. Please note the difference in y axis scales in order to best
visualize the plasmid peak at each time point. B) Plasmid peaks overlayed with 1-hexosaminidase
signal to indicate the late vesicle containing fractions (see next page).
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Figure 3.6B: Plasmid mapping of C32 vector trafficking via DGE with 3-hexosaminidase peaks
overlayed on the plasmid peaks.
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Figure 3.7A: Early vesicle plasmid trafficking time courses for the C32 and small crosslinked PEI
non-viral vectors during the first hour after transfection (see full caption on page 98).
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Figure 3.7B: Late vesicle plasmid trafficking time courses for the C32 and small crosslinked PEI
non-viral vectors during the first hour after transfection (see full caption on the next page).
Figure 3.7: Quantitative early (A) and late (13) vesicle trafficking time courses for C32 and small
cross-linked PEI delivered plasmids. Per cell plasmid amounts were summed for late vesicle
containing fractions via 1-hexosaminidase mapping for each time point replicate and averaged to
show the total per late vesicle per cell plasmid levels over the first hour of delivery. Similarly, the
smaller plasmid peaks to the right of the 3-hex peaks where early endosomes have been shown to
localize were summed to determine early endosomal replicates.
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Figure 3.8: Nuclear trafficking of C32 and small cross-linked PEI delivered plasmids in primary
hepatocytes. Cells were transfected, and at the time points of interest, mechanically lysed. Nuclei
remained intact during lysis and were pelleted and assayed for total per cell plasmid content.
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Chapter 4
A 3-D Perfused Liver Bioreactor for the Study of Non-viral Gene
Therapy Vector Performance
4.1 Introduction
New approaches in tissue engineering are important for a number of applications.
While an ultimate goal in this field is to replace specific organ tissues to address unmet
clinical needs, current and future approaches can also be applied to the development of in
titro systems that can advance our understanding of the biological processes important in
tissue morphogenesis and organ function [188]. The liver is a particularly attractive
candidate for such approaches. Primary hepatocytes quickly lose many of their liver specific
functions when removed from the liver and cultured in standard formats [172]. Systems that
are able to foster the important 3-D microenvironment of the liver, including rebuilding the
architecture of homo and heterotypic cell-cell interactions, providing physiologically accurate
mechanical cues, and delivering the proper spectrum of molecular factors and stimuli over
time, can provide experimental surrogates that better reflect in vivo observations while
allowing for more quantitative and multiplexed analysis. Such systems could advance
understanding of basic liver biology and development, while also providing more useful
information for applied toxicology studies and mechanistic studies of xenobiotic delivery.
A number of improved in vitro model systems have been developed in the attempts
of recapitulating some degree of the 3-D architecture and functional behavior of in vivo liver.
These systems and approaches have been reviewed extensively in the context of the degree
liver function that can be maintained for specific systems and how these systems can be
applied to the drug development process [171]. Notable approaches that move away from
more traditional liver slices, microsome preparations and standard 2-D cultures include a
number of quasi 3-D seeding approaches in basement membrane and extracellular matrix
components, employing novel co-culturing strategies, and 3-D bioreactor systems [189-197].
We have previously developed a three dimensional perfused microarray bioreactor
that allows for long term culture of primary hepatocytes and better maintenance of liver
specific phenotype [161, 162, 171]. This system provided adequate mass transfer of
nutrients and oxygen to cells in functional flow channel units that allowed for the
reorganization of primary hepatocytes into 3-D tissue structures. These tissue structures are
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maintained at the relevant length scales and mechanical flow environment representative of a
liver capillary bed in vivo. Initial versions of this reactor system focused on configurations
that allowed for precise in situ imaging of the tissue units within the cell scaffold, but
contained relatively few channels in the array. This allowed for comprehensive evaluation of
the tissue over time and provided many. insights into ways in which design parameters and
device components could be further optimized. This microreactor demonstrated improved
maintenance of metabolic function and overall liver phenotype compared to traditional
cultures. The system has been applied to drug metabolism and enzyme induction studies
[171] and has showed the potential for providing more in vivo like cell interaction seen in
the liver parenchyma.
An advantage of this system is that these functional channel units are scalable in
number to provide reactors that can hold more total tissue. While imaging and metabolism
studies were suitable for the original system, additional applications which required more
material to meet the sensitivity demands of various quantitative assays or required the
purification of RNA, DNA and protein from the same sample for high information content
analyses were not feasible. One application of interest in our current work is to use the
perfused liver microreactor as a more clinically relevant in vitro test bed for novel non-viral
gene therapy vectors. The liver plays many important roles in in vivo gene therapy, and it has
been seen in past work that novel carriers that perform well in 2-D cell line models of liver
don't necessarily translate this success to in vivo animal models or primary cell cultures. Past
work in the original reactor was able to detect GFP based transgene expression from
adenovirus delivery at relatively high multiplicities of infection via two-photon microscopy
[162]. However for non-viral vectors, which typically yield levels of gene expression that are
orders of magnitude below that of their viral counterparts, more cells are needed to
quantitatively measure significant differences in transgene expression from different carriers.
This motivated the design of a scaled up version of the perfused liver microreactor.
Here we describe the design and fabrication, characterization and initial applications
of a new perfused liver bioreactor which has been significantly scaled up from its
predecessor. This reactor still utilizes the same original channel size and geometry in the cell
scaffold but has employed new chamber designs, components and scaffold fabrication
techniques to achieve a much larger array of channels. Flow rates can be carefully controlled
such that shear stresses and nutrient and oxygen delivery rates are equivalent to the original
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system, allowing for viable primary tissue with well characterized morphological behavior
that can be maintained in long term culture. An analysis of liver specific phenotypic gene
expression is described that compared this new system with other culture systems, and initial
characterization is extended to explore the utility of this system as a test bed for the
quantitative evaluation of novel non-viral therapeutics.
4.2 Materials and Methods
4.2.1 Primary Liver Cell Isolation
Primary cells were isolated from male Fisher rats weighing 150-180 gm using a
modified version of the Seglen 2-step collagenase procedure as previously described [161,
162, 171]. Blendzyme Type III (Roche, USA) was used for digestion instead of collagenase.
Cells that were released by the digestion were suspended in DAG (DMEM (Sigma-Aldrich,
USA), Albumin, Gentamycin) and spun and washed twice at 50g for 3 minutes. The final
pellet was resuspended in hepatocytes growth medium (HGM), as described previously [161,
162, 171, 187], to yield a 95% or greater pure suspension of hepatocytes. The final cell
viability was determined by trypan blue exclusion, and cells were only used if viability was in
the 89- 9 5% range. Cells were kept on ice and seeded into 2-D plates or spinner flasks within
10 minutes of the isolation.
4.2.2 Reactor Design, CFD Simulations, Machining, and Components
A number of main flow chamber geometries were conceived and tested for uniform
flow profiles in Comsol v3.1 (Comsol, Inc., Burlington, MA). Geometries of the flow
chamber were extruded to 3-D, meshed and run with an incompressible Navier Stokes
model in the Comsol Multiphysics package. The Navier Stokes equation was non-
dimensionalized and Reynolds numbers were simulated that represented the range of flow
rates that would be used in the chamber, as well as simulations + one order of magnitude
from this range to ensure robust operation. The geometry that yielded the most uniform
flow and easiest machining was chosen. The three main body pieces for the reactor were
machined from polycarbonate based on this design and tested with qualitative dye tracking
experiments. Satisfactory results were observed, and these pieces were mass produced for
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biological characterization studies. All compartments were fabricated by standard CNC
machining. The fluidic ports in the compartments were fitted with commercially available
polypropylene connectors (Ark-Plas Products, Flippin, Arkansas). The overall size of the 3-
compartment bioreactor housing was approximately 78 x 54 x 21 mm.
Oblong scaffold blanks were cut out of a 230 um thick sheet of polycarbonate
(McMaster-Carr, Dayton, NJ). In each blank, a 20 x 50 array of microchannels was
micromachined using a 9X molybdenum mask on an IX-1000 industrial workstation
equipped with a KrF excimer laser lasing at 248 nm (J. P. Sercel Associates, Hollis, NH). The
entire channel array was scanned with a mask scanning technique to minimize localized
heating of the scaffold. Two alignment holes were also laser-machined in the scaffold. The
holes were used to accurately position the scaffold in the bioreactor pocket furnished with a
pair of Dowel pins. This arrangement ensured precise co-registration of the microchannels
in the cell-holding and support scaffolds. Peristaltic tubes and pumps (Instech Labs, Inc.,
Plymouth Meeting, PA) were integrated in to custom dual pump boxes with digital
potentiometers to control pumps rates. 13.5 V AC adaptors and power jack connectors
were purchased from Radio Shack. With the exception of 5 um Durapore filters for the
reactor chamber (Millipore, Billerica, MA) and inline syringe filters (Pall, USA), all other
components and raw materials were obtained from McMaster Carr including O-rings,
screws, tubing, silicone sheets for punching custom gaskets, reservoirs, and stainless steel for
custom retaining rings.
4.2.3 Preparation of 2-D Collagen Gel Sandwich and Adsorbed Collagen Cultures
Collagen sandwich cultures were prepared as explained in previous methods [171].
35 mm 6-well plates were coated with 600 uL of a collagen solution and allowed to gel
overnight at 37oC and 8.5% CO 2. Cells were seeded at 50,000 cells/cm2 in HGM at a
concentration of 500,000 cells/mL. Cells were incubated overnight, the medium was
aspirated, and a top layer of 300 uL of collagen solution was evenly distributed in each well
to form a top gel layer for an hour. 1 mL of HGM was then added to each well and changed
daily thereafter.
For 2-D transfection experiments, cells were seeded in 60 mm tissue culture dishes
treated with a dried adsorbed collagen monolayer. Collagen type I from rat tail (BD
Biosciences, Bedford, MA) was diluted in sterile 1x PBS at a concentration of 30 ug/mL.
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Plates were incubated with 3 mL of this solution for 2 hours, then aspirated and allowed to
dry in a sterile hood for two hours prior to seeding. Cells were seeded in 3 mL of HGM at a
density of 800,000 cells/mL immediately after isolation. Medium was changed 4 hours post-
seeding to eliminate dead and unattached cells and debris, while ensuring 90-95%
confluency. All experiments were performed within 24 hours of seeding to ensure the best
maintenance of hepatocyte phenotype.
4.2.4 Preparation of 3-D Hepatocyte Spheroids
30 million isolated primary rat hepatocytes were added to 100 mL of HGM in a 500
mL spinner flask (BellCo, NJ, USA) on a spinner table and spun at 85 rpm [198]. The cells
formed spheroidal aggregates and were collected after 3 days of culture just prior to reactor
seeding. Spheroids in the 100-300 um size range were retained by using the appropriately
sized filter meshes (Sefar America, Kansas City, MO). This fraction was spun down at 50g
for 3 minutes, and gently resuspended in 20 mL of fresh HGM to reduce debris in the
seeding. We have previously shown better maintenance of functional tissue phenotype in
perfused microreactor systems seeded with spheroids as opposed to single cells [161, 162].
4.2.5 Assembly, Seeding, and Maintenance of the Liver Bioreactor
Polycarbonate reactor body pieces and scaffolds were sterilized by soaking in 70%
ethanol for 30 minutes, followed by a rinse in sterile 1x PBS. All other reactor components
were sterilized via autoclaving. Prior to assembly, the upper cell holding scaffold was treated
with collagen to promote cell attachment. The scaffold was soaked in a 30 ug/mL solution
of collagen (Type 1 form rat tail, BD Biosciences, USA) in 1x PBS for 2 hours at 370C, and
then aspirated and allowed to dry in a sterile dish for 2 hours. The 5 um middle filter was
coated with 1% BSA (Sigma, St. Louis, MO) for 30 minutes and then rinsed in PBS. Sterile
components were assembled into the reactor body in the order seen in Figure 4.2. The inlet
and outlet connectors were then connected to the tubing and reservoir and loaded onto the
dual peristaltic pump box. Reactors were primed with 25 mLs of HGM (which contains 2
g/L of BSA) for one hours to passivate the inner surfaces of the bioreactor and tubing and
to eliminate any air bubbles from the system. Medium was changed just prior to seeding.
To seed spheroids into the channels, the upper chamber was partially drained and
the top window was removed. A moderate downward crossflow was turned on (1-2
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mL/min range) and 3-4 mLs of the spheroid suspension was gently pipetted over the
scaffold array. The reactor was gently rocked as the crossflow helped pull the spheroids into
the channels. The cell suspension was repipetted up and down in the reactor chamber to
drop over the channel array if seeding looked uneven after visual inspection. Crossflow was
turned off and the top window was then returned to the reactor body. Main flow was
turned on at 3 mL/min and the reactor was held at an incline with the outlet end up to
remove air from the chamber and expel any unseeded spheroids into the reservoir.
Downward crossflow was then turned on at 1 mL/min to help retain seeded cells in the
channel and subject cells to physiological levels of shear stress and nutrient and oxygen
delivery [161, 162]. Medium was changed 2 hours post seeding to remove unseeded cells
and debris from the reservoir.
After 1 day of the culture in the bioreactor, spheroids have attached to the channel
walls and begun to spread and rearrange. Therefore, downward crossflow is no longer
needed to retain the cells in the channels. The crossflow is reversed to an upward direction
at 1 mL/min at this point to remove unattached cells and debris and is maintained in this
direction for the duration of the culture. Now that the crossflow pump was sending
medium into the lower reactor chamber, there existed the danger of pumping these freed
cells and debris in to the lower chamber and clogging the underside of some channels in the
support scaffold. This would cause uneven perfusion flow in some of the channels, which is
usually kept constant across all channels due to the 5 um filter between the upper cell
scaffold and lower support scaffold providing the primary resistance to flow. To maintain
constant flow in all channels, chain of in-line filters was placed in the crossflow line between
the pump and the lower reactor chamber. Since this new reactor system contained
significantly more cells, there is more debris initially in the circulation after crossflow change,
therefore 3 filters are required in series to prevent the reactor from clogging - a 5 um filter, a
1.2 um filter and a 0.8/0.2 filter. This set-up was able to maintain constant flow over long
term culture. The filter chain was primed with HGM prior to the crossflow change, and
medium was changed 1 hour after crossflow change as well to removed most of the debris.
After crossflow reversal, medium was changed every 2 days, and filter chains were changed
every 3 days. Cultures were maintained in an incubator at 370C and 8.5% CO,.
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4.2.6 RNA Isolation and cDNA Generation
Total RNA was recovered from 2-D collagen gel sandwich cultures and 3-D liver
reactor cultures at 7 days post-isolation. For 2-D sandwich cultures, 1 mL of TRIzol®
(nvitrogen, Carlsbad, CA) was added to each well, and the well contents were homogenized
with a 25G needle, collected in an Eppendorf tube, and frozen at -80'C. For 3-D bioreactor
cultures, giant reactors were disassembled and the cell scaffold was placed in a 10 cm Petri
dish and incubated in 3 mL of Dispase (BD Biosciences, USA) for 5 minutes at 37oC.
Tissue was collected in the bottom of the dish via gentle pipetting through the channel array,
transferred to a 15 mL centrifuge tube, and pelleted at 50g for 3 minutes. Supernatant was
removed with a pipette, and the cell pellet was resuspended in 1 mL of TRIzol®, transferred
to an Eppendorf tube and frozen at -80'C. For Milli-F reactors, scaffolds were placed
directly in an Eppendorf tube containing 1 mL of TRIzolo and frozen. Samples were then
thawed and any remaining tissue attached to the channel walls was washed off of the
scaffolds and lysed with a 25G needle. For isolated hepatocytes, 1 million cells were pelleted
at 50g for 3 minutes immediately after the perfusion. Supernatant was removed and cells
were resuspended in 1 mL of TRIzol® and similarly frozen. For in vavo rat liver slices, 1 slice
of each of the four lobes was removed and placed in 5 mL of TRIzol®. The liver pieces
were then broken up using a tissue homogenizer at high speed and frozen at -80'C. 1 mL of
the total 5 mL was processed for total RNA recovery.
To recover RNA, samples were thawed on ice and 200 uL of chloroform was added
to separate the RNA from an organic phase containing DNA and protein. Samples were
mixed by inverting and vortexing and then spun at 12 ,000g for 15 minutes at 4oC to fully
segregate the aqueous and organic phases. RNA was then cleaned and concentrated using
the Qiagen RNEasy Mini kit (Qiagen, Valencia, CA) and stored at -80'C. For conversion to
cDNA, RNA samples were thawed on ice, and sample concentrations and purity were
determined using a NanoDrop (NanoDrop Technologies, Wilmington, DE) and evaluating
the A260 and A260/A280 ratio. 200 ng of total RNA was brought to a volume of 8 uL with
DEPC water (Qiagen). 1 uL of amplification grade DNAse I (Invitrogen) and 1 uL of
DNAse I of 10x DNAse I buffer were added and incubated for 15 minutes at room
temperature to eliminate any genomic DNA contamination. The enzyme was then
inactivated by adding 1 uL of 25 mM EDTA (Invitrogen) and incubating at 650 C for 10
minutes. 9 uL of a master mix solution containing 1 uL of DEPC water, 2 uL of a 5mM
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dNTP mix (Qiagen), 2 uL of a 10 uM stock of random hexamer primers, 2 uL of 10x RT
Buffer (Qiagen), 1 uL of Omniscript RT® solution (Qiagen, 40 units activity/uL), and 1 uL
of a 1:10 RNAse inhibitor dilution in 1x RT buffer (Ambion, 1 unit activity/uL stock). The
samples were mixed, spun down and incubated at 37'C for 1 hour for the reverse
transcription reaction to occur. Samples were then spun down and stored at -80'C.
4.2.7 Primers and RT-PCR
Primers specific for genes indicative of maintenance of liver phenotype in
hepatocytes were designed using mRNA or cDNA sequences from the NCBI database in
the primer3 software at the Whitehead Institute (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www) and have been previously described [171]. mRNA expression
studied in this work used the following primers: 18s (5-GCAATTATATTCCCCATGAACG-3
forward and 5-GGCCTCACTAAACCATCCAA-3 reverse), FABP-1 (5- CCAGAAAGGG
AAGGACATCA-3 forward and 5- GTCTCCAGTTCGCACTCCTC-3 reverse), PEPCK (5-
ATACGGTGGGAACTCACTGC-3 forward and 5- TGCCTTCGGGGTTAGTTATG-3
reverse), Catalase (5- ACATGGTCTGGGACTTCTGG-3 forward and 5- CCATTCGCAT
TAACCAGCTT-3 reverse), HNF3a (5-TCAACGCTTG~ITTCGTCAAG-3 forward and 5-
TCACACTTGAAGCGCTTrTG-3 reverse), HNF-4a (5-CTGAGACTCCACAGCC
ATCA-3 forward and 5-CTAGATGGCTTCCTGCITTGG-3 reverse), CAR (5-GGAG
GACCAGATCTCCCTTC-3 forward and 5-GACCGCATCTTCCATCTTGT-3 reverse),
AHR (5-ACTACACGCCAGACCAGCIT forward and 5-AITCATTGCCAGGA
AACCAG-3 reverse), OATP-1 (5-AACCCTGAAATGTGGTCAGC-3 forward and 5-
GCAGGCAGATAGCITGATCC-3 reverse), OATP-2 (5-CAATTCGGTATCCCCA
CATC-3 forward and 5-CTGCACATCCAACACCAATC-3 reverse), BSEP (5-CCAC
CAGAACATGACAACG-3 forward and 5-CCCAGTGATGACCCATAACC-3 reverse),
FXR (5-ATGTCCGGAGTTCTGTCAGG-3 forward and 5-GCCTICTGCTCGATGTC
CTAC-3 reverse), GST-Ya (5-CTTGGCAAA AGACAGGACC-3 forward and 5-GTTTT
GCATCCATGGGAAGC-3 reverse), MDR2 (5-CTTTGTGGTGGGGACAC TCT-3
forward and 5-CCAAGAAGACCAGCGAGAAC-3 reverse), and HNFla (5-GCCATCTG
GGTGGAGATAAA-3 forward and 5-ACCAGTCCCACAGTG TCCTC-3 reverse).
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For quantitation of mRNA expression levels, 1 uL of cDNA was added to 25 uL of
SYBR Green 2x Master Mix (Qiagen), 21 uL of DEPC water, and 1.5 uL each of the
forward and reverse primers. A Chromo4 real-time PCR detection system (MJ Research,
Waltham, MA) was used with Opticon Monitor 3 software to run standard Qiagen SYBR
Green RT-PCR annealing and melting protocols. Melting curves were analyzed to ensure
primer specificity and threshold levels were kept consistent between runs for accurate
comparison between genes and culture systems. The ribosomal RNA 18s has been found to
be constant relative to total RNA and cell number across these 2-D and 3-D cultures
systems, and was therefore used to internally normalize each gene before replicates were
averaged or expression levels were compared between systems.
4.2.8 Plasmid, Polymers, Virus and Non-viral Complex Formation
Plasmnid gWiz-P-Galactosidase (Gene Therapy Systems, San Diego, CA) encodes the
enzyme P-galactosidase controlled by the human cytomegalovirus (CMV) promoter. The
plasmid DNA was purchased purified and ready for use from a contract plasmid
manufacturing company (Aldevron, Fargo, ND). 25kD PEI was purchased from Sigma-
Aldrich (St Louis, MO). The small cross-linked PEI and the C32 polymer were synthesized
as described previously [105, 106, 108]. The adenovirus serotype 5 with El and E3 deletions
encoding P-galactosidase under a CMV promoter was purchased from Vector Core
(University of Michigan, Ann Arbor, MI).
For transfection via PEI25 and small cross-linked PEI, polymer and DNA were
diluted to the appropriate concentrations in sterile water and combined at an N/P ratio of
20 and 30, respectively. Polymer was added to DNA and left at room temperature for 20
minutes PEI25 and 10 minutes for the small cross-linked PEI to allow for formation of
complexes. For C32, polymer and DNA were diluted in sterile filtered sodium acetate
buffer, pH 5.4, combined at a polymer mass/DNA mass ratio of 100, and left at room
temperature for 5 minutes before adding to prewarmed medium. All complexes and naked
DNA were added to HGM at a DNA concentration of 5 ug/mL. For adenovirus, a master
stock was thawed on ice and diluted 1:100 in a 10% glycerol in 1x PBS buffer to make
frozen working stock aliquots. The appropriate amount of particles were added for a
multiplicity of infection of 20 assuming that there were 1 million cells seeded in the reactor
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cultures and 2 million cells in 2-D cultures. Non-viral particle size was determined via
dynamic light scattering using a ZetaPALS Zeta Potential Analyzer with ZetaPALS Particle
Sizing Software Version 2.3 (Brookhaven Instruments Corporation, Holtzville, NY).
Number averaged particle diameters were determined over a lognormal distribution for each
vector/plasmid complex. The 25kD PEI complexes measured 228.3 ± 47.6 nm in diameter,
the small cross-linked PEI complexes were 167.5 ± 8.2 nm, and the C32 complexes were
152.0 ± 4.2 nm.
4.2.9 Transfection and Gene Expression Assays
For 2-D transfections, cells were seeded and washed on adsorbed collagen
monolayers as described above and cultured overnight. Cells were then transfected with
naked DNA, non-viral vectors, or adenovirus in 2 mLs of HGM at the appropriate
concentrations noted above. Cultures were maintained for 48 hours and then transfection
medium was removed, and cells were washed and collected in 1x Reporter Lysis Buffer
(Promega, Madison, WI) and f-Galactosidase transgene expression levels were measured in
the cell lysate using an absorbance based assay kit (Promega). Transgene expression levels
were normalized to total protein in each sample, using a BCA Total Protein Assay kit
(Pierce, Rockford, IL).
For 3-D transfection, liver bioreactors were seeded as described above and
maintained for 4 days (Day 7 post isolation). To ensure that the inline filter chain did not
lead to significant vector adsorption and loss, the crossflow was reversed back to 1 mL/min
downward through the channels. This allowed for removal of the filter chain without the
danger of clogging the system or developing uneven flow through the channels. Medium
was aspirated from the reservoir cup, and 6 mLs of medium at the appropriate concentration
for each vector was added. Reactor cultures were maintained with 3 mL/min of main flow
across the upper chamber and downward crossflow of 1 mL/min for 48 hours. Giant
reactors were disassembled and the cell scaffold was placed in a 10 cm Petri dish and
incubated in 3 mL of Dispase for 5 minutes at 370 C. Tissue was collected in the bottom of
the dish via gentle pipetting through the channel array, transferred to a 15 mL centrifuge
tube, and pelleted at 50g for 3 minutes. Supernatant was removed with a pipette, and the
cell pellet was resuspended in 1 mL of 1x Reporter Lysis Buffer and processed, assayed and
normalized as above for the 2-D samples.
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4.3 Results
4.3.1 Reactor Design and Fabrication
An exploded view of the large reactor can be seen in Figure 4.1. The reactor body
consists of three main polycarbonate pieces. All scaffold components fit precisely into a
pocket on the bottom side of the middle piece. Two silicone gaskets and a silicone O-ring
with a stainless steel retaining ring provide a seal around the outer edges of the primary
scaffold components, creating an upper and lower flow chamber when the top window and
base are screwed into the middle piece. The top window of the reactor body can be easily
removed after assembly and priming to efficiently seed cell spheroids into the channels of
the top scaffold via pipetting. The 5 um hydrophilic Durapore filter (Millipore) is
sandwiched between the cell holding scaffold and lower support scaffold to provide constant
flow resistance across the scaffold array, regardless of how many cells are seeded into each
individual channel. This results in uniform crossflow in all channels. This filter also helps to
retain cells in the channels initially after seeding. The cell scaffolds were also machined from
polycarbonate, using a laser machining technique that allowed for the precise cutting of 1000
300x300x230 um channels without warping. The channels were arranged in a 20x50 array.
By machining two alignment holes at the sides of the scaffold away from the channel array
and seating two alignment pins in the reactor body pocket, precise co-registration between
the cell scaffold and the support scaffold was consistently achieved and allowed for uniform
perfusion flow for all scaffold pairs. The polycarbonate scaffolds stayed well aligned under a
large range of flow rates, and were much easier to handle and insert into the reactor pocket
due to their flexibility and compatibility with the gaskets than the silicon scaffolds used in
the original reactor system.
The overall fluidic circuit for the reactor is controlled by a dual peristaltic pump
(Figure 4.2). Main flow is controlled by pump A which replenishes the upper chamber and
drives flow over the scaffold surface and out of the upper chamber outlet for reoxygenation
of medium in the tubing and medium reservoir. Pump B controls the crossflow, and can
send flow to or from the lower reactor chamber to create perfusion flow either upward or
downward through the channels. The upper and middle body components were also
designed to have an injection port at the inlet and outlet of the upper flow chamber so that
media could be directly sampled from the reactor, probes could be inserted for monitoring
oxygen, and drugs or gene vectors could be administered without opening the reservoir or
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detaching any tubing. Media flow rates in the main chamber were adjusted such that the
scale-up of main flow and of upper chamber volume and scaffold surface area would yield
the same scaffold shear stresses as previously modeled [162]. Per channel perfusion cross
flow rates were maintained at the same rate as the original system. To insure that the cell
scaffold experienced a uniform velocity field and shear stresses across the entire channel
array, different upper flow chamber geometries were designed and subjected to
computational fluid dynamics simulations at the desired flow rates. The optimal design,
which yielded uniform velocity and no recirculation of flow over the channel array (Figure
4.3), was machined as a prototype and tested before mass production via standard CNC
machining. Figure 4.4 shows a fully assembled giant reactor with the optimal inlet and outlet
geometries. The upper laser machined scaffold can be seen through the top window, which
still allows for in situ light microscopy of the channels during culture.
4.3.2 Reactor Seeding, Tissue Reorganization and Maintenance of 3-D Cultures
A 95% pure fraction of isolated rat hepatocytes was cultured in a spinner flask for 3
days to form spheroidal aggregates. Prior to assembling reactors, the top cell holding
scaffold was treated with collagen to promote cell attachment and the Durapore filter was
treated with 1% bovine serum albumin (BSA) to prevent cell adhesion and potential clogging
of perfusion flow in the channels. Reactors were then assembled and primed with HGM to
passivate all of the inner surfaces of the fluidics circuit. Spheroids were sized fractionated to
acquire aggregates with diameters in the 100-300 um range. It had been previously shown
that seeding reactors with spheroids as opposed to single cells resulted in superior tissue
morphogenesis and function [162]. These spheroids were pelleted and resuspended in fresh
HGM, and medium was also changed in the primed reactors. The fact that this new reactor
has a removable top window makes for fast and efficient seeding of the channels. Channels
were evenly packed with spheroids in under 1 minute. For the first 24 hours of culture,
downward crossflow was maintained at a rate of 1 mL/min, or 1 uL/channel/min, with a
main flow of 3 mL/min. This helped retain the cells in the channels as they began to attach
to the collagen coated walls. By 24 hours, cells attached very well to the channels walls and
had already begun spreading and reorganizing. Cross-flow was then reversed in an upward
direction at the same flow rate. This expelled debris from the channels as well as any dead
or unattached cells, leaving viable adhesive cells that could further reorganize. The cross
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flow line was outfitted with a chain of in-line filters to prevent clogging of the channels due
to debris build-up in the lower flow chamber against the support scaffold channels.
These 3-D cultures were typically maintained until day 7 post isolation before
experiments were performed. The tissue in the channels showed extensive attachment to
the walls and formation of annular tissue structures at this point (Figure 4.5). The
polycarbonate scaffolds demonstrated excellent retention of tissue under these flow
conditions. At day 7 post isolation, an average of just over 1 million viable cells were
recovered from the channels of each large reactor, as determined by total RNA
measurements and RT-PCR of 18s ribosomal RNA, followed by comparison to a standard
curve. This is a vast increase over the original Milli reactor system, which usually housed an
average of 40,000 cells. A protocol was developed that allowed for efficient recovery of
these cells for various downstream quantitative assays. Incubation of the cell scaffold in
Dispase (BD Biosciences), a bacterial amino-endo peptidase, for 5 minutes effectively
loosens the tissue structures from the channel walls. Intact cells can be collected by gently
expelling them from the channels via gentle pipetting after this short incubation. Cells can
then be pelleted and frozen or processed for any number of assays.
4.3.3 Quantitative Comparison of Liver Phenotype via RT-PCR
In order to more definitively gauge the maintenance of liver phenotype in this new
system, quantitative RT-PCR was performed to measure the level of liver specific mRNA
transcripts in comparison with in vivo liver, freshly isolated hepatocytes, standard 2-D
collagen gel sandwich cultures, and the original Milli microreactor system. This analysis
could answer a number of questions including how the reactor compared to in vivo
transcript levels, if this new system was superior to traditional 2-D cultures in maintenance
of hepatic phenotype, and also if the changes made to scale up the reactor significantly
changed its performance from its smaller predecessor.
RNA was isolated from in vivo liver slices and isolated hepatocytes immediately after
surgery and isolation, and from day 7 cultures for the collagen sandwich and liver bioreactor
cultures. cDNA was generated from each RNA sample and optimized primer sets for genes
indicative of liver specific function were quantified via real-time SYBR Green PCR. A
microarray analysis using Affymetrix Rat Genome Array (U34A) Gene Chips had previously
been performed to identify which genes were most significantly upregulated in liver tissue in
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comparison with other tissues [171] and a subset of these genes were examined in this study.
For each culture system, normalized replicates were averaged for these genes and then all
data was normalized to the in vivo liver transcript levels (Figure 4.6). The genes tested
represented a panel of liver enriched transcription factors: HNF-la, HNF-3a, and HNF-4a;
membrane transporters and general metabolism genes: FABP-1, BSEP, Catalase, MDR2,
OATP-1, and OATP-2; phase II metabolic enzymes: GST-Ya; and liver enriched nuclear
receptors: CAR, AHR, and FXR. In general, it could be seen that the large reactor maintains
more upregulated liver phenotype at the transcript level than 2-D collagen sandwich cultures,
and that the overall pattern of expression for this new system is comparable to the original
microreactor, suggesting that scaling up the system did not significantly alter the hepatocyte
culture at the functional level.
4.3.4 Transfection Experiments in 2-D and 3-D Culture Systems
2-D adsorbed collagen monolayer and 3-D Giant reactor cultures were transfected as
described in sections 4.2.8 and 4.2.9 with five gene therapy vectors: naked plasmid DNA,
traditional PEI25 complexes, next generation non-viral complexes small cross-linked PEI
and poly(P-amino ester) C32, and a canonical viral vector, adenovirus serotype 5. All
delivered the same P-galactosidase transgene under the same CMV promoter. Samples were
lysed and quantitatively assayed for transgene expression at 48 hours after transfection.
Normalized replicates were averaged and then globally normalized to the respective PEI25
expression level in each culture system (Figure 4.7).
The Giant reactor provided enough transfected cells to detect PEI25 expression well
above control levels, which was not possible due to signal to noise limitations in the original
Milli reactor system. Naked DNA yielded expression that was slightly above control levels
in 2-D transfections, but was not significantly different from the control in the 3-D system.
In 2-D, the small cross-linked PEI transfected primary hepatocytes with 80 times the
efficiency of PEI25 and yielded expression that was almost half that of adenovirus, which
gave 170 times the expression of the PEI25 vector. Meanwhile, the C32 vector was slightly
less efficient but still gave high expression in 2-D, with over 30 times the gene expression of
PEI25. Interestingly, in 3-D this trend was reversed between the next generation non-viral
vectors. The small cross-linked PEI transfection resulted in a slightly more than 3 times the
gene expression of PEI25 in the Giant reactor, while the C32 vector provided a nearly 7 fold
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increase in expression. The adenovirus was once again the most efficient vector in the 3-D
system, giving a 20 fold increase over the PEI25 levels.
4.4 Discussion and Conclusions
Here we describe a new, scaled up perfused liver bioreactor for maintenance of
primary liver cultures in a 3-D microenvironment. This new "Giant" reactor is based on the
same design principles as a previously developed system that demonstrated the ability to
culture primary hepatic cells in 3-D tissue structures over longer periods of time than
conventional 2-D cultures with improved maintenance of liver phenotype and function [161,
162, 171]. While the previous system focused on providing high resolution imaging
capabilities with less total cells in each culture, our new system provides added versatility for
performing multiple experiments on the same reactor as well as housing enough cells to
perform a number of quantitative assays with higher sensitivity demands.
The functional channel units in the cell scaffold that provide a substrate for
attachment and reorganization of primary liver tissue, as well as a controllable platform for
perfusion flow, were kept consistent with our previous design. This allowed for careful
control of the levels of shear stress and oxygen and nutrient delivery that showed the best
results previous for tissue morphogenesis and enhanced phenotypic function. Operation
parameters were optimized to yield a system which robustly recreated these conditions in the
context of a larger fluidic circuit and reactor chamber. These conditions, as well as optimal
reactor chamber geometries, were validated via a number of computational fluid dynamics
simulations and qualitative dye tracking experiments in early prototypes. These studies,
coupled with computational analysis in our previous work [162], confirmed that cells
throughout the larger cell array experienced uniform flow with no recirculation, physiological
levels of shear stress, and more than adequate nutrient and oxygen delivery.
New features were incorporated in this design to allow for faster and more
consistent seeding over the larger array of channels in the cell scaffold. A three part reactor
body was employed to allow for direct addition of cells via pipetting, as dependence on the
original hydrodynamic seeding technique could not achieve uniform cell seeding over the
larger 1000 channel array. This dramatically sped up the seeding procedure and also
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increased seeding efficiency, with 5 fold less total cell spheroids (on a per channel basis)
required per reactor to attain fully seeded channels. This improvement provided the benefit
of increasing the number of total reactors that could be seeded for each spheroid
preparation and also paved the way for future design work in systems that aim to culture
human liver cells, where seeding efficiency is of the utmost importance since cell supplies
can be quite scarce as compared to an animal source.
New machining approaches were adopted to use scaffold materials that were more
practical for the size and assembly constraints of the larger system. Scaffolds achieved
precise channel alignment for uniform crossflow, and their mechanical properties allowed
for faster reactor priming and assembly without the danger of breaking that existed with
silicon scaffolds. An optimized collagen treatment protocol was devised in order to achieve
comparable cell adhesion for the polycarbonate channel walls as compared to the original
silicon scaffolds. The polycarbonate scaffolds successfully recreated the qualitative cell
adhesion and tissue reorganization observed in the original system. These scaffolds
demonstrated excellent retention of cells, consistently providing over 1 million cells per
reactor at the relevant time points. This provides for more than enough material to purify
RNA, DNA, protein and metabolites from the same sample, allowing for simultaneous
characterization for a given experimental applications at many levels. Increased cell seeding
and retention over the culture period also results in increased debris in the fluidic circuit,
especially at early time points following crossflow reversal. New protocols were adapted to
efficiently handle this debris and maintain culture well beyond the previously established
time period over which the hepatocytes stabilize to more in vivo-like hepatic function and
morphology, which is typically day 7 post isolation for most applications [171].
Optimized protocols for the fast recovery of intact cells from the polycarbonate
scaffolds also provide another degree of flexibility for this system. Cells can be collected and
pelleted and then subjected to smaller volumes of lysis or assay buffer in order to attain a
higher degree of sensitivity for hard to measure molecules. This has also allowed proof of
concept for subcellular fractionation approaches to study intracellular trafficking and
distribution of therapeutics, as well as uptake and metabolism studies for drugs such as non-
viral gene therapeutics that have much higher temporal resolution than is possible in animal
models. Due to the success of polycarbonate as a scaffold material, work is also underway
to mass produce large polycarbonate scaffolds via novel drilling approaches. This would
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provide low cost scaffolds that would essentially be disposable and facilitate a number of
new experiments that would require directly placing the scaffolds in more abrasive lysis or
assay buffers, as well as allow for sectioning of multiple scaffolds to study cell morphology
and distribution throughout the 3-D tissue structures. With such a large scaffold array, some
channels could also be prepared for sectioning and various imaging analyses while another
portion of the culture could be subjected to functional assays, corroborating these data from
the same sample and gaining a greater understanding of the underlying mechanisms involved
in tissue morphogenesis for a given seeding condition or cell type distribution.
In order to more broadly characterize liver phenotype in the new system, an RT-
PCR approach was utilized to quantitatively measure the mRNA expression levels for a
panel of liver enriched genes responsible for a wide variety of hepatocyte specific functions.
The genes tested included liver enriched transcription factors, membrane transporters and
general metabolism genes, phase II metabolic enzymes, and liver enriched nuclear receptors.
Gene expression patterns were compared between the new "Giant" reactor and its
predecessor, the smaller Milli-F reactor, to determine if the design and parameter changes
made in scaling up the system had a significant affect on the on the overall maintenance of
liver phenotype. Overall, the patterns compared favorably in nearly all cases. Both 3-D
systems were significantly less downregulated compared to 2-D collagen sandwich cultures
relative to the in vivo levels, suggesting enhanced in vitro maintenance of hepatic phenotype.
The giant reactor was particularly effective in maintaining the expression levels of the
hepatocyte nuclear factor (HNF) family of transcription factors. Liver specific gene
expression is thought to be controlled primarily at the transcriptional level [199]. The HNFs
play an important role in promoting a variety of liver specific gene expression, and many
liver specific genes have promoter sites for multiple HNFs [200-202]. HNF4a and HNF la
are considered to be two of the most important transcription factors in this class, coupled
with other HNF variants, they are thought to play an important role in the expression of
cytochrome p450 enzymes. HNF4a regulates metabolism of fatty acids, glucose and
cholesterol, it plays a role in multiple biosynthesis processes, and also factors into liver
development [203-209]. Gene expression of HNF10a, HNF3a, and HNF4a were all
maintained at close to in uivo levels (Figure 4.6), suggesting a solid foundation for liver
specific function for this new 3-D culture system. The fact that the majority of the
downstream metabolism and transport related genes that were measured, such as BSEP (bile
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salt export pump), the OATPs (organic anion transporter polypeptides), MDR2 (multiple
drug resistance 2 P-glycoprotein) and GST-Ya (glutathione S-transferase Ya), are also
upregulated corroborates with the upregulated transcriptional control elements. Two genes,
FABP-1 (fatty acid binding protein 1) and catalase, showed moderate downregulation from
2-D levels. Interestingly, the transcript levels for both of these genes were brought back to
in vivo levels when reactors were run without bovine serum albumin (BSA) in the medium.
In general, this RT-PCR approach can be used to examine the effects of medium
formulations or operating parameters on gene expression patterns in order to optimize the
3-D system for the specific application of interest. In the case of these studies, however,
BSA was left in the medium, since this serum protein plays an important role in non-specific
adhesion to gene therapy vectors, potentially changing their physical properties and/or
causing non-viral particle aggregation. By leaving BSA in the system, the 3-D reactor would
serve as a more in vivo-like test bed for new gene therapy vectors.
As a potential first application for this new reactor system, 2-D and 3-D
transfections experiments were carried out to examine the gene delivery efficiency of novel
non-viral gene therapy vectors in comparison to a viral vector and an established non-viral
carrier. It was hoped that this study would first show if gene expression would be
quantitatively measurable with the higher number of cells in the scaled up reactor, and
secondly, if it could provide insight as to whether or not relative gene delivery efficiencies
could change as a function of the culture system used to study the vector. PEI25 vectors,
for which gene expression levels were difficult to quantitatively measure in the cell numbers
provided by the original microreactor system, provided significant levels of f-Galactosidase
transgene activity over no dose and naked DNA controls. This vector was set as the
benchmark for comparison for the next generation non-viral carriers and the adenoviral
vector. The small cross-linked PEI vector performed exceptionally well in 2-D
transfections, giving an 80 fold increase in gene expression, and perhaps more impressively,
was only a little under 2 fold less efficient than the adenovirus in 2-D. The C32 vector,
which had been shown to be highly efficient in Cos-7 and IHepG2 cell line, yielded less
transgene expression than the cross-linked PEI vector but still greatly outsurpassed the
PE125 vector with a 30 fold improvement in 2-D expression.
The most interesting results from this study came from the comparisons between the
2-D and 3-D experiments. In 3-D tissue transfections, it was expected that the gene delivery
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vectors would likely be less efficient on the basis of transgene expression per total DNA
dose. This could be explained by the fact that not every cell in the culture is readily
accessible to the complexes in the medium. Vectors would have to carry their DNA payload
through the tissue structures, be it through vessels structures that can sometimes form in the
tissue due to the presence of a small fraction of non-parenchymal cells such as endothelial
cells in the hepatocyte isolate or through matrix proteins that are secreted by the hepatocytes
as they reorganize in the channels. Additionally, non-viral complexes may aggregate over
time in the fluidic circuit, and either become too large to be endocytosed by the cells or
potentially sediment in the reservoir with increased size. This decreased overall efficiency
was observed, but what was more unexpected was that the two next generation non-viral
vectors gave resulting expression levels that were opposite the case seen in 2-D
transfections. In the liver bioreactor, the small cross-linked PEI was doubled in efficiency
by the C32 vector, while the cross-linked PEI had more than doubled the C32 efficiency in
2-D. A number of explanations for this phenomenon can be postulated. For instance, the
C32 may stay more stable in the fluidic loop over time and result in more prolonged delivery,
whereas in the 2-D case, the complexes sediment onto every cell and can be easily
endocytosed. Additionally the slightly more hydrophobic character may allow the C32 to
bind to cell membranes more efficiently under flow conditions.
While significant mechanistic analysis would be required to prove or disprove these
or other theories, the primary conclusion that can be made from this initial study is that the
success of a gene therapy vector can depend heavily on the system in which it is tested.
While quantitative and mechanistic studies of vector delivery, the majority of which are
performed in cell lines in 2-D cultures, can be useful to understand why or why not a vector
is efficient, they may be irrelevant in many cases when extending these therapeutics to
clinical applications. This strengthens the need to study vectors in pre-clinical animal
models, though simply relying on these models will not necessarily drive vector development
significantly. This is due to the fact that quantitative and mechanistic analysis is highly
difficult to conduct in animal models. If a vector is marginally effective in a given animal
model, it is difficult to deduce why it was effective, or more importantly, how it can be made
more effective. It is now clear that endpoint level screening alone will not result in many
non-viral vectors that are as effective as their viral counterparts. Approaches in rational
design of vectors show promise for improved carriers, but experimental systems that allow
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for quantitative analysis are needed that more faithfully mimic the in vivo environment and
cell phenotypes that a vector will need to contend with. These systems can provide feedback
that will be more useful in designing functionality to overcome various barriers to
expression. Our scaled up liver bioreactor provides a new system where such work can be
performed. By combining quantitative intracellular level assays for gene vector trafficking
and expression coupled with qualitative imaging analysis in this system, it is hoped that
mechanistic data can be generated that drives the development of efficient vectors for in
vivo liver gene therapy applications.
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Figure 4.1: Exploded view of the Giant reactor components. All internal components fit over the
alignment pins in the central pocket. The three polycarbonate body pieces screw together to form an
upper and lower flow chamber around the cell holding scaffold, the middle filter, and the lower
support scaffold.
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Figure 4.2: Fluidic circuit for the giant reactor. Two peristaltic pumps drive the flow of medium to
and from the reactor inlets and outlets. Medium is reoxygenated in the reservoir cup and the tubing.
Pump A controls the main flow over the top of the scaffold in the upper flow chamber, and pump B
controls the perfusion flow, or cross flow, through the scaffold channels. The direction of the
crossflow can be run either upward or downward through the channels at different stages of the
culture. An inline filter is placed in the crossflow lined when pump B sends media from the reservoir
to the lower flow chamber to prevent clogging.
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Figure 4.3: Computational fluid dynamics simulation of flow in the upper chamber of the giant
reactor. The cell scaffold is exposed to a uniform velocity field that remains consistent over the
entire channel array. High velocities are tempered shortly after chamber entry. Streamlines indicate
no recirculation in the system. Velocity is normalized to the value at the inlet. Only half of the
upper chamber was modeled due to symmetry to speed computation.
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Figure 4.4: A) Top view of an assembled Giant reactor containing a laser machined polycarbonate
scaffold with an array of one thousand 300x300x230 um channels. The overall size of the 3-
compartment bioreactor housing is approximately 78 x 54 x 21 mm. B) The top window is easily
removed from the assembled reactor to seed cells into the channel array. (See next page.)
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Figure 4.5: In situ light microscopy image of reorganized liver tissue structures in the channels of
the collagen treated polycarbonate scaffold seven days after hepatocyte isolation.
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Figure 4.6: Relative liver specific gene expression across culture systems. RNA was purified from
in vivo liver slices, freshly isolated hepatocytes, day 7 post isolation collagen gel sandwich cultures,
day 7 post isolation Milli-F 3-D liver bioreactor cultures, and day 7 post isolation 3-D Giant Reactor
cultures. cDNA was generated from RNA and RT-PCR was used with optimized primers to quantify
previously determined liver enriched genes. Samples were internally normalized to ribosomal RNA
18s levels. Replicates were then averaged and globally normalized to in vivo expression levels to show
the log fold 2 upregulation or downregulation of each transcript relative to native liver. In vivo and
isolated hepatocytes samples were performed in quadruplicate, and 2-D and 3-D cultures systems in
triplicate. RT-PCR was performed in technical triplicate.
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Figure 4.7: Transgene expression levels 48 hours after gene delivery to hepatocytes cultured in 2-D
on adsorbed collagen monolayers and in 3-D in the liver bioreactor. Left axis denotes 2-D
expression levels relative to PE125, and right axis denotes relative 3-D expression levels. All 2-D and
3-D transfections were performed in experimental and technical triplicate.
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Chapter 5
Quantitative Comparison of Next Generation Non-viral Gene Therapy
Vectors with a Canonical Viral Vector: Quantitative Intracellular
Trafficking Studies and Modeling Analysis
5.1 Introduction
As discussed in Chapter 3, mathematical modeling approaches and quantitative,
mechanistic analysis in general can provide added insight for non-viral gene therapy vector
development. However, it is apparent that new models must be developed that are more
accurate and informative if this approach is to truly drive the rational design of vectors that
are as efficient as viral carriers while offering the benefits of enhanced flexibility and overall
safety.
To date, most mathematical models that have been applied to the study of non-viral
gene therapy have utilized a compartmentalized, pharmacokinetics based approach [113, 132,
179, 182, 210]. In order to obtain accurate model fits, many compartmentalized models and
quantitative studies must abstract the level of spatial detail in cellular compartmentalization
and overall steps to a point where lumped parameters and model simulations are not
successful in identifying rate limiting steps or in generating biologically relevant hypotheses
[179, 183]. One way to potentially get around this problem is to collect rate information for
specific steps from the literature [113]. However, this is potentially dangerous, since some
processes are vector dependent and also most likely cell type dependant, so information
must be chosen with care, taking into account the system and cell type the data was
generated in and considering how the previous observation will translate into the application
of interest.
Other attempts have explored the idea of integrating elements of stochasticity in
model simulations of gene delivery and using single cell imaging data to corroborate model
predictions [181]. While this certainly lends merit to the overall effort of improving gene
therapy models, and may be advantageous to better describe certain portions of the delivery
pathway, more immediate progress may be made by utilizing methods that allow for more
quantitative analysis on a populational level. Efforts to this extent have been made in
examining millions of transfected cells via FACS-based analyses but to date have mainly
focused on isolated portions of the delivery pathway [135] or more generally on end metrics
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of gene expression or insensitive toxicity assays [176, 211]. Approaches that could offer true
compartmentalized quantitative measurement for a large number of cells may build data sets
that can lead to model structures that can more robustly deal with populational variation
within a cell or tissue type and also address the need for data that can help to fit parameters
that describe hard to measure intracellular rate processes
The work in this chapter looks to extend the methods established and described in
Chapter 3 to a more complete and rigorous analysis of vector trafficking. The primary goal
is to mechanistically compare two next generation non-viral vectors, the previously
introduced small cross-linked PEI and C32 poly(f-amino ester), with a canonical viral
vector. While it has already been seen in Chapter 4 that these new vectors achieve highly
efficient gene transfer and transgene expression in primary hepatocytes compared to more
traditional non-viral vectors, it is interesting to explore if these carriers reach these results
with any notable differences at the intracellular level. It is hoped that by employing the
novel methods developed in this thesis work to build quantitative trafficking data sets with
higher spatial resolution than was previously available, more accurate mathematical models
can be created that can allow for extended analysis on vector performance and delivery
mechanisms.
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5.2 Materials and Methods
5.4.1 Primary Cell Isolation and Culture
Primary cells were isolated from male Fisher rats weighing 150-180 gm using a
modified version of the Seglen 2-step collagenase procedure as previously described [161,
162]. Blendzyme Type III (Roche, USA) was used for digestion instead of collagenase. Cells
that were released by the digestion were suspended in DAG (DMEM (Sigma-Aldrich, USA),
Albumin, Gentamycin) and spun and washed twice at 50g for 3 minutes. The final pellet
was resuspended in hepatocytes growth medium (HGM), as described previously [161, 162],
to yield a 95%. or greater pure suspension of hepatocytes. The final cell viability was
determined by trypan blue exclusion, and cells were only used if viability was in the 89-95%
range.
Cells were seeded in 60 mm tissue culture dishes treated with a dried adsorbed
collagen monolayer. Collagen type I from rat tail (BD Biosciences, Bedford, MA) was
diluted in sterile 1x PBS at a concentration of 30 ug/mL. Plates were incubated with 3 mL
of this solution for 2 hours, then aspirated and allowed to dry in a sterile hood for two hours
prior to seeding. Cells were seeded in 3 mL of HGM at a density of 800,000 cells/mL
immediately after isolation. Medium was changed 4 hours post-seeding to eliminate dead
and unattached cells and debris, while ensuring 90-95% confluency. All1 experiments were
performed within 24 hours of seeding to ensure the best maintenance of hepatocyte
phenotype.
5.4.2 Plasmids, Polymers, Virus and Non-viral Complex Formation
Plasmid gWiz-o-Galactosidase (Gene Therapy Systems, San Diego, CA) encodes the
enzyme 0-galactosidase controlled by the human cytomegalovirus (CMV) promoter. The
plasmid DNA was purchased purified and ready for use from a contract plasmid
manufacturing company (Aldevron, Fargo, ND). The small cross-linked PEI and C32
polymers were synthesized as described previously [105, 106, 108]. The adenovirus serotype
5 with El and E3 deletions encoding 0-galactosidase under a CMV promoter was purchased
from Vector Core (University of Michigan, Ann Arbor, MI).
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For transfection via small cross-linked PEI, polymer and DNA were diluted to the
appropriate concentrations in sterile water and combined at an N/P ratio of 30. Polymer
was added to DNA and left at room temperature for 10 minutes to allow for formation of
complexes. For C32, polymer and DNA were diluted in sterile filtered sodium acetate
buffer, pH 5.4, combined at a polymer mass/DNA mass ratio of 100, and left at room
temperature for 5 minutes. Both complexes were added to HGM at a DNA concentration
of 5 ug/mL. Adenovirus particles were diluted in a 10% glycerol in Ix PBS buffer to make
working stocks, and the appropriate amount of particles was added to the media to achieve a
multiplicity of infection of 20. Non-viral particle size was determined via dynamic light
scattering using a ZetaPALS Zeta Potential Analyzer with ZetaPALS Particle Sizing Software
Version 2.3 (Brookhaven Instruments Corporation, Holtzville, NY). Number averaged
particle diameters were determined over a lognormal distribution for the two complexes.
The small cross-linked PEI complexes measured 167.5 ± 8.2 nm in diameter, while the C32
complexes were 152.0 ± 4.2 nm.
5.4.3 Quantitative Trafficking Assays
Hepatocytes were transfected with 2 mLs of medium at the complex and virus
concentrations indicated above. Cells were collected and fractionated at 10, 20, 40, 60 and
120 minutes after transfection. At each time point of interest, the transfected plate was
placed on ice to halt endocytosis, scraped, lysed and subjected to DGE fractionation as
described in Chapter 3 (see section 3.2.3). After mechanical lysis, 400 uL of the whole cell
lysate was aliquoted and frozen for plasmid quantification and normalization. After the
nuclear spin, 400 uL of the supernatant was similarly retained. The total volume of the
whole cell lysate and the post-nuclear supernatant were carefully measured to calculate total
plasmids for each fraction based on the aliquot values. After completion of each DGE
separation run, 24 1.25 mL fractions were collected and frozen.
Total plasmids were quantified in whole cell, nuclear, cytoplasmic, and all DGE
fractions via Taqman real-time PCR. Organelle mapping assays were also performed on
DGE fractions as described previously in Chapter 3 to determine the location of late and
early vesicle fractions for each run. The relevant fractions were summed and these early and
late vesicle quantities were subtracted from the post-nuclear supernatant quantity to
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determine the total amount of free cytosolic plasmids. Total collected cell number for each
sample was determined via real-time PCR quantification of the rat GAPDH gene as
described below and comparison to a standard curve. All five fractions, whole cell, nuclear,
cytosolic, early vesicular, and late vesicular, were normalized to a per cell basis. Normalized
triplicate replicates were averaged for each fraction and time point to build the quantitative
trafficking time courses.
5.4.4 DNA Isolation and Taqman Quantitative PCR
Plasmid DNA was purified from each fraction of a given DGE run using the
DNEasy 96 Tissue Kit (Qiagen, Valencia, CA). Samples from each cell fraction were pooled
in a round bottomed collection plate (Qiagen) for cell lysis. 200 uL of whole cell lysate and
post-nuclear supernatant were used from each sample, while the entire nuclear pellet was
resuspended in 150 uL of room temperature PBS and added to the collection plate. A
multiwell pipette was used to thoroughly mix the contents of all DGE fractions, and 200 uL
of each fraction was added to the collection plate. Samples were lysed for 30 minutes at
700C, and then subjected to the standard Qiagen purification protocol. Plasmid
quantification was performed using the MJR Chromo 4 system (Bio-Rad, USA). j-
Galactosidase plasmid forward and reverse primers and probe were designed using Primer
Express Software (Applied Biosystems) and yielded sequences for forward primers, reverse
primers, and dual labeled probes. Two sets of forward and reverse primers with probe were
ordered and tested for optimal efficacy, as determined by widest spread of linear standard
curve range and steepest slope of standard curve (Applied Biosystems, Foster City, CA).
The resulting primers and probe spanned an 80bp region in the n-Gal coding region of the
plasmid and had sequences: forward primer (5'-TTA CAG GGC GGC TTC GTC T-3'),
reverse primer (5'-TAA GCC GAC CAC GGG TTG-3', and dual labeled probe (5'-6FAM-
CTG GGT GGA TCA GTC GCT GAT TAA ATA TGA TG-TAMRA-3'), used at
concentrations of 400nM/400nM/25nM, respectively. PCR cycle conditions were 500 C for
2 min, 95 0C for 10 min, followed by 40 cycles of 950 C for 15 s and 60 0 C for 1 min. In order
to normalize samples to a per cell basis, genomic DNA was also purified and quantified
from a whole cell sample from each DGE run. Taqman primers and probe were similarly
designed to quantify the rat GAPDH gene which spanned an 80bp region with the following
sequences: forward primer (5'- TGG GAT AGC CAG TGC TCT TA -3'), reverse primer
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(5'-ACA GGA GAT GGG TTG GAA CT -3ý, and dual labeled probe (5'-6FAM-TGA
GCC ATC ATC ATC TCC GCT G-TAMRA-3'). The primers and probe were used at
concentrations of 900nM/900 nM/225 nM respectively. PCR cycle conditions were 500C
for 2 min, 950C for 10 min, followed by 40 cycles of 950C for 15 s and 540C for 1 min.
5.4.5 Computational Modeling and Analysis
A linear system of ordinary differential equations (ODEs) was formulated to
describe the intracellular delivery processes involved in vector uptake, trafficking, vesicular
escape, degradation, unpackaging, and nuclear binding and uptake (Figure 5.1 and 5.2). This
model structure was based on a previously developed ODE model [113] which has been
experimentally validated in quantitative C3A cell line transfection experiments [132], but
employed some added steps and more freedom to fit model parameters due to availability of
more experimental data per vector in this current study. Rate constants that described
delivery steps that are inherently dependant on the physical properties of the polymer or
viral vector were subjected to parameter fitting routines to build vector specific mathematical
models. Model simulations and parameter fitting routines were initially performed in Matlab
(The Mathworks, Natick, MA), but were unable to provide acceptable model fits. Analysis
was moved to Jacobian (Numerica Technology, LLC, Cambridge, MA) for more rigorous
parameter estimation and sensitivity analysis capabilities. First, a graphical structure for the
model steps was built in Teranode (Teranode Corporation, Seattle, WA). This model
structure was then converted to SBML format and imported into Jacobian.
Predefined functions were used in Jacobian to perform parameter estimation by
simultaneously fitting model parameters to all data sets for a given vector. After parameter
fits were attained with minimized residuals, model simulations were also performed within
Jacobian to assess the quality of the fit to each time course. Predefined sensitivity analysis
functions were carried out in Jacobian to determine the delivery steps that had the greatest
potential effect on the number of free nuclear plasmids achieved by each vector. Jacobian
calculates instantaneous sensitivities and also outputs the integral of the time course, which
is reported in the results section. Multistart algorithms were also employed to explore over
four thousand parameter fits and ensuing sensitivity analyses to ensure that the best possible
model fits were being attained. Principal component analyses on these larger data sets were
performed in Matlab, using a predefined function in the Statistics Toolbox. All Matlab and
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Jacobian code, as well as the Teranode model structure used in these model fits and analyses,
can be found in Appendix 15.
5.3 Results
5.3.1 Mathematical Model
A linear system of differential equations was used to describe the intracellular gene
delivery processes illustrated in Figure 5.1. This model was adapted from a previously
developed system of equations [113, 132], with added steps and species due to the fact that
more compartments could be experimentally monitored. Each step in the delivery pathway
is approximated as a first order mass action rate process and follows the vector/plasmid
non-viral complex or free plasmid from cell binding and uptake through to nuclear import
and transgene expression from unpackaged plasmids in the nucleus. Overall, the model
contains 17 ordinary differential equations, with 6 model parameters being dependent to
some extent on vector chemistry and physical properties: k,_,Upt, kTraff, kEscape, kDegVeside,
kUnpack, and kBindector (Figure 5.2).
A full model description, as well as the rational for inclusion, combination and
omission of the various steps in the delivery process has been previously discussed [113,
132]. Additionally in this new model, the internalization and trafficking rate processes have
been modified slightly since plasmids can now be quantified in early endosomes and in late
endosomes/lysosomes. The uptake process is described as entry into the cell into these early
vesicles, with a new vector dependent rate constant, kTrff, describing the progression into
late vesicle compartments. Since the experimental data showed the majority of the delivered
plasmid to accumulate in these late vesicles, even at relatively early time points, it was
rationalized to limit the process of vesicular escape to the late vesicle compartments.
However, it is not out of the question that vectors may escape from early compartments,
and alternate model structures that can account for this and other processes may be
examined in future analyses and model extensions. This model structure was successfully
implemented in Teranode and imported into Jacobian for all forthcoming model fitting and
data analysis.
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5.3.2 Quantitative Trafficking Time Courses
To examine intracellular trafficking of plasmids with higher spatial resolution,
primary hepatocytes were transfected with small cross-linked PEI, C32, and adenovirus
vectors and processed for subcellular fractionation at multiple time points during the first
two hours of gene delivery. Density gradient electrophoresis (DGE) was implemented in
conjunction with high throughput DNA purification and quantitative Taqman real-time PCR
to separate and recover early and late vesicle fractions and subsequently quantify plasmid
trafficking over time. During the lysis and processing of each sample for DGE
fractionation, other cell fraction aliquots were retained such that plasmids could also be
quantitatively tracked in whole cell, cytosolic and nuclear fractions at each time point,
allowing for a highly comprehensive analysis of cellular plasmid distribution.
Trafficking time courses can be seen in Figure 5.3. All three vectors show highly
efficient cell uptake and nuclear delivery. The C32 vector appears to traffic its genetic
payload to the nucleus faster than the adenovirus or PEI vectors which show a more gradual
increase in nuclear associated plasmids. However, at the 120 minute time point the two non-
viral vectors have delivered roughly the same amount of plasmid to the nucleus. The non-
viral vectors both deliver just under 50% of the total available per cell extracellular plasmids
within 2 hours, since the 10 ug of total DNA in the initial dose equates to roughly 5x105
plasmids per cell. Once again, the C32 polymer displays slightly faster overall uptake
kinetics, but levels off after 60 minutes and decreases slightly at the last time point, which is
possibly due to degradation. Meanwhile, the PEI vector shows fairly linear uptake kinetics
over the entire time course. The adenovirus is even more efficient, with nearly 75% of the
dose per cell being taken up at 2 hours. The virus is taken up very quickly at first, and then
the uptake rate slows at the late time points, most likely due to the fact that there is less of an
extracellular excess of viral vector since a fairly low multiplicity of infection (MOI) was used
in these experiments. This MOI was maintained at a low level since higher dosages have
been shown to cause adverse affects in primary hepatocytes in 2-D culture. As was seen in
gene expression results in Chapter 4, this is still more than enough vector though, since
adenovirus is highly effective at maintaining transgene expression once the viral DNA has
been delivered at the nucleus.
Figure 5.3B shows only the vesicular time courses in order to better evaluate the
qualitative dynamics of trafficking in these compartments. The early endosome trafficking
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looks fairly uninteresting for all of the vectors. A near constant level of plasmids is
maintained that is much lower in magnitude than the amount of plasmids seen in the late
vesicles. This result agrees with general observations in primary hepatocyte trafficking in the
endocytic pathway, which is highly active. In optimizing pulse chase regiments for labeling
only early endosomes in primary hepatocytes, pulses had to be kept to 3 minutes or less to
keep signal only in early endosome DGE fractions. It appears that these vesicles may
quickly and repeatedly form and cycle the internalized complexes to the late vesicle
compartments, such that their instantaneous quantity of plasmid is not exceptionally high
but their overall contribution to uptake and trafficking is significant. Substantially different
dynamics are seen in the late vesicle fractions. The C32 vector achieves a very rapid pulse of
plasmids into the late compartments with an early peak at the 20 minute time point. The
decrease thereafter could suggest efficient escape, vesicular degradation, or a combination of
the two processes. The cross-linked PEI vector once again shows a more consistent build
up of plasmids, and the adenovirus shows more of an intermediate dynamic between those
of the two non-viral carriers.
5.3.3 Vector Specific Model Fits to Experimental Data
While the quantitative trafficking time courses showed some interesting mechanistic
differences between the three vectors, they can provide more utility for overall analysis
through the creation of vector specific mathematical models. All quantitative data was
imported into Jacobian, and estimation functions were used to systematically vary the values
of the vector dependent rate constants: kBid Uptake kTrafi, kEscape, kDegVesicle, kunpack, and
kBindVecto, while all other rate constants in the model were held constant. Parameter sets
were determined which best fit the experimental data for each vector. Model fits with these
optimized parameter sets can be seen in Figure 5.4.
The parameter values which gave the best fits for each vector are listed in Table 5.1.
Additional mechanistic insight regarding the specific steps represented by the fit parameters
can be postulated from these results. The C32 vector seems to be the most efficient carrier
at cell binding and uptake, and possibly related to this also shows the fastest trafficking rate
constant for trafficking into the late vesicles. While these were fairly intuitive conclusions
from the experimental data, other results of the fits were not. For instance, according to the
model fits, the small cross-linked PEI actually undergoes endosomal escape an order of
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magnitude faster than the C32 and Ad5 vectors, which may have seemed counterintuitive
when only considering the late vesicle trafficking time courses. Interestingly, adenovirus
unpackages more slowly than the PEI vector, but faster than the C32 vector, yet overall
shows slower vesicular degradation than both non-viral vectors.
5.3.4 Parameter Sensitivity Analysis
Vector specific models were subjected to parameter sensitivity analyses in Jacobian
to determine what steps in the gene delivery process could be rate limiting for each vector.
While vector specific parameter values can suggest where a vector is efficient or inefficient at
a given step relative to other vector, it does not necessarily indicate whether or not that step
is potentially rate limiting for the overall success of nuclear plasmid delivery. Sensitivity
analyses take into account the contribution of all steps when a given parameter is varied as
well, so consideration can be given to parameters that were not varied for the fits and stay
relatively constant for all of the vectors.
The previously discussed model fits were the best possible fits for a set of initial
parameter guesses and other constraints placed on the fitting routine. These guesses and
constraints were determined by using a multistart script which ran a matrix of over 4,500
initial guesses and conditions for each vector that were input to the fitting routine. The fits
were then ranked ordered and the top 5% of model fits were examined. The parameter
values for each vector specific model general fell into a very tight range around the best fit
values that are reported in table 5.1. However, in order to ensure that sensitivities weren't
biased by this specific parameter fit, a similar recursive fit was run on the top 500 fits for
each vector, to ensure that model parameter sets that were only slightly less good at
describing the experimental data didn't show vastly different sensitivities and contest the
validity of the best fit.
Figure 5.5 shows the overall average sensitivity values for each parameter and vector.
Sensitivities were incredibly consistent over all of the parameter sets, as denoted by the
relatively tight standard deviations. The most sensitive or potentially rate limiting steps for
all three vectors are kBind_Uptake and kin, the steps representing cell entry and nuclear import.
All three vectors were also sensitive to binding nuclear import machinery and unpackaging
to some extent. Adenovirus showed some sensitivity to vesicular degradation, while both
polymers were largely insensitive to this step. The virus was also somewhat sensitive to
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endosomal/lysosomal escape, with the PEI vector being less sensitive and the C32 vector
being fairly insensitive to this step.
With all three vectors displaying sensitivity to multiple steps, and the largest
discrepancies between vector sensitivities existing at moderate steps, a principle component
analysis was performed on the parameter value and sensitivity values for the top 500 fits for
each vector (Figure 5.6). Principle component analysis provides an efficient way to visualize,
analyze and compare higher dimensional data by collapsing the contributions or multiple
parameters or variable onto new coordinates, the basis vectors of which define the "new"
combinatorial dimensions that show the greatest variation in the overall data set. Data sets
were normalized and collapsed onto two principle components. Clustering was seen to
some extent for the vector specific parameters, denoting that they were more similar to each
other than to the parameters, but overall there was still a fairly random distribution overall
which made this first pass analysis difficult to interpret. However, the most interesting
results came from the principle component analysis of the sensitivity values. The
sensitivities for each vector collapsed to three primary, unique clusters. This suggests that
the vectors do indeed have unique sensitivities that depend on a weighted subset of the
model parameters and therefore, steps in the gene delivery process. This result warrants
more in depth future analysis on the makeup of these principle components and the
implications they can have for vector development.
5.4 Discussion and Conclusions
We have demonstrated a combined experimental and modeling approach that
provides a more comprehensive mechanistic analysis for the intracellular trafficking of gene
therapy vectors. This approach has been directly applied to primary hepatocytes in order to
generate quantitative data sets that describe the dynamics of gene delivery for an adenoviral
vector and two next generation cationic polymer vectors. These new cationic polymers have
been previously shown to be highly efficient carriers, and methods that provide insight into
their success could translate to a better overall understanding of how to approach rational
design of new carriers. It is generally more difficult to generate repeatable quantitative data
in primary cells as compared to immortalized cell lines, but the methods developed in these
studies were robust enough to deal with animal to animal and isolation to isolation
differences in the hepatocytes. This was important in the context of our end goals of driving
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future development for in vivo liver gene therapy, as it is becoming increasingly apparent
that vectors should be evaluated in their primary cell or tissue type of interest to truly gauge
if they can be useful for clinical application.
With increased spatial resolution in the cellular compartments that play an important
role in uptake and transport to the nucleus, mechanistic differences could be observed in the
delivery processes of the individual vectors. Additionally, these data sets provided the basis
for more accurate mathematical model fits, which offer the potential and flexibility for more
in depth analysis. Though direct observation of the experimental data was able to reveal
some clues as to how vectors differed as delivery agents (Figure 5.3), more direct
conclusions could be made from vector specific mathematical model fits and model analysis.
Rate constants that described steps in the delivery process that are dependent on polymer or
virus properties were fit to the experimental time courses. In these initial fits, model
parameters were varied to best describe four simultaneous data sets: whole cell plasmids,
cytosolic plasmids, total vesicular plasmids, and nuclear plasmids. It was found that
separately fitting to all five time courses yielded inferior parameter fits, likely because
information exists in multiple compartments for many of the rate constants. For instance,
fitting endosomal escape and degradation parameters to the late vesicle time course alone is
less accurate, since knowing the amount of plasmids that have already escaped and trafficked
to the cytosol and nuclear compartments gives a more informative overall picture than just
looking at how many plasmids are in the late vesicles at certain time points. Slightly non-
intuitive results from overall parameter fits that are not immediately obvious when
examining single time courses by eye show why it's powerful to fit to all data at once.
Examination of the late time points in the C32 late vesicle time course suggested enhanced
escape or increased vesicular degradation, but a comprehensive model analysis revealed that
this was more likely due to enhanced uptake and trafficking relative to the other vectors.
This conclusion began to make more physical sense when the nuclear, cytosolic and late
vesicle time courses were all examined, a process which is done far more efficiently in siico.
Additionally, a total vesicle time course gave the best results for fitting in concert
with the whole cell, cytosolic, and nuclear trafficking data (Figure 5.4). This was most likely
due to the fact that the other four compartments greatly outweighed the early endosome
compartment in plasmid per cell magnitudes, consequently giving them more overall weight
in minimizing the residual error during the fitting process. More temporal resolution is likely
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needed at early time points to accurately fit early endosome time course information, but as
was discussed in the results, the low magnitude and rather constant dynamics of this
compartment do make mechanistic sense in primary hepatocytes. Future analyses may focus
on different model structures and fitting procedures that can utilize this information more
effectively.
Overall, vector specific rate constants varied over five orders of magnitude and
showed interesting differences at certain steps. As reported in the results section, interesting
differences between vectors were seen in endosomal escape, unpacking and vesicular
degradation steps that were not obviously apparent when examining the time courses. The
enhanced uptake and binding ability of C32 could explain why it was able to attain increased
success in 3-D transfections examined in Chapter 4, while the PEI vector may have greatly
outperformed the C32 in 2-D cultures due to its increased ability to escape endosomes in a
system where binding and uptake were less important.
Sensitivity analyses were carried out on all model parameters to surmise which steps
in the overall delivery pathway could be rate limiting for successful delivery of nuclear
plasmids (Figure 5.5). While the vector specific steps are obviously important to focus on
since they can be directly addressed through chemical modifications to the vectors, all steps
should be considered, since the overall model structure resulting from specific parameter fits
can actually cause the processes with unvarying parameter values to also be more or less rate
limiting. This was observed for all three vectors. The most sensitive step in all cases was
nuclear import, followed again for all three vectors by cell binding and uptake. These results
were encouraging when considering past analyses of less efficient vectors in the C3A cell
line, where only the most efficient vectors showed sensitivity to nuclear import [132]. This
suggests that both polymers are very efficient overall at navigating through the endosomal
pathway and escaping efficiently, essentially building up at the entryway to the nucleus and
waiting to get in. Achieving more efficient nuclear import could greatly enhance delivery
efficiency, as well as finding more efficient ways to achieve cell uptake. There are many
practical strategies that could be employed to address these enhancements. Incorporation of
enhanced nuclear localization sequences on either the plasmid or the vector could allow for
improved nuclear import [212]. Similarly, targeting moieties could be attached to the vector
to allow for cell specific binding and increased uptake by triggering receptor mediated
endocytosis events, rather than relying on nonspecific association with the plasma membrane
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and internalization via general fluid phase endocytosis. In the specific context of primary
hepatocytes, strategies could be pursued to target the asialoglycoprotein receptor for cell
specific uptake. However, many efforts to date have been largely unsuccessful to this end.
In general, careful consideration has to be taken for how incorporation of these cell and
nucleus targeting groups will affect the overall structure and properties of the non-viral
complexes.
Another observation that indicates vast improvement in these new vectors comes
from looking at the relative magnitudes of the sensitivity values for the three vectors. In this
study, the polymer sensitivity values are at the same order of magnitude as those for
adenovirus. In our past comparison, adenoviral sensitivities were two to three orders of
magnitude lower than those for all non-viral vectors examined. This suggests that the
properties of the two next generation vectors have allowed them to become more efficient at
overcoming all of the barriers in general. As a result, more intermediate sensitivity values are
also observed, instead of the one or two blaringly sensitive steps that were observed for the
less efficient non-viral vectors. The most interesting differences between vectors can be
seen at these intermediate sensitivities, such as endosomal escape and vesicular degradation.
Since these vectors do have sensitivities to multiple steps, in order to maximally
optimize a vector, further analysis may be required that takes multiple parameter
contributions into account. While substantial improvements to new vectors could be made
by addressing the common most sensitive steps for both vectors, looking at unique
characteristics of each vector could lead to more customized improvements for each base
chemistry. One method that can take this higher dimensional analysis and abstract it to an
easier to digest format is principle component analysis, which can reduce complex,
multidimensional data to a reduced set of basis vectors that are described by a combination
of weighted contributions from the individual parameters. A preliminary principal
component analysis was performed on the sensitivity values and the sensitivity contributions
from the 11 analyzed parameters were collapsed to two principal components. Parameter
data from hundreds of fits for each vector were fed into this analysis and surprisingly the
points for each specific vector mapped together in distinct clusters. This suggested that each
vector had a unique dependency on some combination of steps, and also gave clues to how
similar one vector was to another in terms of how close their respective clusters were in this
collapsed space. The two polymer vectors seem to be more similar to adenovirus than they
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are to each other, which corroborates with the different trafficking dynamics that were seen
for the two carriers. However, to truly gain insight from this approach and to gauge if these
unique dependencies can actually translate to tractable physical approaches for vector
improvement, more in depth analyses must be performed to better understand the
breakdown of the principle components. Investigations into the how the overall model
structure and parameter space affect the principle components and degree and localization
of clustering can also be instructive. In general, this quantitative time course data and
subsequent model analyses can generate a number of interesting hypotheses for future
experimental efforts and extensions of model analysis and in silico simulation. These efforts
have the potential to drive more rational vector design to improve non-viral delivery
efficiency.
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Figure 5.1: Mathematical Model Schematic
Figure 5.1: Mathematical model schematic depicting the intracellular delivery steps that are described
in the mathematical model and the different species that can be measured via quantitative trafficking
assays. Rate constants which describe various steps of the process are shown in yellow. Species are
shown in blue. For clarity, species names were not shown for the multiple states that exist during
nuclear import. These include VectPlasBound_Cyt, VectPlasBound_NPC, VectPlasBound_Nuc,
PlasBoundCyt, PlasBound_NPC, and PlasBound_Nuc.
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Figure 5.2: Mathematical model used to describe the rate processes discussed in the model
schematic. Steps in the delivery process are modeled as first order rate processes, yielding a system
of ordinary differential equations with the appropriate rate constants and species in each cellular
compartment. VectPLas represents the intact non-viral complex, while Vect and Plas represent the
unpackaged polymer or viral protein coat and the DNA plasmid or recombinant viral DNA
containing the transgene, respectively. Subscripts denote the location and state of each species.
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Figure 5.3 A): Quantitative trafficking time course data for Adenovirus, C32 and Small Cross-linked
PEI with increased spatial resolution via DGE fractionation and quantitative Taqman real-time PCR.
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picture of the vesicle dynamics of plasmid trafficking for the three vectors.
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X-Linked PEI
kBi nd_Uptake
kTraffic
kEscape
kDeg_Vesicle
kBindVector
kUnpack
5.14 x 10-3
9.50 x 101
9.50 x 100
9.99 x 10-1
9.46 x 10-1
9.89 x 10-1
1.99 x 10-2
1.07 x 102
9.15 x 10-1
9.53 x 10-1
2.99 x 10-1
2.79 x 10-1
1.17 x 10-2
1.17 x 101
1.15 x 100
3.84 x 10-1
3.98 x 10-1
3.48 x 10-1
Table 5.1: Vector Specific Parameter Values: Each first order rate constant is reported in units of
min -1.
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Figure 5.4: Vector specific model fits. Jacobian output for model simulations compared to
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Figure 5.6: Principal component analysis of multiple model parameter fits and ensuing sensitivity
analyses. Collapsing this multidimensional data to two combinatorially weighted vectors in 2-D
space shows some interesting phenomena that can drive more in depth future analysis. Normalized
sensitivities for each vector map to unique regions in this principal component space.
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Chapter 6
Conclusions and Future Directions
Non-viral gene therapy holds a good deal of promise in providing safer gene delivery
strategies with increased flexibility and application specific functionality. However, current
non-viral vectors are inefficient compared to available viral carriers, and are largely
underrepresented in gene therapy clinical trials today. Novel approaches for the rational
design of non-viral vectors may be able to aid in the development of new vectors that safely
transfect specific cell types with the efficiency of recombinant viruses. However, more tools
are needed to provide quantitative, mechanistic information that can be used to improve
vectors for specific applications. This thesis work aimed to provide new devices and assay
methods that would contribute to this end, and specifically drive further development of
non-viral vectors for primary liver cells.
An improved density gradient electrophoresis device was built and an optimized
assay method was developed to successfully perform quantitative trafficking assays on
primary hepatocytes, and provided further insight on the dynamics of gene delivery via next
generation non-viral vectors. This approach was able to generate data sets that allowed for
the creation of more comprehensive vector specific mathematical models. Additional
analyses were performed with the models that can drive hypotheses for future experiments
and for potential vector improvement. This more complete data set can also generally be
used to train different mathematical model structures to improve these in siico analyses and
learn more about parameter fitting techniques, sensitivity analyses, and principal component
analyses in a well defined system.
In concert with this subcellular fractionation work, quantitative gene expression
assays were moved into a new, 3-D perfused liver bioreactor that succesfully maintained
enhanced liver phenotype of cultured primary hepatocytes and provided enough reorganized
liver tissue to compare gene expression between novel and established vectors. It was hoped
that this system would better reflect how a vector would perform in vivo, while still providing
the ability to perform quantitative measurements. This system, when compared to 2-D
transfection studies, provided very interesting results, revealing that vector success can be
dependant not only on cell type but also on the culture environment. These preliminary
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results make a strong argument for moving more vector studies into in vitro models that do a
better job of recapitulating in vivo structure and phenotype.
This work served as a first step into exploring the utility of quantitative intracellular
trafficking and gene expression studies in primary cells to learn more about how researchers
can bridge the gap between cell line and animal studies to potentially develop better vectors
or identify suitable applications for a given type of vector. Many direct extensions can be
made in these systems to acquire more useful information for vector evaluation. One of the
most obvious next steps is to fully combine the two main experimental approaches
developed in this thesis work to study intracellular trafficking in primary hepatocytes that
have an in-vivo like 3-D tissue structure and enhanced liver phenotype. The next generation
vectors used in this study internalized and trafficked so efficiently that the overall time
course had to be shifted to earlier time points than those used in our previous studies in
C3A cells. This made it exceptionally difficult to acquire consistent data at the 10 and 20
minute time points in 3-D cultures. Additionally, when examining the quantitative time
courses in Chapter 5, it can be concluded that an even earlier time point at 5 minutes post
delivery may be useful in deciphering some of the early uptake and trafficking dynamics in
the different compartments.
A new multiwell liver bioreactor that has been recently developed in the Griffith lab
could address these issues quite effectively. In the current iteration of this new system,
twelve cell scaffolds are assembled and seeded in an array of isolated wells within the reactor
plate, and are all consistently perfused by a novel microfluidic pumping system. Preliminary
work has been performed in this system with new scaffolds that have on the order of 800
channel units, meaning each well in the array would provide enough transfected cell material
for expression or trafficking studies. Liver tissue in each well could be dosed with a
vector/plasmid complex, and then individual scaffolds could be quickly recovered, washed
and lysed for more accurate 3-D uptake assays with increased resolution. Without the risk of
dedifferentiation that existed with performing multiple back to back DGE runs on the same
batch of 2-D cultures, stabilized 3-D cultures could provide more throughput for
performing full trafficking analyses as well. Overall this could allow for higher temporal
resolution and the ability to compare more vectors more efficiently.
One of the primary limiting factors in this study that affected how many vectors
could be examined and at how many time points was the rather long and involved process of
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the DGE separation protocol. While this method did provide excellent separation over an
order of magnitude faster than other available approaches, throughput was limited to one
sample at a time, and at best, two runs could be performed in a day. Approaches that could
multiplex this separation process would be highly beneficial to studying more vectors with
better temporal resolution, yielding more informative quantitative data sets for model fitting
and analysis. It appears that many efforts are on the verge of moving microfluidic separation
systems that have achieved success with DNA and protein analytes to applications with cell
organelles. This analysis would stand to benefit substantially from these developments, not
only by gaining higher throughput and detection sensitivity, but also by potentially increasing
the resolution of the overall separation and allowing for more detailed models to be
accurately created.
The current data set generated from these studies can also be subjected to a number
of mathematical model extensions. Different model structures can be explored that describe
various steps in the delivery process with greater or less detail or additional steps altogether
can be added which may explain alternate mechanisms. Analyzing goodness of model fits,
sensitivity analyses and principal component analyses on these structures may help to reveal
which structure is actually best, and suggest additional hypotheses into the nuances of the
delivery mechanism for each vector. The gene delivery pathway provides a fairly linear and
deterministic process as compared to many of the cell signaling networks that are often
analyzed with these approaches. As a result, this data could provide an ideal training set for
evaluating the utility of many of these approaches before applying the new techniques to
more complicated or incomplete data sets and models.
Additionally, for models to become truly informative for non-viral vector
development, more attention has to be given to the processes that occur after successful
delivery of plasmids to the nucleus. It is becoming increasingly apparent that nuclear
delivery may actually only represent half of the battle in attaining successful and safe non-
viral gene therapies. Many novel non-viral carriers, including the vectors studied in this
work, appear to deliver orders of magnitude more plasmid to the nucleus than viral vector
yet still result in lower and less sustained transgene expression levels. Lessons need to be
learned from viruses in regard to strategies for enhanced transcription factor recruitment and
avoidance of gene silencing. Novel DNA constructs such as minicircle DNA coupled with
integrase or transposase systems that achieve highly specific, site-directed insertion of
159
transgene into chromosomes that does not lead to aberrant expression of genomic DNA are
attractive options that have emerged in recent times. It is hoped that further mechanistic
study of these processes may lead to models that can lead to rational design of both
components of the non-viral complex yielding a specific combination polymer and I)NA
that gives a highly safe and efficient therapy tailored for the clinical application of interest.
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Appendices: Protocols and Detailed Experimental Methods
Appendix 1- Isolation and Viability Assessment of Primary Rat
Hepatocytes
IPreparation
(Prepare these items at LEAST a day in advance of the perfusion)
Perfusion Kit
Materials
* Tray and Cover
* Scalpel Holder
* 1 pair of Tissue Forceps
* 2 pairs of Small Tooth Curved Forceps (VWR 25601-010)
* Hemostat (Henry Schein 100-2376)
* Small Scissors
* Q-Tips (Puritan)
* Nu Gauze 2x2in, 4 ply (ohnson&Johnson via VWR #7632)
* EthiconTM Silk - 4 Strands of 4-0 Silk (VWR 25942-249)
* Blue Paper
* 100l m Nytex Filter
* Funnel
Method:
1. Place 100Itm Filter on Funnel, tape edges of filter to funnel with autoclave tape, and
Wrap in Blue Paper. Seal with autoclave tape.
2. Assemble and Wrap Kit in Blue Paper.
3. AUTOCLAVE DRY Cycle 45 : 15
Ca2+ Free Buffer (1L)
Materials Qty Notes
Milli-Q Water 1L
NaCI 8 .3g Sterile Perfusion Stock
KCI 0.5g Sterile Perfusion Stock
Hepes 2.3 83 g Sterile Perfusion Stock
NaOH 2 Tabs
Method:
1. Mix together in a Sterile, Autoclaved Bottle. Use a stir bar.
2. Ensure that the NaOH Tabs have fully dissolved
3. Adjust pH to 7.45 - 7.5 with 1N NaOH or HCl
Notes:
1. Use chemicals on Perfusion Bench
2. Keep these chemicals Sterile! Do not put excess chemicals back into the original
container, use a new scooper for each chemical
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10X CaC12 (H20) 2 Solution
Materials Qty Notes
Milli-Q Water
CaCl2 (H,20) 2  6.36g/L
DAG
Materials Qty Notes
DMEM 500mL (one bottle)
BSA 1g
Gentamicin 500uL (one aliquot)
500mL Sterile filter unit 0.2um pore size, Nalgene
Method:
1. Measure 1g BSA
2. Pour BSA into DMEM bottle and gently swirl until suspended - wait until BSA is
completely dissolved
3. Put DMEM + BSA, filter unit, and gentamycin into TC room hood.
4. Vacuum filter
5. Add gentamicin and swirl solution.
6. Aliquot into 50mL centrifuge tubes (one 30mL aliquot for every four 40mL aliquots)
II Perfusion Apparatus Setup
Peristaltic Pump
Materials
* Pump
* MasterflexTM Tubing
* Small (96410-14)
* Slightly Larger (96410-16)
* 2 - 500mL Orange Cap Bottles filled with -350mL 70% Ethanol
* 2 - 500mL Orange Cap Bottles
* Milli-Q Water
Method:
1. Prime the Pump by recirculating the attached 70% Ethanol for -5min in each bottle at
the highest flow rate (86mL/min). Ensure that the bubble trap fills and empties.
2. Remove lines from Ethanol and allow each line to air dry for -5min or longer. Save
and Recap the Ethanol bottles.
3. Run 200-400mL of Milli-Q water through each line using a clean 500mL "Rinse"
Bottle and a 500mL "Waste" Bottle. Ensure that the bubble trap fills.
4. Remove lines and allow the lines to air dry until the perfusion time (86mL/min).
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Notes:
* The 70% Ethanol should be changed once every 3 weeks. Make a note of when it is
changed on the Rat Logbook Sheet.
* You can reuse the "Rinse" and "Waste" bottles. Just rinse and shake them with -100mL
Milli-Q water a few times, and recap them for next time.
Rat and Animal House
Notes:
* Call the DCM office (x3-3050) and request 1-2mL of Pentobarbitol, or leave a message.
* Bring Key Card and the rat room key.
* Update and Initial the Green Rat Inventory Sheet outside the Rat Room
* Note Rat Weight (160-230 g)
* Get Pentobarbitol
Water Bath
Materials
* Milli-Q Water (ddFH20)
* Celsius Thermometer
* 1 Sterile 500mL Orange Cap Bottle
* 250mL Graduated Cylinder
* 50mL Graduated Cylinder
* 375mL Ca2" Free Solution
* 2 Red Water Bath Weights
* Filter Flask, 0.2jtm Nalgene
Methods
1. Set bath Temperature to 430 C
2. Sterile Filter 250mL of Ca 21-Free Buffer through a 0.2VpM filter and place in bath.
Connect the filter solution to the pump and fill up the bubble trap.
3. Prepare Blendzyme 3 Solution. The aliquot of Blendzyme 3 should thaw and be kept on
ice until it's ready to be added to its solution.
Notes:
* The 430 C provides for a 37 0C liquid temperature through the catheter.
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Liberase Blendzyme 3 Preparation
Reconstitution:
70mg bottle
1. Add 10mL HPLC quality H20
2. On ice, let powder rehydrate for 30min. Mix occasionally by swirling.
3. Aliquot into lmL- centrifuge tubes [715uL each = 5mg]
4. Makes approximately 13-14 aliquots
5. Save extra little bit in a separate tube
6. Label with info: Name, 5mg, date of aliquot, lot#, volume
Materials:
* 28mL 10X CaC1, (H20)2 Solution
* 222mL Ca2 + Free Buffer
* Filter Flask, 0.24tm (Nalgene)
Materials Qty Notes
Ca 2+ Free Buffer 222mL
o10X CaC1 120)2 28mL
Roche Liberase Blendzyme 3 5mg Cat# 1814184
Method:
1. Combine Ca 2 + Free Buffer and 10X CaC1, Solution in a stert
bottle.
2. Place in water bath until needed
3. AT THE APPROPRIATE TIME (mentioned later)
Add Blendzyme 3 to the 250mL of solution
4. Sterile Filter (0.2ýtm) and place in bath. Attach to the pump.
ile 500mL Orange top
Animal Preparation
Materials
* Male Fisher Rat (160-230g)
* 1.25" 20 Gauge Polyethylene Catl
* 2 1mL Syringes (Be
* 1 "Blue" 25G Needle (Be(
* Sodium Pentobarbitol
* Phosphate Buffered Saline (PBS)
* DecapiConeTM
* Procedure Board, Covered with I
* Autoclave Tape
* Hair Clippers
* Dust BusterTM
* Gauze
* 70% Ethanol
* Betadine
heter-JELCO, Johnson and Johnson
:ton Dickinson-VWR #309602)
:ton Dickinson-VWR #305122)
lue Paper
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III Perfusion
Method:
1. Using a "Blue" 25G Needle anaesthetize rat with Na-Pentobarbitol according to animal
weight, diluted with an equal volume of 1x PBS. Inject into the intraperitoneal (IP),
just to the left of the midline. Pull back on the plunger and make sure there is a
visible bubble to ensure that you are in the body cavity and not in the bladder,
intestine, etc.
2. As soon as the rat shows no reflexes to quick blows of air, check the drug effect
through tail pinches. Do not continue until the rat does not respond to the pinches.
Pinching in between the toes is also a good indicator.
3. Working Quickly, shave the rat over the entire incision area.
4. Apply Betadine using gauze (Optional).
5. Secure the animal to the procedure board with autoclave tape.
Fully extend the lower legs and tape them down
Raise the upper legs and gentl, tape each arm separately.
8. Open the lid of the Surgical Kit without touching the inside of the kit or lid.
9. Carefully open the Catheter and 1mL Syringes onto the Surgical Kit without touching the
instruments.
Notes:
* Refer back to the Rat Perfusion Logbook to check how much Pentobarbitol to inject
given the weight of the rat.
* The most prominent Tail Pinch response is flexing of the abdominal muscles just
above the lower legs. It's almost like a shiver.
The Perfusion
Materials:
* Surgical Gloves (Allegiance #2D7254)
* Sterile Gauze (Johnson&J ohnson Nu-GauzeTM )
Silk (Ethicon)
Q-Tips (Puritan)
* 2 Forceps (V\VR)
* Tissue Forceps (Henry Schein)
* Scissors (He:nry Schein)
* Additional Materials listed above
Method:
1. From this point move as quickl as possible to maintain adequate bloodpressure and to minimize the
effects of other unforeseen events.
2. Don surgical gloves. Keep these sterile to avoid contamination. Only touch the
instruments within the Kit and the rat body. Do not touch anything else.
3. Make an "I" incision on the ventral side using the Tissue Forceps and Scissors. The
incision should run from the lower abdominal area around the bladder to the Zyphoid
process and Rib area. Avoid nicking the liver. As you cut towards the ribs, you may have
to gently massage liver through the skin to loosen it from the skin.
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4. Gently displace the guts to the right with a fresh Q-Tip, exposing the Inferior Vena Cava
(IVC) and Portal Vein (PV).
5. Using fresh, dry Q-Tips further expose the IVC inferior to the liver from the bladder
region up to the liver. To do this, apply pressure to the connective tissue in opposite
directions until the IVC is completely visible. Be sure not to hinder blood flow while
you clear away the excess tissue.
6. Using the forceps, make openings in the connective tissue to the left and right of the
IVC just above the branch to the kidney.
7. Pull a silk suture through the opening and tie a loose ligature around the IVC. To do
this: grasp the right end of the silk with the left forceps and wrap it twice around the tip
of the right forceps. Keeping hold of the right end, grasp the left end of the silk with the
right forceps and pull it through the loops.
8. Insert Catheter into the IVC 0.5-1cm away from loose ligature. Remove metal piece and
maneuver the catheter past the knot. If there is no blood flowing freely from the
catheter, you may have to gently palpate the chest area to draw the blood down, or use a
syringe to gently pull blood to the end of the catheter. Tightly tie off the loose ligature
around the catheter.
9. Begin perfusing with Ca2+ Free Buffer at 25mL/min (15 mL/min to retrieve a greater
fraction of NPCs). Immediately cut the Portal Vein (PV) to allow for drainage and
prevent over-inflation of the liver. Cut the IVC below the Catheter.
10. Puncture the diaphragm to expose the IVC superior to the liver and tie a ligature around
it using the same technique as before.
11. Check to make sure that fluid is freely flowing from the PV. If there is a clot, gently
massage the PV until the flow resumes.
12. At this point prepare the Blendzyme 3 Solution. See Blendzyme Preparation.
13. Perfuse for 6 to 7 minutes. The liver should clear of blood. Gently roll the liver between
two moist cotton swabs to help. The liver should be a light caramel color.
14. After the allotted time for the Calcium free buffer, switch over the Blendzyme solution
and perfuse the entire 250mL volume. It should take about 10 minutes at 25mL/min.
15. Throughout the perfusion keep the liver moist by wetting a fresh Q-Tip with run-off
buffer and gently dabbing the liver.
16. Remove the liver from the rat and place it in a 50mL Centrifuge Tube filled with 30mL
DAG. Avoid cutting or poking other organs to prevent contamination.
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VHepatocyte Isolation
Materials:
* Ice Bucket
* DAG
* Pre-Autoclaved Funnel with 300pm mesh
* Trypan Blue
* Hemostat and tissue forceps
Methods:
1. Prepare an ice bucket with 4- 50mL centrifuge tubes filled with 40ml DAG.
2. Obtain the liver from the perfusionist. Also take with you a flat ice pack, an
autoclaved funnel with 100-pm mesh, and a hemostat and tissue forceps with tips
wrapped in sterile gauze.
3. In the hood, gently pour the liver with 30ml DAG into a 100mm petri dish. Use the
hemostat and forceps to peel back the capsule on each lobe.
4. Use the hemostat to clamp down on the connective tissue of the liver, and gently
agitate the liver by knocking the hinge part of the hemostat on the sidewall of the
petri dish. Your other hand should hold the petri dish to prevent it from sliding off
the ice pack which may become slippery due to condensation. Try to keep most of
the liver submerged under liquid and pay attention not to squeeze the liver between
the bottom of the dish and the tip of the hemostat. The tip of the hemostat should
not touch the bottom of the dish.
5. Break more areas of the capsules if the liver is not breaking up well. Otherwise, when
the solution looks like the color of caramel, the shaking should be enough.
6. Prepare a clean 50ml tube and place the funnel into it. Place the remains of the liver
on the mesh with the hemostat. Use a pipette to transfer all liquid into the tube
through the mesh.
7. Replace the liver in the Petri dish and wash again with 40mL DAG to isolate all the
cells you can. Filter this as before into another 50mL tube.
8. Dispose of the mesh and the liver remains. Equilibrate the two tubes by pouring the
liquid back and forth between the two tubes. Pour down the walls of the tube to
minimize stress to cells.
9. Spin the two cone tubes of cell solution at 50g for 3 minutes at 40 C.
10. Remove supernatant (save it if NPC's are needed). Re-suspend the cell pellets with
fresh DAG, 40mL per tube. Carefully pour each tube of DAG into the tubes with
the cell pellet. Be careful not to let liquid directly land on top of the pellets. Tilt both
tubes so that the liquid is flowing slowly on the tube wall. After both 40ml tubes of
DAG are transferred, cap the tube with cells and start re-suspending cells by rocking
both tubes gently. Do this until the pellet is completely in suspension.
11. Spin again at 50g for 3 minutes at 40 C.
12. During this spin, prepare the Trypan blue: 700uL DAG, 200ul Trypan blue. Or, if
using Vi-Cell Coulter Counter make a 1:10 dilution of the cells suspension by
pipetting 900uL of DAG, and 100uL of the final cell solution.
13. Remove supernatant (save it if NPC's are needed). Re-suspend each cell pellet with
20mL of fresh DAG. Make sure that when pipetting in the liquid, the liquid flows
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slowly on the wall instead of hitting the pellets directly. Pour one tube of solution
into the other to consolidate down to one tube (about 45mL total).
14. Take 100itm from the tube and place it into the Trypan blue tube. Use the
hemacytometer to count the cell viability and cell concentration as the first final
count. Count all 8 squares.
15. Record on the HIepatocyte count document and save under the date.
VI Troubleshooting
Working Quickly
* Working quickly during the preparation of the rat, and the surgery up to the time of
perfusion will help minimize the effects of, for example, the rat dying. It will also help
with issues related to blood pressure, and the length of time the liver is exposed to air.
* After the Perfusion has started, quickly cut the Portal Vein to prevent over-inflation of
the liver, which can cause cell damage.
Rat Dies
1. Working quickly should minimize the effects of premature rat death. Try to
perfuse as soon as possible.
2. Gently palpate the upper abdominal region, near the ribs, to help resuscitate the
rat.
3. Be aware that the perfusion with Ca"2 Free Buffer may take longer to fully clear
out the Red Blood Cells and to become a caramel color.
4. Try to keep the liver moist on the outside by wetting Q-Tips with run-off buffer
and gently dabbing the liver.
IVC Catheter Insertion and Placement
* Insertion: Keep the catheter parallel to the IVC. Keep the bevel up, and the catheter as
horizontal as possible, as to not poke all the way through the vein. Once inserted, gently
push the catheter further into the vein until the plastic portion of the catheter is just in
the vein. Avoid twisting the catheter because you may accidentally create new hole in
the IVC. Try to create opposing tension by pulling the IVC downward with a Q-tip.
Position the Q-tip on the muscle to the left or right of the IVC and apply gently
pressure. This will anchor the IVC a little and make it less apt to stretch as you try to
cannulate. Once you remove the metal part, you should feel no resistance at all, and the
catheter should readily slip into the vein when you apply even the slightest pressure. Do
not push the metal needle of the catheter into the vein more than you need to; once the
white plastic is visible inside the vein, remove the needle while inserting the catheter
farther up the IVC. Follow the IVC past the loose ligature. Remember this is easier to
do if you flex the catheter so you can see the tip through the top of the vein. The vein
changes direction as it meet the liver, navigate the catheter accordingly. Note that the
degree to which the IVC direction varies from rat to rat.
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Portal Vein (PV) Perfusion
1. Expose the Portal Vein.
2. Tie a loose ligature around the Portal Vein, making sure it is located above any
branches.
3. Make a small cut approximately 1/2 way through the portal vein. Be careful not to
cut through the entire vein.
4. Insert Catheter into portal vein, while using gauze to control blood loss.
5. Remove Metal Portion of catheter and then slide catheter past ligature and tie it off.
Connect the pump and start flow of Ca2+ Free Solution at 8mL/min.
6. Immediately cut the IVC inferior to the liver to prevent over inflation.
7. Puncture the diaphragm to expose the IVC superior to the liver, then tie a ligature
around it.
8. Inflate the liver occasionally by placing a Q-tip on the IVC. Do not over inflate.
9. Perfuse until the liver is cleared of blood.
10. Throughout the perfusion keep the liver moist by wetting a fresh Q-Tip with run-off
buffer and gently dabbing he liver. Otherwise, there should be no need to touch the
liver.
11. Perfusion with Blendzyme 3 Solution.
Isolation Information
* Qualitative, Cell Count, and Viability information can be used in conjunction
with one another to assess the effectiveness of the perfusion with Blendzyme 3.
* Qualitative information about how the liver "breaks up" during the isolation can
clue you into how effective the digestion with Blendzyme 3 was. It is generally good
when the liver completely disintegrates, and there is little intact liver. If the liver does not
readily disintegrate, the collagenase may not have run long enough to allow for proper
separation of the cells.
* Cell Counts: High cell counts indicate good separation of the cells. This is usually
accompanied by nearly complete disintegration of the liver during isolation. Low cell
counts indicate that the perfusion may not have run long enough.
* Viability: Low viability may indicate that the cells were exposed to Pentobarbital for too
long, the surgery took too long, that the Blendzyme was at a too high/low concentration,
etc....
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Appendix 2 - Culture Media Formulations for Primary Hepatocyte
Culture
HGM (Hepatocyte Growth Medium) Preparation 11/05
Block et al., J. Cell Biol. (1996), 132(6): 1133-1149 (with corrections of typos in paper)
Base Medium:
DMEM, low glucose, pyridoxine HC1, sodium pyruvate,
no glutamine, no phenol red; (500ml)
GIBCO 11054-020
Add to Base Medium:
1. 0.015g L-Proline;
2. 0.050g L-Ornithine;
3. 0. 15 25 g Niacinamide;
4. 0.5 00 g D-(+)-Glucose;
5. 1.000g D-(+)-Galactose;
0.03g/l in medium;
0.10g/l in medium;
0.305g/l in medium;
2
.
2 5g/1 in medium (already has 1g/l);
2g/1 in medium;
6. 1.000g Bovine Serum Albumin, Fraction V; 2g/l in medium;
7. Trace Metals : Add 5pl from stock solutions:
Stock concentrations:
5.44 mg/ml ZnCh2
7.50mg/ml ZnSO47H 20
2.0mg/ml CuSO 45H20
2.5mg/ml MnSO 4
(Use 1 Liter of MilliQ water to prepare each stock solution)
SIGMA P-4655
SIGMA 0-6503
SIGMA N-0636
SIGMA G-7021
SIGMA G-5388
SIGMA A-9647
Filter the above solution with Nalgene PES .2 um Filter Unit, and then add the frozen aliquots.
Add to Sterile Filtered Medium:
8. 500ul Gentamycin (sterile)**;
dispense stock (50mg/mL) into 520ul aliquots, store at -20oC.
9. 2.5 ml L-Glutamine (sterile); 1mM in medium;
Dispense 200mM stock into 13.0 ml aliquots, store at -20cC.
SIGMA G-1397
GIBCO, 25030-081
10. 500gl Insulin-Transferrin-Sodium Selenite (sterile); ROCHE 1074 547
5mg/1-5mg/1-5gg/l in medium; ROCHE 1074 547 (50mg); 1213 849 (250mg); dissolve 50mg or 2 50mg
powder in 5ml or 25ml sterile milliQ water, dispense into 520gl aliquots, store at -20oC.
11. 400gl Dexamethasone (sterile); 0.1gM in medium; SIGMLA D-8893
dissolve 1mg in lml EtOH using sterile syringe and needle, after powder is dissolved add 19ml PBS, mix
thoroughly, dispense into 420gl aliquots, store at -20oC, expires 3 months from date of reconstitution.
Add to Medium Immediately Prior to First Use:
12. 200il Epidermal Growth Factor (EGF) (sterile); BD Biosciences 354001
20ng/ml in medium; dissolve 100ug powder in 2 ml sterile milliQ water, dispense into 220pl aliquots, store
at -20oC, expires 3 months from date of reconstitution.
**Note: In early experiments, Penn-Strep was used as an antibiotic instead of gentamycin. In some cases
during giant reactor characterization, this recipe was used without bovine serum albumin for comparison to
previous experimental results in the lab.
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Appendix 3 - 2-D Adsorbed Collagen and Collagen Gel Sandwich
Protocols
2-D Adsorbed Collagen Protocol
As was described in Chapter 2, optimal DGE separation were obtained when
primary hepatocytes were cultured on dried adsorbed collagen monolayers that are prepared
as follows:
1. Prepare a 30 ug/mL solution of Collagen Type 1 from Rat Tail (BD
Biosciences #356236) with sterile 1x PBS and keep on ice. Immediately
return the collagen stock to the fridge.
2. Add 3 mL of the solution to each 60 mm treated tissue culture dish.
3. Gently swirl each plate to evenly coat the bottom.
4. Place plates in the incubator at 370C for 2 hours.
5. After two hours, put plates back in the hood and aspirate the collagen
solution. Make sure there is no excess solution on the walls or stuck on the
plate top and completely remove all solution from the bottom. Tilt the plate
for an additional 3 seconds after the brunt of the solution has been aspirated
and run the tip along the circumference of the bottom edge to make sure the
plate can completely dry.
6. Let the plates stand in the hood for 2 hours. Place them next to the airflow
ducts near the back of the hood. Make sure the UV light doesn't get turned
on during this time.
7. Seed 3 mLs of cell suspension to each plate at 800,000 cells per mL, making
for a total of 2.4 million cells/plate. Swirl plates and move back and forth to
evenly seed.
8. Culture at 370 C and 8.5% CO 2.
9. At 4 hours post seeding, gently aspirate plates and add 3 mLs of fresh HGM.
This ensures - 90- 9 5% confluency while removing debris and unattached
cells to prevent overcrowding.
10. To ensure maintenance of hepatic phenotype and consistency of data,
perform DGE assays within 24 hours of the medium change.
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Collagen Gel Sandwich Protocol
Surfaces - Treated plates tend to keep a more uniform gel during culture.
35mm dish or 6-wellplate 9.61 cm2 surface area per well
Bottom layer: 600uL collagen gel solution
Top layer: 300uL collagen gel solution
12-wellplate 3.8 cm2 surface area per well
Bottom layer: 240 uL collagen gel solution
Top layer: 120 uL collagen gel solution
24-wellplate 2.0 cm 2 surface area per well
Bottom layer: 125 uL collagen gel solution
Top layer: 62 uL collagen gel solution
Reagents
Collagen Type I, from Rat Tail, Solution
BD Biosciences #356236 More consistent than Vitrogen
10x PBS mix
10x PBS (w/o Ca++ or Mg++)
20 g/L glucose
37 g/L sodium bicarbonate
Sterile filter solution and equilibrate in hood for 30 min
pH to 7.4 using sodium bicarbonate or HCI
Collagen gel solution preparation (%'s are by volume)
80% Collagen solution (3 mg/ml)
10% Sterile diH2 O (autoclaved, sterile-filtered)
10% 10x PBS mix
Store at reagents at 40 C. Prepare on ice to prevent gel formation. Shake 10x PBS mix
solution well. Heat in water bath if necessary to fully dissolve. If collagen solution comes at
a concentration >3 mg/ml, each time prepare collagen gel solution by using extra sterile
diH2,O. For example, if collagen solution comes as 4.8 mg/ml, use 50% collagen solution
and 40% sterile diH,O (and 10% 10x PBS mix). Collagen gel solution can be stored for 4-6
hrs at 40C.
Add the necessary amount of collagen gel solution to each well. Pipette evenly around the
well and move the plate back and forth on the sterile hood floor to evenly distribute.
Incubate at 370 C for at least 2 hrs for the bottom layer (until gel solidifies). Before seeding,
rinse gel once with PBS. Seed hepatocytes in HGM and incubate at 37 0 C for 4-6 hours.
Using a pipette, carefully aspirate media (and non-attached cells) and add second layer.
Incubate without medium for 1-2 hrs (until second layer has solidified) then add media for
the duration of the culture. Medium is usually changed daily, and for a 6-well plate, at 1
ml,/well. Scale accordingly for the other plate sizes.
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Appendix 4 - Detailed Density Gradient Electrophoresis Protocol
Preparation of Cell Samples for DGE
Date: # Petri dishes: Gene Delivery: Dyes Ono
Performed by: # cells/dish: Polymer:
Perfusion Viability: % confluence: Time Pt:
Perfusion Density: DGE Buffer: DNA/plate:
Media: Pulse-Chase: Dyes Ono N/P ratio:
CHECKLIST
1. If doing pulse chase, make 1.5 ml (per 60 mm dish) of 2 mg/ml HRP in HGM in a
centrifuge tube. Warm in 370 C water bath along with a centrifuge tube of 5 ml of HGM
in.
2. If doing a transfection, make 2 ml (per 60 mm dish) of 5 ug/ml total DNA in HGM
in a centrifuge tube. Pre-warm 2 mL of media in 370 C water bath before making the
NV complexes.
3. Put rotor in cold room.
4. Turn on ultracentrifuge (upstairs 6th floor Essigmann Lab). Set to 2 C and turn on
vacuum, make sure door is closed.
5. Turn on centrifuge in BPEC and set on fast cool (for PNS spin).
6. Check the cells under the microscope at 10x for debris and confluence.
Comments:
7. Gather above materials and the following:
E1 PBS++ and DGE buffer (keep on O Syringe and needle
ice) O Ice tray for washes and media
El Cell scraper changes
O1 Ice bucket with ice
PULSE-CHASE-PULSE LABELING (OPTIONAL)
* Keep dishes on ice at all times when performing washes and media changes (ice block or
wetted ice).
1. Wash the dishes lx with 3 ml cold PBS++.
2. Label cells for 4 min with 1.5 ml of warm HRP labeled HGM.
3. Recollect HRP medium into centrifuge tube and return to water bath.
4. Wash the dishes on ice 1x with 3 ml cold PBS++.
5. Chase for 15 min with 3 ml of warm unlabeled HGM.
6. Start setting up DGE Device in cold room during your free time.
7. Wash the dishes on ice 1x with 3 ml cold PBS++.
8. Label cells for 3 min with 1.5 ml of warm HRP labeled HGM.
9. Recollect HRP medium into centrifuge tube and return to water bath.
CELL COLLECTION
1. Wash cells 2x with 3 ml cold PBS++.
2. Wash cells lx with 3 ml cold DGE.
3. Scrape cells with rubber policeman in 2 ml cold DGE buffer. Use a large hard plastic
scraper.
4. Collect in pre-chilled centrifuge tube.
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5. Re-scrape uncollected cells in 1 ml cold DGE buffer and collect in same centrifuge tube.
6. Check plate for cells and nuclei. Comments:
LYsis
1. Resuspend cells by gently tapping the tube against a hard surface.
2. Incubate on ice for 20 min, gently re-suspend pellet every 5 min.
3. Prepare pre-chilled Eppendorf tubes if gene delivery was performed to collect cell
fraction aliquots.
4. Lyse with 21G x 2 inch needle with 12 pumps (8 counts up, 8 counts down) with needle
tip at wall.
5. Inspect 10 ul in microscope on hemacytometer. # Nuclei: # fWhole Cell:
Comments:
6. Save 400 Il of lysate as "Wvhole cell sample" for PCR.
7. Centrifuge 15 min at 2500 rpm to collect nuclei (In the meantime, prepare BSA assay).
8. Remove the supernatant (PNS) with a pipette. PNS volume = ul
9. Save 250 ýIl of PNS for PCR.
10. Freeze nuclear pellet for PCR.
PROTEIN ASSAY
1. Prepare 1.5 ml protein assay reagent (50% A, 48% B, 2% C 4 750 ýd A, 720 [il B, 30 pl
C).
2. Make BSA standards (0, 2, 4, 6, 8, and 10 ug) by using 0-5 ul of 2 mg/ml BSA, prepare in
duplicate.
3. Use _ ul of PNS (usually 10 ul).
4. Add filtered water for final volume of 100 ýl in each well.
5. Add 100 ul reagent to each well and incubate for 10 mmin for at least 10 min at 370 C.
6. Once most diluted sample is purplish, read the plate at 562 nm in the plate reader. Make
sure the well with 0 ýl of BSA is called blank. The PNS protein concentration: ug
for __ 1
TRYPSIN AND PROTEASE INHIBITOR TREATMENT
1. Defrost trypsin and protease inhibitors on ice.
2. Warm trypsin in 370C water bath for 1 min. Warm PNS for 1 minute.
3. Calculate the total protein in PNS. Total protein in PNS = mg.
4. Add ul of 1 ug/ul trypsin and incubate in water bath for _ minutes (typically 6
min). Use 25 ug per mg of total protein. Trypsin Type: Type 12 A Bovine Pancreas in
DGE buffer.
5. Return sample to ice, and add _ ul of 4 ug/ul trypsin inhibitor (in -80C freezer, keep
on ice!).
Use 4 ug of trypsin inhibitor per for every 1 ug of trypsin (so use same volume).
6. Final volume = PNS + trypsin + trypsin inhibitor + PBS buffer =
(typically 8100 1d)
7. Add roughly 7 mL of cold PBS to the PNS before adding protease inhibitors.
8. Add protease inhibitors at the following final concentrations
1 mM PMSF (stock=0.2 M) 4 0.005 * final PNS volume = (typically 40.5 jpl)
2.5 ug/ml Aprotinin (stock=2.5 mg/ml) 4 0.001 * final PNS volume = (typically 8.1 tl)
10 ug/ml Leupeptin (stock=5 mg/ml) + 0.002 * final PNS volume = (typically 16.2 ld)
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ULTRACENTRIFUGATION
1. Transfer sample to plastic Beckman centrifuge tube (pre-chilled on ice). Top off with
PBS at or past fill line.
2. Put stopper and cap on and weigh.
3. Make a balance tube with water within 0.001 g of the sample tube.
4. Place tubes in the Beckman Ti 70.1 rotor and screw on the top firmly.
5. Centrifuge for 1 hour at 100,000 g at 40 = 40,000 rpm.
6. Set up the DGE device in the cold room during the spin time.
NOTES
1. Total protein above 1 mg prevents adequate separation of organelle peaks. Aim to load
an endosomal pellet that has around 800 ug of total protein.
2. For best cell collection: press hard on the cell scraper while turning the Petri dish over
720 degrees in a continuous motion so that you accumulate a band of cells on the
scraper. Then move the scraper to the center to scrape the cells in the middle in one
continuous motion. Then "vibrate"/move quickly from side to side in the DGE buffer
to coax the bands of cells off the scraper.
CHECKLIST FOR ALIQUOTS
O 400 [d Whole Cell
E1 250 jil PNS
O Nuclear pellet
E1 150 il endosomal pellet
L PES
1 Plate of DGE fractions
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DENSITY GRADIENT ELECTROPHORESIS DEVICE SETUP
ASSEMBLING THE COLUMN
1. Clear, clean and level the table using the bike pump and level (from the toolbox).
2. Take the DGE column and DGE base out of the soap (no chlorine groups!) solution.
Rinse well with de-ionized water and gently dry with KimWipes and compressed air.
3. Cut a square piece of cellophane (7 cm) and soak in de-ionized water along with the O
ring.
4. After the membrane is soft, fold it into fourths, and cut into a circle.
5. Place the membrane over the opening of the inner column, wetting the column edge
with finger.
6. Using two fingers from each hand spread the 0 ring over the inner chamber until it fits
into the groove. Make sure that excess membrane is evenly sticking out along the
membrane.
7. Check for leaks with a little bit of water (dry with a KimWipe so it's easier to see if it's
leaking).
8. Grease bottom of the outer column with Vaseline and screw on bottom lid, then place
on the stand in the cold room. (all the rest of the steps are done in the cold room)
9. Connect wire to the palladium cathode (bottom electrode).
10. Connect the syringe to the T shaped tubing.
11. Clamp the short tube and fill syringe with 10% Ficoll through the medium length tube of
the T shaped tubing. Push out the bubbles from the syringe and tubing.
12. Tighten the C-clamp about halfway up the longer outlet tube.
13. Then unplug the short tube and push 10% Ficoll to fill the short tube.
14. Flick the T connector while holding the short tube end to get all of the air from the
connector to the top of the short tube.
15. Push the Ficoll to the end of the short tube and connect it to the DGE device's lower
chamber at the bottom inlet (don't put the short tube completely onto the entire length
of the inlet stem-just enough to be secure).
16. Fill lower reservoir with DGE buffer with the three 50 ml empty syringes on the upper
rack.
17. Insert long tubing ends from the pumps into the channels.
18. Slowly fill the inner chamber with about 2-3 ml of 10% Ficoll using the syringe pump.
Adjust the tubing from the syringe pump to make sure there are no bubbles.
19. Then fill separation column with 10% Ficoll to the top using a pipettor.
LAYING THE LOWER GRADIENT (Do JUST BEFORE LOADING THIE SAMPLE, WILL TAKEI 5-10
MIN)
1. Wipe a little bit of Vaseline around the lip of the top cone and screw on the top cone.
2. Slowly maneuver the gradient mixer so that its tubing connects to the top cone and there
are no kinks in the connecting tubing.
3. Secure in place using the Perspex holder and the screw.
4. Slowly infuse 10% Ficoll into the top cone at 3 mL/min and into the tubing of the
gradient mixer until it is flush with the floor of the mixing chamber.
5. Fill right leg with 3.5 ml of 7% Ficoll and clamp the tube between the legs using the blue
clamp when the fluid rushes into the tube (making sure there are no air bubbles). Put
any 7% that rushed into the left leg back into the right leg.
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6. Slowly fill the left leg with 3 ml of 10 % Ficoll. (left leg is one connected to the DGE
device)
7. Slowly insert stirrer and plug in, let the solution start stirring, with the power source at 6
V and then unclamp the blue clamp.
8. Slowly loosen the metal clamp until the solution is dripping into the 10% Ficoll
container at an approximate rate of 1 drop per second. Adjust the clamp at times to
maintain a steady flow rate
9. Run the gradient mixer until the entire gradient enters the column and the level of the
solution inside the column is about one third of the way down the cone (to leave enough
room for sample loading). Then tighten the metal clamp on the outlet tube.
10. Disconnect the stirrer and slowly loosen the Perspex holder to carefully free the gradient
mixer. Balance on two of the three legs of the gradient mixer and slowly lift at an angle.
11. Put up warning sign on the door of the cold room - asking people to open/close
carefully and to mind the vibration sensitive experiment.
12. Wash the gradient mixer and stirrer with de-ionized water. Dry with KimWipes &
compressed air.
APPLYING THE SAMPLE
1. Collect the Post Endosomal Supernatant (PES) in an Eppendorf tube and keep for PCR.
Resuspend the pellet in 650 pl of cold 6% Ficoll-70 in DGE Buffer with a 21G x 2
syringe. Break up the pellet a bit more gently than the during the lysis step.
2. Transfer to an Eppendorf tube and spin at full speed in the small table top centrifuge for
15-20 seconds to determine success of the resuspension. Give a few extra pumps
through the syringe if a pellet forms and respin to check again.
3. Take up 500 p1 for DGE run.
4. Using your left hand, slowly squeeze the T tubing between the T and the column so that
the level inside the inner column rises to the top of the cone.
5. Using your right hand, slowly pipette 500 gl of sample using a P1000 onto the top of the
cone, while letting go of the tubing slowly. Try to match the rate of addition and
downward flow from the release.
LAYING THE UPPER GRADIENT
1. Slowly maneuver the gradient mixer so that its tubing connects to the top cone. Secure
in place using the piece of Perspex and the screw.
2. Slowly infuse the sample into the inner column of the gradient mixer using the syringe
pump (max speed 2 ml/min) so that the solution inside the top cone enters the tubing of
the gradient mixer and ends just below mixing chamber. Leave the sample roughly 3-4
mm below the bottom of the left leg floor or you will get a mushroom in the sample
band.
3. Carefully fill right leg with 13 ml of DGE buffer (0% Ficoll solution) and clamp the tube
between the legs using the blue clamp, when the fluid rushes into the tube connecting
the two legs.
4. Fill the left leg with 12.5 ml of 5% Ficoll --- Add very slowly so you don't disturb the
sample band using the 2 ml pipette to add at least the first 2.5 ml (stick the pipette to
the bottom of the gradient mixer column. Add the remaining 5% Ficoll with a 10 mL
pipette release it very slowly right at the upper water level and against the wall.
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5. Slowly insert stirrer and plug in, let the solution start stirring, with the power source at 6
V and then unclamp the blue clamp.
6. Slowly loosen the metal clamp until the solution is dripping into the 10% Ficoll
container at an approximate rate of 1 drop per second.
7. Remember to adjust the clamp at times to maintain a steady flow rate until the entire
gradient enters the column and level of the solution has dropped to the top of the inner
column.
8. The sample should appear in one flat whitish disc. If you get a mushroom the run is
ruined, so perform these steps very carefully.
9. Disconnect the stirrer and slowly loosen the Perspex holder to carefully free the gradient
mixer.
10. Wash the gradient mixer and stirrer with de-ionized water. Dry with KimWipes &
compressed air.
FILLING THE TOP CHAMBER AND STARTING THE RUN
1. Carefully remove the top cone. Place metal sieve on top of the inner column
2. Turn on the syringe pump at 2 mL/min until the top gradient wets the sieve.
3. Using one or two syringes + tubes, carefully fill the upper chamber with DGE buffer
until it reaches the bottom of the horizontal outlet. Squeeze the tubes slightly to slow
down the filling rate when the water level approaches the sieve and covers it.
4. Slowly remove the metal sieve without disturbing the contents of the inner chamber
5. Slowly pivot the upper electrode (platinum anode) into the top chamber and secure in
place with the Perspex holder.
6. Turn on the pumps to circulate the DGE buffer in the lower chamber. Put 400-500 ml
fresh DGE buffer in the recycling beaker.
7. Turn on ammeter to read current. Turn on the power supply. Set to "constant current
mode".
Time= 80 min, Voltage = 300V, Current = 1 mA, unless otherwise specified:
8. During the run, wipe top electrode with paper clip to get ride of bubbles every 10
minutes.
9. Check that the current is around 10.5-10.7 mA.
ENDING THE RUN AND COLLECTING THE SAMPLES
1. Turn off the pumps, power source, and amp-meter.
2. Slowly unscrew the upper electrode and remove from the top chamber. Slowly replace the
metal sieve, entering the upper buffer chamber at an angle to prevent large disturbances.
3. Using a syringe and tubing, suck up DGE buffer and dispose in Erlenmeyer waste flask.
4. Loosen brown clamp and allow for about 20 drops to leave the column, so that the level of
the solution inside the inner chamber comes below the metal sieve.
5. Remove the metal sieve, then screw on top cone again (with thin tubing already attached).
6. Screw in the long Perspex arm with the same screw as before and thread tubing through the
hole on the long arm, adjust tubing height accordingly over the box and collection plate.
7. Infuse at rate of 2 ml/min to fill the cone and tubing, then the flow rate can be
switched to 3 mL/min. Collect 24 fractions from the end of the thin tube in the 96 deep
well plate (average volume of fraction = 1.25 ml).
8. Mix the 2 rows of samples at least 10 times with a multichannel pipette set to 200 uL. Next
take 200 uL of the mixed samples out and add to a DNEasy collection plate for storage
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before DNA purification. Freeze this plate along with the original deep well collection plate,
which will provide material for b-Hex assays and backup samples.
9. Switch input at the power supply, take off top cone, fill upper chamber with buffer and put
the short holder back on to secure the upper electrode.
10. Run for the same amount of time in reverse current mode in order to recharge the palladium
electrode.
11. Current was reversed for minutes.
96 Well Plate Assays for Fraction Identification
HRP ASSAY (TEST FOR EARLY AND LATE ENDOSOMES)
1. Transfer 100 ul of the sample.
2. Add 200 pl of the I-IRP reagent to each well using the multipipettor. Mix well, but NO
BUBBLES. Make sure reagent hasn't turned orange and that it is freshly prepared or no
more than 3-4 days old if stored in the fridge.
3. Incubate at room temperature until orange color appears (incubation time is approx 60 min).
4. If there are any air bubbles, pop with a syringe needle.
5. Read absorbance at 455 nm.
BCA ASSAY (TEST FOR TOTAL PROTEIN)
1. Transfer 40 ul of the sample.
2. Add 60 tl of water
3. Make BCA reagent. Number of wells needed ( )
50% A -( )*100 l-=
48%0/B =( )*96dl =
2% C -( )*4 dl =
4. Add 200 Vl of BCA reagent to each well, mix and incubate for 2 hour at 37 oC.
If there are any air bubbles, pop with a syringe needle.
5. Read absorbance at 562 nm.
p-HEX ASSAY (TEST FOR LYSOSOMES)
1. Transfer 60 ul of the sample.
2. Make B-Hex start master mix. Number of wells needed ( )
Start = ( ) * 150 il
Triton = ( )* 3 l
3. Add 153 pl of master mix to each well, mix and incubate for 2 hour at 37°C.
4. Add 90 ul of stop reagent and wait a few minutes.
5. If there are any air bubbles, pop with a syringe needle.
6. Read absorbance at 405 nm.
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Solutions for DGE Runs and Assays
A. DGE Buffer
The DGE Buffer is used in both sample preparation and the actual density gradient
electrophoresis run itself. To make DGE buffer, combine the following ingredients.
for 500 mL for 1 liter for 2 liters
250 mM sucrose (g) 42.78 85.56 171.12
10 mM acetic acid (ml) 0.286 0.572 1.144
10 mM triethanolamine (ml) 0.6665 1.333 2.666
NaEDTA
1 mM (Titriplex) (g) 0.186 0.372 0.744
Then add milliQ water until within 5% of the desire final volume.
pH to 7.4 with NaOH and then fill with milliQ water to the final volume.
Typically, three to four 2-liter bottles of DGE buffer are made at a time (total of eight
liters). A 2-liter bottle of DGE buffer can typically last for about six to eight DGE runs
if you recycle the bottom chamber buffer.
B. 10% Ficoll-70
Typically, one or two liters of 10 % Ficoll-70 are made, using ten or twenty grams of
Ficoll-70 dissolved in one or two liters of DGE buffer respectively. The Ficoll-70
powder is very light and floats easily so be careful when measuring and use a cap when
putting the solution on the stirrer plate. The Ficoll-70 also takes a long time to dissolve -
around one hour. Usually the 10% Ficoll-70 is made in a bottle with a screw cap so that
it can be inverted and shaken to help the dissolving process. Once the Ficoll is
dissolved, the entire solution should be clear. It may be a good idea to de-gas the
solution if using immediately.
C. 5%, 6%, 7% Ficoll-70
The 5%, 6% and 7% Ficoll-70 are typically made by diluting the 10% Ficoll-70 to avoid
the complications of dissolving the Ficoll-70 powder. Usually 100 to 200 ml of each
concentration is made.
D. PBS ++
Important for cell collection step. Add 1 ml of MgCl2 and 1 ml of CaCl2 to 500 ml of
Phosphate Solution Buffer (PBS). Keep refrigerated at 40 C
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E. Beta-hexosaminidase Assay Start Reagent (200 ml, 0.2 M NaAC, 4mM PNP)
1. Dissolve 3.28 g NaAc (MW= 82.03g/mol) in 150 ml of MilliQ water.
2. pH 5.4 with HAc.
3. Warm until 500 C then dissolve 274.4 mg of PNP (MW=342.4 mg).
4. Fill up to 200 ml and store in Refrigerator (40C).
F. Beta-hexosaminidase Assay Stop Reagent
Make 2M glycine, pH10 by:
1. Dissolve 75.07 g glycine (MW = 75.07) in 450 ml of MilliQ water.
2. Then pH- to 10 with NaOH.
3. Fill up to 500 ml and store in Refrigerator (40C).
G. Substrate for Horse Radish Peroxidase Assay
It is preferable to make the reagent a few hours to immediately prior to performing the assay as
the reagent is degrades easily. To retard the degradation process, cover the test tube containing
the HRP reagent in foil. When the reagent turns yellowish like a straw color, it is no longer
suitable for use.
HRP Reagent 15 ml 25 ml 50 ml Final Conc. Storage
10 mg/ml o-dianisidine 150 pC 250 dtl 500 tl 0.342 mM in - 80
3% H12O, 1.5 dtl 2.5 tl 5 .tl 0.003% v/v in fridge
0.5 M NaPi pH 5.0 1.5 ml 2.5 ml 5 ml 50 mM in fridge
10% Triton 0.45 ml 0.75 ml 1.5 ml 0.3% v/v on shelf
deionized water 13.05 ml 21.75 ml 43.5 ml -- -
H. BCA Total Protein Assay Master Mix
The standard proportions for the BCA master mix components are used.
BCA Master Mix for 1 ml for 7.5 ml
50% Solution A (pl) 500 3750
48% Solution B (pl) 480 3600
2% Solution C (pl) 20 750
193
Additional Pointers and Figures for DGE Protocol Steps
1. Cell Scraping and Collection Technique
Use the hard plastic white scrapers in the lab. Add 2 mL of DGE buffer and scrape in a circular
motion along the outer periphery of the plate by pressing the beveled edge of the scraper down
firmly and rotating the plate two times fully with your other hand. Then, tilt the plate so that the
DGE buffer pools in the bottom and scrape the small island of cell remaining in the middle
down into the buffer. Shake the scraper to remove the large cells clump into the DGE buffer
and immediately collect the cells in a prechilled tube on ice. Then add an additional mL of
buffer and scrape the entire surface of the plate in a downward motion and collect the extra cells
that are pushed into the pool of buffer.
2. Mechanical Lysis Tips
When expelling the cell suspension out of the syringe to lyse the cells, place
the beveled edge of the needle flush with the angled wall at the bottom of the
15 mL centrifuge tube and press down fairly hard. Don't put the needle tip
too close to the bottom though, the cell suspension will accelerate off the
floor and out of the tube, and you can also puncture the tube fairly easily.
Keep the syringe one 1/2 to 2/3 up the side of the angled wall. Remember
that for different cell types, different swelling times in the hypotonic buffer
and different needle gauges might be required.
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Appendix 5 - SDS-Page and Western Blotting Protocols
Gel R-ig Assembly & Sample Preparation
a. Assemble gel rig with shorter plates facing inside as according to the Bio-Rad
protocol. If running only one plate, be sure to use the buffer dam.
b. Add running buffer (1X TGS) to inside compartment of the gel rig until the
buffer overflows and outside compartment is filled to about one centimeter
below the height of the longer plates. This way the temperature along the
gels stay stabilized during the electrophoresis.
c. Turn on the heat block (100C).
d. Add equal volume of 2x sample buffer to samples and positive control if
sample buffer not yet added. Each well can load 50 ld of sample.
e. Boil samples on heat block for 3 min (Hint: Add plastic caps so tube tops
don't pop off).
f. Meanwhile, carefully remove the combs from the gels and using a plastic
pipette, wash the wells with the running buffer.
2. Gel Loading and the Run
a. Load 5ul of pre-stained Molecular Weight standard.
b. Load up to 50 ld of each sample, including negative and positive controls.
c. Run gel at 100V for approximately 1.5 hours @ room temperature until the
dye front has reached the bottom of the gel.
3. Western Blotting
a. Five to ten minutes prior to the SDS-PAGE run ends, make the transfer
buffer and soak pre-cut transfer membrane in 100% methanol for a few
minutes until the entire membrane is translucent. (Note: always handle
membrane with gloves or forceps to prevent contamination).
b. Then transfer the PVDF membrane into the transfer buffer 1.
c. Add 2 pieces of thick Whatmans to the transfer buffer container 2.
d. Place blotting apparatus in transfer buffer with the clear face down.
e. Add a sponge to the clear face and massage out any air bubbles.
f. Lay 1 thick pre-soaked Whatman on the blotting apparatus and then lay the
PVDF membrane in the center on top of the Whatman, making sure that
there are no bubbles between the two.
g. Disassemble the gel by removing the smaller plastic plate (the gel should
remain stuck to the larger plastic plate). Cut off top portion of the gel, where
the well lanes and the stacking gel are.
h. Carefully place the gel on top of the membrane. The lower the percentage of
polyacrylamide in the gel, the easier the gel will break.
i. Smooth out the bubbles carefully with your gloved finger or a flat headed
instrument.
j. Optional: Use a waterproof pen or pencil to mark the position of the
standards on the membrane (they don't always transfer).
k. Place the other thick Whatman on the blotting apparatus. Make sure it is
flush with the other Whatman.
1. Add the second sponge and close the sponge rack.
m. Place the sponge rack in the transfer chamber (pre-filled with transfer
buffer). (Note: The black side of the sponge rack faces the black electrode.
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n. Place the transfer apparatus on top of a stir plate in the cold room.
o. Run the transfer 1 hour at 100V at 40 C (Note: 2h at 40V, or overnight at 20V
at 40 C also works).
4. Blocking
a. Cut off the corner of the membrane for orientation and keep the membrane
protein side up throughout subsequent steps.
b. Remove the membrane from the transfer apparatus and rinse in PBS. Note:
The gel can be stained in Coomassie or the membrane can be stained with
Ponceau S to ensure transfer has occurred.
c. Place membrane in - 30 mL Blocking Solution 1 hour at room temperature
on the rocker.
d. Wash membrane three times in approximately 20 to 30 ml TBS-T 5 minutes
each.
5. Optional: Coomassie Stain
a. For the Coomassie stain (Coomassie dye dissolved in methanol, glacial acetic
acid, & water) allow it to incubate for at least lh-overnight (for low MW
proteins).
b. Destain the gel in the previously mentioned solution without the Coomassie
dye. This leeches out the stain to clear the background and leave stained
protein bands that can be visualized and photographed.
6. Primary Antibodies
a. Place membrane heat-sealable bag.
b. Add the 40 [l primary antibody to 10 ml TBS-T making a 1:250 dilution.
c. Seal bag and nutate the membrane overnight at 40 C, then empty the contents
into a small tray, slightly larger than the blot itself and designated for primary
antibody incubation, and incubate for an additional 1 hour at room
temperature on the rocker.
7. Secondary Antibodies
a. Wash membrane three times in approximately 20 to 30 ml TBS-T 5 minutes
each.
b. Place membrane in a second plastic container, designated for secondary
antibody incubation.
c. Add the 12 [l HRP-conjugated secondary to 30 ml of the blocking solution
(5% milk powder in TBS-T) making a 1:2500 dilution.
d. Incubate at room temperature for 1 hour on the rocker.
8. Visualization
a. Wash membrane three times in approximately 20 to 30 ml TBS-T 15 minutes
each. This higher wash time is to compensate for the higher antibody
concentrations.
b. Mix equal volumes of visualizing reagents 1 and 2 together (1 to 5 ml each) in
a 15 ml centrifuge tube.
c. Pour into the container designated for the visualizing reagent and put the
membrane face down onto the reagent. Incubate for at least one minute.
d. Visualize on the Kodak Electronic Developer.
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SDS-PAGE and Western Blotting Solutions
5 ml of 2X sample buffer (Store at -80 'C in 1 ml aliquots)
* 0.625 ml 1 M Tris, pHi 6.8 (125 mM)
* 1 ml 20% SDS (4%, or 0.2 g)
* 1 ml glycerol (20%)
* 0.1 ml 1% bromphenol blue in 10% EtOH (0.022%)
* Optional: Add 200 mM D'T = 0.1542 g or 10% BME if needed for reducing
conditions
* Fill to 5 ml with H,20 (-2.275 ml)
2 L of 1X TGS running buffer (Store at room temperature)
* 5.8 g Tris base (240 mM)
* 28.8 g glycine (1.9 M)
* 2 g SDS
* Volume to 2 L with MilliQ water (don't pH)
2 L of 2x Transfer Buffer without MeOH (Store at room temperature)
* 5.8 gTris base (12 mM)
* 28.8 g glycine (100 mM)
* 2 m 20% SDS
* Volume to 1.8 L with MilliQ water (don't p 1H)
1 L of Ix Transfer Buffer with MeOH (Make fresh, do not store)
* 450 ml of 2X Transfer Buffer
* 450 ml of MilliQ water
* 100 ml of MeOlH
TBS-Tween (Stable for weeks at room temperature although Tween can oxidize)
* 40 ml 1 M T'Iris-HC1, pH 7.5 (20 mM)
* 54.8 ml 5 M NaCl (137 mM)
* Volume to 2 L with I-20,, then add:
* 2 ml Tween (0.1%, Fisher Scientific-for TBS just omit this)
Coomassie blue staining solution
* 0.1% w/v Coomassie blue R250
* 40% MeO-I
* 10% lHAc
Destaining solution
* 30% MeOt-
* 10% fI Ac
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Lysis Buffer (Use 100 pl per million cells)
* 1% 0.1M PMSF
* 10% protease inhibitor cocktail
* 89% HNN solution
o 10 mM Hepes (pH 7.6 in distilled water)
o 150 mM NaCl
o 1% NP40
Blocking Solution (Make fresh for each run)
* 5 g Carnation Milk Powder
* 100 ml of TBS-T
Alternate Lysis Buffers:
General BPEC Lab Lysis Buffer and Method
1. To make lysis buffer, make 10mM Hepes pH 7.6 and 150mM NaCl in MilliQ water
and autoclave before adding NP40 (1% final concentration).
2. Add the Sigma protease inhibitor cocktail at 1:10 (v/v) and PMSF (0.1M final
concentration) just before use. The lysis buffer should be ice cold.
3. 100 tl of lysis buffer is added for every million cells. This would thus include 1 [tl of
PMSF, 10 C.l of the Sigma protease inhibitor cocktail, and 89 L1 of the Hepes, NaC1,
and NP40 solution.
4. The whole cells and lysis buffer should be mixed with a standard pipette, vortexed,
and incubated on ice for 10 minutes before spinning in a centrifuge at 40C and 10000
rpm for 5 minutes.
5. Transfer the supernatant to a new Eppendorf tube. This whole cell lysate can be
stored at -200 C for several months.
DAL Lab's Lysis Buffer Formulation
Final Concentration. Ingredient Amount to add for 10 ml
Solutions stored at 4 OC
-- ddH,O 5.665 ml
50 mM 0.5 M |-glycerophosphate, pH 7.3 1 ml
10 mM 0.1 M NaPP 1 ml
30 mM 0.5 M NaF 0.600 ml
50 mM 1 M Tris, pH 7.5 0.500 ml
1% 20%: Triton X-100 0.500 ml
150 mM 5 M NaCl 0.300 ml
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Appendix 6 - Detailed Giant Reactor Assembly, Seeding, Maintenance,
and Cell Recovery Protocols
Giant Reactor Assembly Protocol
Materials List:
* 1 top window
* 1 middle body
* 1 bottom piece
* 6 small screws
* 6 large screws
* 2 injection port screws w/ O-rings
* 1 medium-sized silicone O-ring
* 1 large-sized silicone O-ring
* 4 screw end-barbed end connectors w/ silicone O-ring on screw end
* 2 oblong silicone gaskets w/ pin holes
* 2 polycarbonate scaffolds w/ pin holes
* 1 oblong 5 micron Millipore filter w/ pin holes
* 1 Metal retaining ring (oblong shape)
* 6 barbed end-barbed end connectors
* 6 female luer-barbed end connectors
* 2 female luer-sealed end connectors
* 4 male luer-barbed end connectors
* 2 0.093" ID silicone peristaltic tubes
* 1 7.5 cm silastic tube for main flow connection from pump, 1 12 cm tube for x-
flow connection, and 1 18 cm outlet tube, 1 2 cm tube to block bottom port
* 1 reservoir w/ 2 inner silastic tubes at 3.5 cm for inlets and 1 inner silastic tube at
.5 cm or less for outlet , 2 outer openings sealed with a 3-4 cm tube, 1 outer tube at
-3 cm for air filter, and 2 7.5cm res input tubes
* 1 5 um inline filter, 1 1.2 um inline filter, and 1 0.8/0.2 um inline filter for in-line
filters
* 1 0.2 um filter for the reservoir top
* 1 extra reservoir bottom (2 extra per rxr for some experiments)
* 3 150 X 75 Pyrex dishes
* 1 complete peristaltic pump (w/ 2 instech pumps)
* 2 13.5/35 VDC power supply (CAUTION: ALWAYS SET AT 13.5 VDC)
* Autoclaved blue paper (at least 3 squares for RXR assembly in the hood, include
some extra sheets for the incubator as well)
* Tools: screwdrivers, tweezers, flat-head tongs, hex wrench
* 30 ug/mL type I rat tail collagen in 1X PBS, prepared fresh and kept on ice
* 1% w/v BSA in 1X PBS, can store at 4 'C after sterile filtering
* 1X PBS
* Pump Grease
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Assembly protocol
1. Autoclave the screws, connectors, reservoir with connected tubing, silastic tubing,
O-rings, tools (except screwdrivers), gaskets, Millipore filter, retaining ring, 2 Pyrex
dishes and blue paper in sterilization packets, with the exception of the
reservoir/extra tubings and the Pyrex dishes, which get wrapped in blue paper and
sealed with autoclave tape. Make sure that the silicone gaskets don't touch one
another in the sterilization pouch before autoclaving.
2. Gently scrub the polycarbonate Giant RXR body parts w/ alconox, rinse with milliQ
water, place parts in a previously autoclaved Pyrex dish, and cover the parts with
milliQ water.
3. Replace the water with 70% EtOH-I and let stand at least ten minutes before putting
in the hood. Make sure all RXR bodies are completely submerged. CAUTION:
POLYCARBONATE SHOULD NOT BE EXPOSED TO EtOH FOR MORE
THAN 30 MINS.
4. Place the polycarbonate scaffolds in a Petri dish, cover with alconox water, shake
gently, remove alconox, cover with milliQ water to rinse, shake gently, rinse
repeatedly.
5. Place the polycarbonate scaffolds in a Petri dish w/ milliQ water, put in the
sonicator for 2 mins. Make sure that scaffolds are in their correct pairs if using laser
machined scaffolds and write the scaffold numbers on the dish.
6. Remove milliQ water, cover scaffolds with 70% EtOH, sonicate for 2 mins. Leave
scaffolds in EtOH. CAUTION: POLYCARBONATE SHOULD NOT BE
EXPOSED TO EtOH FOR MORE THAN 30 MINS.
7. Place the RXR body parts in the Pyrex dish and the scaffold pairs in Petri dishes in
the sterile hood, along with: the autoclaved the Pyrex dishes, tools (including EtOH
sprayed-down screwdrivers), connectors, screws, reservoir, tubing, O-rings, gaskets,
Millipore filters, retaining ring, and blue paper. Spray all autoclave packets
thoroughly with EtOH before putting them in the hood and keep them away from
the blue paper surface that the reservoir is on.
8. Cover surface of working area in sterile cabinet with autoclaved blue paper.
9. Fill one autoclaved Pyrex dish 3/4 full with 1X PBS, this will be used to rinse all parts.
Fill a 10 cm Petri dish with 1X PBS to rinse the scaffolds separately from other parts.
10. Fill the other smaller autoclaved Pyrex dish / full with 70% EtOH, and use the flat
tongs (not the tweezers as the tubes are easily punctured) to place the two peristaltic
tubings in the ethanol, swirling the tubes around the dish to get the inner tubing
surfaces exposed as well. Make sure all tube ends are submerged in the ethanol.
11. Place the collagen solution (at least 10-15 mL) in a 10 cm Petri dish. Do the same for
1% BSA solution. Be sure to label the plates.
12. Rinse both scaffolds in 1X PBS. Put the top scaffold (lower numbered scaffold of
the pair for laser machined scaffolds) into the collagen solution, shaking gently until
no air bubbles are seen. The corresponding bottom scaffold can stay in the PBS or
be put in another Petri dish with PBS if you are keeping track of many RXRs. For
polycarbonate scaffolds, keep in collagen solution for 2 hours, and then dry for 2
hours inside the hood by balancing the scaffold on a 60 mm dish inside a 10 cm dish.
For silicon scaffolds only 30 min in the collagen solution is required.
13. Rinse the filter in PBS and then place in the BSA solution for at least 30 minutes.
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14. Use the tongs and tweezers to take out the middle body part (sides may be touched
by gloved hands, but should be avoided) from EtOH, rinse in 1X PBS, and place on
the blue paper top-side up.
15. Using tweezers, rinse the middle-sized silicon O-ring in 1X PBS (this helps the parts
interact with each other more smoothly), place the O-ring in its channel on top of
middle part. Use tweezers to hold down O-ring while the flathead of tongs are used
to smoothly place the O-ring into the channel to avoid tearing the O-ring.
16. Rinse the top window in 1X PBS and place on top of middle body part.
17. Use the 6 small screws to secure the window onto the middle part (PBS rinsed).
Tighten the screws (lightly at first) in a crisscross pattern, eventually tightening firmly
but without cracking polycarbonate parts. Make sure that the O-ring is compressed
uniformly.
18. Screw in the injection port screws slowly and loosely to middle body part, make sure
there are no burrs on the screw threads catching as you tighten, as this can
permanently damage the threading on the reactor body.
19. Tighten the port screws, stop when you feel a little resistance and the O-rings have
been compressed. Otherwise you can break the flow channel inlet and outlet,
compression of the O-ring is all that is needed to seal the injection port.
20. Keep middle/top window assembly open chamber face down on the sterile blue
paper. Use the hex wrench to lightly-tighten 2 screw end-barbed end connectors to
middle body part, ensuring that the O-rings are well compressed.
21. Flip the RXR body around so that the open pocket is facing up. Be very careful not
to wave hands or arms over the reactor now.
22. Using tools, rinse 1 silicone gasket in PBS, place the gasket in the middle body part,
using the pins/pin holes as a guide. Use the flathead tongs to lay the gasket down flat
and make sure that no air bubbles are stuck under the gasket.
23. Place the dried top scaffold in the middle body atop the gasket, using the pin/pin
holes as a guide. Make sure the scaffold is flat on the gasket and that the letter or
number symbol is facing you at the top pin to ensure alignment with the bottom
support scaffold.
24. Place the filter in the middle body atop the scaffold using the pin/pin holes as guide.
Flatten with tongs onto the scaffold. Be especially careful not to tear the filter, as
this will affect control over the cross-flow.
25. Using tools, rinse the support scaffold in PBS if not already in PBS, place scaffold in
middle body atop Millipore filter using pin/pin holes as guide. Make sure the
scaffold is flat and that the letter or number is at the top pin and facing you to ensure
the best channel alignment.
26. Using tools, rinse the second silicone gasket in PBS and place the gasket in middle
body atop the support scaffold using the pin/pin holes as guide. Flatten with tongs
onto the scaffold. The pins should only extend about halfway up into the holes on
this gasket.
27. Using tools, rinse the metal retaining ring in PBS, place the ring in the middle body
atop the gasket with the channel for the large O-ring facing upward.
28. Using tweezers, rinse the large-sized silicon O-ring in 1X PBS, place the O-ring in its
channel between the retaining ring and the middle part. Use tweezers to hold down
the O-ring while the flathead of tongs is used to smoothly place the O-ring into the
channel.
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29. Rinse the bottom piece of the RXR in PBS. Place on the middle body part, and use
the large screws to secure them together. As with the top window, tighten the screws
(lightly at first) in a crisscross pattern, eventually tightening without cracking
polycarbonate parts (don't overly tighten). Make sure that the O-ring is compressed
uniformly.
30. Use the hex wrench to lightly-tighten the 2 remaining screw end-barbed end
connectors to the bottom piece. Flip the RXR top-side up with bottom connectors
towards the assembler.
31. Place the 18.5 cm silastic tube onto the top right side connector and the 12 cm cross
flow silastic tube on the bottom-right connector. Place the 2 cm silastic tube onto
bottom-left connector and a 7.5 cm tube onto the top left side connector.
32. Put dual barbed end connectors into each silastic tube, with the exception of the 2
cm tube at the bottom left port. On this tube attach a female luer barbed, and then
screw in a threaded sealed end stopper. Note: It's easiest and safer to avoid
contamination to add these connectors onto the tubing before they are wrapped up
in blue paper with the reservoir and other tubing and autoclaved.
33. Rinse the peristaltic tubes in PBS and connect the two inlet tubes on the reservoir to
the main flow line and cross flow line on the reactor.
34. Lightly grease the peristaltic tubes with pump grease between the plastic knuckles.
35. Put the 0.2 micron filter onto the extra tube on the top of the reservoir. The system
is now closed.
36. Add 25 mL of HGM media to the reservoir, unscrewing and screwing the reservoir
from the bottom so that the tubes don't get tangled. Be careful that the reservoir
stays upright after it's filled so media doesn't get in the filter line
37. Lightly spray a peristaltic pump with ethanol and put it in the hood. Lightly spray
and dry two power cords with ethanol and connect to the pump.
38. Turn the main flow pump on to a slow speed and guide the main flow peristaltic
tube into the Instech pump. Keep pump going on for a short period to allow all PBS
to clear out.
39. Turn on the left Instech pump at 3 mL/min or greater, counterclockwise (calibration
should be done before run). Allow top chamber of RXR to fill with HGM, and since
the cross flow tube hasn't been loaded onto it's pump yet, the bottom chamber
should completely fill as well if the RXR was properly assembled.
40. Turn on the right Instech pump at lmL/min, clockwise and load the cross flow
peristaltic tubing onto the pump. Flip RXR, bottom-side up, put reactor at a 450
angle so that any trapped air in the chamber can flow out towards the reservoir.
41. Let the system prime for -1 hour.
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Seeding protocol
All seeding is done inside the sterile hood. Spheroids should be filtered (50 pm and 300
pm mesh), spun down at 50 g for 3 mins, resuspended in cold fresh medium, and put on ice
immediately before beginning this protocol. Two spinner flasks seeded with 30 million
hepatocytes each can be filtered together, and resuspended in 20 mL of cold HGM. This
provides enough spheroids to seed at least 6-8 giant RXRs. Note: It is much easier and
seeding is far more efficient if the system is primed and seeded with HGM that contains
BSA.
1. Turn off the main flow pump and turn up the downward flow on the cross flow
pump to quickly drain the top chamber halfway. Unscrew top window by removing
injection port screws first and then the 6 small screws (this order will insure that the
window won't crack). Remove the top window and place it on sterile autoclave
paper.
2. Set crossflow rate to 2.5 mL/min downward. Leave main flow at 3 mL/min but
keep pump turned off unless there isn't enough media in the chamber.
3. Seed reactor by gently pipetting -2 mL of spheroid suspension evenly on seeding
scaffold. Pipette gently, making sure spheroids are evenly distributed.
4. Gently rock the RXR body at 45 degree angles towards and away from you as the
cross flow slowly draws the spheroids into the channels. Media in the chamber can
be gently pipetted up from the bottom end of the tilt and slowly repipetted over the
channel array at the top of the tilted chamber. This leads to very uniformly seeded
cells if you alternate pipetting up and down on each end as you rock the RXR body.
Be careful not to suck up too much of the cell suspension each time though to keep
the cells in the channels wetted and to prevent air from being drawn into the filter
between the scaffolds.
5. Observe channels as well as possible. If all channels are not seeded properly, a
smaller volume of spheroid suspension may be added to the required area of the
scaffold. Make sure top chamber liquid level is always above scaffold by turning on
main flow if it is too low since the downward cross-flow will have removed a good
deal of the media at this point. This prevents cells from being exposed from air and
getting air trapped in the filter between the scaffolds.
6. Turn off all flow. Replace top window and screw back on in a similar fashion as
done during assembly to ensure uniform compression of the medium sized O-ring.
Turn main flow on at 3 mL/min, and crossflow at 2.5 mL/min. Gently tilt the
reactor with the main flow outlet facing upward so the air easily leaves the top
chamber. Wipe down the reactor body with an ethanol soaked Kimwipe. Put
reactor in 370 C incubator.
7. Depending on the experimental protocol, you can change medium 1-2 hours after
seeding to remove excess cells or simply change the medium when the cross flow is
changed the following day. When changing medium, aspirate media out of the
reservoir cup and put 30 mL of fresh medium in the reservoir. At 1-2 hours post
seeding, two black rubber feet can be screwed into the bottom of the main flow
outlet end so that air doesn't collect in the top chamber.
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Inserting In-line Filters and Reversing Cross Flow
This protocol should be followed such that cross flow is reversed 24 hrs after seeding.
Downward cross flow during the first 24 hrs helps to retain the cells in the channels as they
attach to the walls and reorganize. Changing to upward cross flow after this initial period
removes debris, as well as unattached and dead cells from the channels. Priming of filters
requires an extra reservoir. However, all filters necessary can be primed from the same pump
assembly.
1. Soak one peristaltic tube in 70% EtOH for <15 mins.
2. While the tube is soaking, open all in-line filters, screw autoclaved barbed-
end/female luer-end connectors onto the broad luer end of each filter and connect
the tubes with autoclaved 4 cm segments of silastic tubing. The filters should be in a
sequential chain of 5 microns (green), 1.2 microns (red), and .8/.2 microns
(blue/green). Connect all of the chains together with autoclaved barbed-
end/barbed-end connectors and leave on sterile paper in the hood.
3. Rinse the peristaltic tube in 1X PBS, insert one barbed end-barbed end connector
into each end of peristaltic tube and attach one end to a media reservoir and the
other end to the filter chain. Connect the outlet end of the filter chain to the
reservoir.
4. Put 30 mL of fresh medium into reservoir.
5. Lightly grease the peristaltic tube between the plastic knuckles and load the tube
onto a pump head by turning pump on to a low setting. Once loaded, turn the
pump to a high flow rate.
6. Hold filters up such that they will be filled from the bottom up so that most air is
removed from the filter. After filters have been filled with medium, shake them and
tap them gently to shake out any air bubbles that may have been trapped inside
them.
7. Once all air bubbles are cleared, allow filters to prime for -1 hour.
8. Take reactor out of incubator and place in sterile cabinet. Turn off pumps.
9. Remove the reservoir cup and replace with a new autoclaved cup with 30 mL of
fresh HGM. This gets rid of a lot of the circulating debris and insures that the filter
chain won't get clogged or provide too much resistance to the cross flow pump.
10. Clamp the cross flow silastic tube near it's meeting point with the peristaltic tube.
11. Clamp one set of three filters off from the primed filter chain and remove.
12. Gently remove the peristaltic tube from the cross flow line and attach to the 3 filter
chain with the 5 micron filter on the peristaltic tube end. Remove the clamps and
turn the cross flow pump to forward flow. Let the pump flow to remove any excess
air in the filters from the act of connection. Let media drip from the free .8/.2 filter
end of the line onto an ethanol soaked Kimwipe as the line finishes priming.
13. Turn off the pump and set to the desired upward cross flow rate. Gently remove the
old silastic crossflow tube from the RXR with that reactor inlet tilted up so that
media does not leave the chamber. Connect the filter chain onto the RXR and turn
on both upward cross flow at 1 mL/min and main flow at 3 mL min. Note: To be
absolutely sure that no short-circuiting is happening between the crossflow input and
the main flow outlet. The cross flow input can be switched with the blocked off
lower inlet, meaning the crossflow line would be placed onto the lower left chamber
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inlet and the blocked 2 cm line would be switched to the lower right chamber inlet.
This was normally performed in order to insure more uniform cross flow through
the channels.
14. Check that no air bubbles are trapped in the RXR chambers and return to the
incubator.
Media and Filter Changing Regiment
After the cross flow change and addition of in-line filters, media should be changed
every 48 hours. Media can be aspirated from the reservoir cup after both pumps are turned
off, and then 30 mL of fresh media can be added to the same cup.
Filters should be changed every 3 days for long term cultures. A new filter chain
should be assembled and primed, and replaced following the above protocol. A filter chain
can remain in the cross-flow line for up to 4 days for shorter term cultures before the lines
begin to get clogged and seize the pump. This is useful for some transfection experiments
for day 3 spheroid seeded reactors that are dosed with gene vectors on day 7 after isolation,
since in-line filters typically aren't used during the transfection period to cut down on
adsorption of the gene therapy vector in the circulating media. This isn't a problem for the
short term transfection period since the vast majority of debris is removed by day 7.
Cell Recovery from the Reactor
Cells can be removed very efficiently from the polycarbonate scaffolds by using
Dispase and adhering to the following protocol.
1. Prior to taking down the reactor, thaw frozen aliquots of Dispase and allow them
to warm to 37oC. Make sure that you have at least 3 mL of Dispase for each
reactor that will be taken down.
2. At the time point of interest, spray down the pump and reactor and place in the
hood on autoclaved blue paper.
3. With the pumps still running, remove the peristaltic tubes form the pumps.
Turn off the pumps and take out of the hood.
4. Quickly unscrew the top and bottom RXR pieces from the middle RXR body.
Gently remove these pieces and then use the flat tongs to slowly push the
scaffolds, filter, retaining ring and bottom silicone gasket out of the RXR body
and into a 10 cm Petri dish.
5. Pick up the scaffold sandwich and very slowly and gently shear the top, cell
containing scaffold away from the filter in a perpendicular direction to the
scaffold and filter faces. This prevents loss of cells on the filter, and all of the
cells will be retained in the scaffold channels.
6. Place the cell containing scaffold in a 10 cm Petri dish and pipette 3 mL of warm
Dispase over the channel array.
7. Place the dish in an incubator for 5 minutes.
8. Take the dish out of the incubator, and in the hood, tilt the plate, lift the scaffold
with the flat tongs and gently pipette the Dispase through the channels. The
channels should be completely clean in less than a minute.
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9. Keeping the Petri dish tilted, gently scrape the cells with a disposable scraper to
the bottom of the dish. Collect the cells with a pipette and put into a pre-chilled
15 mL centrifuge tube.
10. Add fresh, chilled media to the plate to collect any cells that remain and add to
the same centrifuge tube.
11. Spin down the collected cells at 50xG for 3 minutes.
12. Carefully remove the supernatant with a pipette, and resuspend the cell pellet in
the buffer of interest that is optimal for the ensuing assay to be performed, e.g.
Trizol for RNA extraction, the appropriate lysis buffer for westerns or gene
expression assays, DGE buffer for cell lysis and organelle recovery.
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Appendix 7 - RNA Purification Protocol
Standard RNA Isolation Protocol
This protocol utilizes Trizol to lyse cells from any variety of culture systems and stabilize the
RNA in the sample for long term storage at -80'C. RNA is then acquired from these thawed
samples by a chloroform extraction and the resulting aqueous RNA phase is further purified
using a commercial kit such as the Qiagen RNEasy Mini Kit with a modified protocol that is
included here.
To initially collect the sample:
1. Aspirate media and wash cells once with PBS.
2. For 6 well tissue culture plates: Add 1mL Trizol to each well; detach cells with cell
scraper and transfer sample to RNAse free Eppendorf tube; invert and vortex to
mix.
3. For spheroids: Pellet spheroids at 50xG for 3 minutes, aspirate the supernatant and
resuspend in 1 mL of Trizol, sample can be transferred to an Eppendorf tube and
vortexed to mix.
4. For reactors with polycarbonate scaffolds: Quickly recover the cells from the
scaffold via Dispase digestion (See Appendix 5), pellet cells and tissue at 50xG for 3
minutes. Aspirate supernatant and add 1 mL of Trizol. Transfer to an Eppendorf
tube and vortex to mix.
5. In uivo liver tissue samples: Cut a piece of each of the four lobes of the liver. Put
each piece in a separate 15 mL centrifuge tube in 3-5 mL of Trizol. Use a tissue
homogenizer at a high speed setting to completely break up the sample, aliquot or
keep in the large tube to freeze.
6. Freeze all samples at -800C for a minimum of 15 min (until completely frozen) to a
maximum of 2 months.
Note: From this point it's recommended not to do more than 8 samples at a time to
minimize RNA degradation during time of procedure.
7. Thaw sample on ice (or at room temperature as long as you watch it carefully!).
8. Homogenize sample by passing through a 26g needle/syringe (1 ml) 12-15 times.
9. Add 200uL Chloroform to each sample.
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10. Invert a few times by hand and then vortex for 5 seconds.
11. Incubate RT for 2-3 mins; sample will start to settle (clear w/ RNA on the top; pink
w/ DNA and Protein on the bottom).
12. Centrifuge samples for 15 min @ 12,000 RPM (Cold Room 16-447).
13. (In preparation for later) Warm DEPC Water to 550C (Bench #3) and label
Eppendorf collection tubes.
14. After spin, carefully remove top layer of supernatant (clear; contains the RNA) and
place in 1.5mL Eppendorf tube. To do this, set pipette to 200 ul and leave some
behind if necessary so that there is no contamination with the pink layer (contains
DNA and other cellular components).
a. Keep track of how much material was removed (should yield about 550-600
ul).
b. Remaining sample (DNA/Protein) will go into -80C.
From here onward, keep all samples on ice! Follow RNEasy Mini Handbook (Qiagen) from
step 4 of protocol (with afew modifications):
15. Add equal volume (or more) of 70% EtOH to sample: mix by tipping and pipetting
(do not vortex).
16. Remove up to 700uL solution and place in an RNEasy column with collection tube.
a. Centrifuge for 15 sec @ 2 8000g (10,000 RPM) .
b. Repeat spin by returning eluent to top of filter (15 seconds).
c. Discard waste (solution in the bottom of filter unit) after the 2 centrifugation
steps.
d. Add remaining and repeat centrifugation steps 7a-7c .
17. Add 700ul of Buffer RW1 to the RNEasy column. Centrifuge for 15 sec @ 2 8000g
(10,000 RPM) and discard flow-through and collection tube.
18. Transfer column to a new collection tube and add 500uL of RPE Wash Buffer to
filter. Centrifuge for 15 sec @ 2 8000g (10,000 RPM) and discard waste.
19. Add another 500uL of RPE Wash Buffer to System and centrifuge for 2 min (15 sec
@ 2 8000g) to dry membrane.
a. RECOMMENDED: Place column in new collection tube and centrifuge at
full speed for 1 minute to ensure that all ethanol is removed.
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20. Add 30uL DEPC treated water (heated to 65TC) to filter; incubate RT for 2-3
minutes.
a. Centrifuge for 2 minutes in a clean Eppendorf tube to elute.
b. Repeat with another 30uL DEPC water (if desired, this is requisite if there
are one million cells or more).
To measure quantity and purity of RNA:
21. For a traditional spec, remove 2uL water from sample and add to 98uL water in new
Eppendorf tube
a. Also make blank (100ul DEPC water)
22. Return samples (both the Trizol sample and the RNA sample) to the -80C
23. Bring 100uL samples on ice (and blank 100uL DEPC) to spectrophotometer
24. To use Spectrophotometer (Samson lab spec, 56-230):
a. Nucleic acid (260/280)
b. Turn Vis on, UV on (wait 1-2 min after machine is ready)
c. Wipe casings with kimwipes
d. Insert blank (red dot towards front); click "blank"
e. Insert samples, click "read sample"; repeat 3x for each sample
f. Print results, Quit, OK, UV Off
25. To use the NanoDrop in BPEC:
a. Open ND-100 v3.1.2 on the BPEC PCR computer.
b. Select "Nucleic Acid" tab.
c. Clean the sample pedestal with RNAse free water and a Kimwipe.
d. To initialize, add 2 uL of RNAse free water, put top arm down and click OK.
e. Select RNA-40 in the sample type window in the upper right corner.
f. Wipe off the sample pedestal and blank the device with 2 uL of the buffer
that the sample is in, which for RNA is usually DEPC water.
g. Wipe off the sample pedestal and pipette 2 uL of your sample, put the arm
down and click on measure.
Notes: Only read a volume of sample once, you can read another 2 uL and so on if you want
replicates. The reading will change on subsequent reads of the same sample. The sample
pedestal only needs to wiped clean with a Kimwipe between multiple samples. Keep RNA
samples on ice at all times during measurement.
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Appendix 8 - cDNA Generation Protocol
This cDNA protocol is based on synthesis from 200 ng of total RNA and will yield
20 uL of cDNA. This is enough to run real-time PCR on 5-6 genes. If you need to measure
more genes, or if you want to store some cDNA long term since it degrades less rapidly than
the RNA samples, you can double or triple all of the volumes in the protocol and get 40 or
60 uL of cDNA from 400 or 600 ng of RNA, respectively.
1. Add the following to a 0.5 mL Eppendorf tube:
a. Calculate the volume of the RNA sample to make 200 ng total RNA from
nanodrop reading. Make sure to re-read your RNA sample if it's been stored
for a while.
b. Calculate the remaining volume of DEPC water so the total volume
(RNA+H 20) is 8 uL.
c. Add DEPC water, and then RNA and keep all samples on ice.
d. Add 1 uL of 10x DNAse Buffer to each sample. Mix buffer well with a
pipette before adding.
e. Add 1 uL of DNAse I enzyme (Invitrogen) to each sample. Take DNAse
out just before adding (don't need to thaw it) and mix with a pipette before
adding.
2. Let the sample sit at room temperature for 15 minutes. Put the remaining RNA
back in the -80'C freezer. Turn on the heating block and set to 650C. Prepare
Eppendorfs for dilution in step 5.
3. Add 1 uL of EDTA to each sample (25 mM, Invitrogen) to each sample and return
the samples on ice. When EDTA has been added to all samples, centrifuge them at
2000 RPM for ~5 seconds. Incubate samples at 650C for 10 minutes.
4. Get from the -20'C freezer: Random Hexamer Primers, RT Buffer (Qiagen), RNAse
Inhibitor (Ambion). Keep on ice!
5. Make dilutions of 10x RT buffer, Random Hexamers, and RNAse Inhibitor:
a. RT Buffer: 1:10 dilution of the 10x RT buffer to use in step 5c. Add 9 uL of
DEPC water for every 1 uL of 10Ox RT buffer. Make a little extra so volumes
will be correct.
b. Primer dilution: 1:10 (e.g. 9 uL of DEPC water and 1 uL of Primer working
stock. Again, plan to make 1-2 rxns worth extra so volumes will be accurate.
Make the dilution fresh every time.
c. RNAse Inhibitor: 1:4 Dilution with 3 uL of lx RT buffer from step 5a for
every 1 uL of RNAse inhibitor. Make fresh each time, and again make 1-2
rxns additional dilution so volume will be accurate for stock solution.
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6. Make the Stock Solution containing for each sample (make one to two extras):
a. 1 uL DEPC water
b. 2 uL dNTP (Qiagen)
c. 2 uL Primer dilution (step 5b)
d. 1 uL RNAse inhibitor dilution (step 5c)
e. 2 uL 10x RT buffer (Qiagen)
f. 1 uL Omniscript Reverse Transcriptase (RT O, Qiagen)
7. Remove samples from heat at the end of 10 minutes from step 3. Centrifuge for -5
seconds at 2000 RPM. Return samples to ice.
8. Add 9 uL of the Stock Solution from step 6 to each sample to make the total volume
20 uL.
9. Spin down samples for -5 seconds at 2000 RPM.
10. Incubate samples at 37oC in the water bath. Make sure bottom of tube is in the
water but that tube tops aren't submerged.
11. Remove samples from the water bath, centrifuge '5 seconds at 2000 RPM, and store
samples at -80'C.
Note: Catalogue numbers and sources for all currently used reagents are listed in the master
lab supplies file.
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Appendix 9 - Real-time, Reverse Transcriptase SYBR Green PCR
Protocol
This is a general protocol for any primer set of interest to measure mRNA expression using
the Chromo4 Real-time PCR set-up and Opticon Monitor 3 software.
1. Make "Master Mix" containing (or 20x):
a. 25uL SYBR Green (500uL)
b. 21uL DEPC water (420uL)
c. 1.5uL forward primer (30uL) (primers boxes, -200 C freezer #5)
d. 1.5uL reverse primer (30uL) (primers boxes, -20 0C freezer #5)
2. Vortex sample and spin down. Vortex master mix and spin down.
3. Get BioRad 96-well plate (white plastic) and place in a black plate tray.
4. Add 49uL master mix (step 1) to each well.
5. Add luL cDNA to each sample. Use triplicates. Leave one triplicate for no RT spaces.
6. Cover each well with a sample in it with a clear plastic cap.
7. Return cDNA samples to -800 C freezer.
8. Insert sample into RT-PCR machine. Gently close the top and secure the latch.
9. Open "Opticon Monitor 3" program on the BPEC PCR computer.
10. Open your user profile. Open Master file (top set) and make changes to plate and
protocol setup.
11. Change the plate setup so each grid spot where there is a sample has a red circle. Make
sure that the proper plate type (MJ White) and dye types (SYBR Green, in this case) are
selected - these cannot be changed later.
12. Change the protocol to have the optimal primer annealing temperature and number of
cycles. Make sure that the proper reaction volume is typed in (50 uL here) - this cannot
be changed later.
13. Save the protocol file, then the plate setup file, then the master file.
14. Click Run: the computer will prompt you for a file name for the data file. The computer
automatically saves this file at the end of the run protocol.
15. You can click on 'quantification' during the run to check the status of your sample.
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16. When the run is complete, set the threshold magnitude by looking in both the log view
and regular view to make sure it is in the early linear range of the amplification. Keep
this value consistent between runs for accurate comparison of CTs between samples.
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Appendix 10 - Vector Specific Gene Delivery Protocols
Deliver 5 ug of plasmid DNA for a 35 mm dish, and 10 ug of DNA for a 60 mm dish.
Keep the concentration at 5 ug/mL in transfection media and add 1 mL for 35 mm and 2
mL for 60 mm to get good coverage and stay consistent between different samples and
systems.
For PEI25:
To make NV PEI25 particles at N/P=20:
For every 5 ug of DNA:
1. Add 24 uL of .0005 ug/uL PEI25 solution to 26 uL of sterile water
2. Add this 50 uL of polymer solution to the DNA which has been diluted to .1
ug/ul previously in aliquots.
3. Pipette vigorously and let the tube sit at room temp for 20-25 minutes.
4. Do not prepare more than 800 total volume in one tube (40 ug DNA)
5. By 25 minutes, add 100 uL complex solution for every 900 uL of media.
Add appropriate amount of transfection solution to each plate and incubate at 37C.
Wash 2x in PBS++ at time point of interest.
Scrape up cells, collect with pipette, and spin at 50G, 4C for 4 min.
Aspirate supernatant and freeze pellet at -20C for short-term and -80C for long-term.
Notes:
Make fresh PEI25 at .0005 ug/uL by diluting the stock PEI25 in ethanol (at 100 mg/mL
currently) 200 fold in sterile water, making final ethanol concentration less than 0.5%.
For Small X-Linked PEI and Linear PEI22 from the Klibanov Lab:
X-linked PEI at N/P=30 (frozen stock is at 150 mM) for 10 ug of DNA
1. Make a 1:10 dilution of the stock XPEI in water.
2. Add 61.5 uL of the 1:10 polymer dilution to 38.5 uL of water.
3. Add 20 uL of .5 mg/mL plasmid stock to 80 uL of water.
4. Add the 100 uL of polymer to the 100 uL of DNA.
5. Pipette vigorously and let stand at room temp for 10 minutes.
6. Add to 2 mL of pre-warmed medium and add to a washed 60 mm dish. Scale
volumes accordingly for other plate types and cell numbers.
Linear PEI22 at N/P=10 (frozen stock is at 150 mM) for 10 ug of DNA
1. Make a 1:10 dilution of the stock LPEI22 in water.
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2. Add 20.5 uL of the 1:10 polymer dilution to 79.5 uL of water.
3. Add 20 uL of .5 mg/mL plasmid stock to 80 uL of water.
4. Add the 100 uL of polymer to the 100 uL of DNA.
5. Pipette vigorously and let stand at room temp for 10 minutes.
6. Add to 2 mL of pre-warmed medium and add to a washed 60 mm dish. Scale
volumes accordingly for other plate types and cell numbers.
For C32 and Other Langer Lab Poly(j-amino ester)s:
Combine all polymers and DNA at a mass/mass ratio of 100:1.
1. Dilute the 100 mg/mL polymer stocks in DMSO 1:10 in sterile filtered 25
mM sodium acetate buffer.
2. Add 20 uL of plasmid at .5 mg/mL to 80 uL of the sodium acetate buffer.
3. Add 100 uL of the polymer dilution to the 100 uL of DNA (10 ug DNA
total).
4. Pipette vigorously and let stand at room temperature for 5 minutes.
5. Add to 2 mL of pre-warmed medium and add to a washed 60 mm dish. Scale
volumes accordingly for other plate types and cell numbers.
For Adenovirus:
These amounts are for an MOI of 10 for transduction of 2 million cells in a 60 mm dish. It
is not wise to use MOIs greater than 20 for gene delivery experiments in primary
hepatocytes.
1. Make a 1:100 dilutions of an Ad5 stock aliquot in 10% glycerol in PBS. Keep the
volume small enough in the 1:100 aliquots that one tube will only be thawed
once or twice.
2. Thaw a 1:100 aliquot on ice.
3. Add 6 uL of the 1:100 aliquot to 2 mL of pre-warmed medium and add to a
washed 60 mm dish. Scale volumes accordingly for other plate types and cell
numbers.
Overall Notes:
Adding the polymer to DNA and not the DNA to the polymer is important for good and
consistent complex formation.
Do not freeze-thaw DNA plasmid aliquots more than three to four times, keep already
thawed aliquots away from the new aliquots in the freezer box.
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Appendix 11- Plasmid and Genomic DNA Purification Protocol
OBJECTIVE:
Purify plasmid DNA in high throughput from total cell or nuclear samples using a
Qiagen DNEasy 96 Plate. This is a modified protocol from the standard Qiagen protocol
which works well with mechanically lysed samples, nuclear pellets, and samples lysed with
1% NP-40 lysis buffer. Delivered plasmid DNA and endogenous genomic DNA are
copurified for the whole cell and nuclear fractions.
METHOD:
1) Thaw frozen samples for 30 min. at room temperature.
2) Add 200uL of room temperature PBS to each nuclear sample, resuspend by
repeatedly pipetting.
3) Transfer samples into wells of round-well block. Be sure to note sample layout
in the provided plate templates.
4) Add 200uL Buffer ATL + Proteinase K (2mL Proteinase K + 18mL Buffer ATL
per plate) to each well. Carefully seal with Qiagen caps and mix by shaking
vigorously for 15 sec. Centrifuge at 3000 rpm briefly.
5) Incubate at 70C for 30 min. Tape the clear top down to the blue base so the
caps don't pop off.
6) Remove plate from the hybridization oven. Carefully remove the clear top and
reseal the caps carefully. Wait 30 seconds to make sure the temperature change
of any opened and resealed caps doesn't cause them to pop open.
7) Return top and shake vigorously for 15 sec. Centrifuge at 3000 rpm briefly.
8) Remove caps. Add 410uL Buffer AL/E to each well. Seal with Qiagen caps and
mix by shaking vigorously for 15 sec. Centrifuge at 3000 rpm briefly.
9) Place QIAmp 96 plate on a clean S-block. Transfer samples from round-well
block to the QIAmp 96 plate. Plate can take up to 900 uL per well.
10) Seal QIAmp 96 plate with AirPore tape. Centrifuge at 6000 rpm for 10 min.
11) Remove tape. Add 500uL Buffer AW1 to each well. Seal QIAmp 96 plate with
new AirPore tape. Centrifuge at 6000 rpm for 5 min.
12) Remove tape. Add 500uL Buffer AW2 to each well. Seal with AirPore tape.
Centrifuge at 6000 for 5 min.
13) Remove tape. Place DNEasy plate on Qiagen rack of elution tubes. Incubate at
70C for 15 min. to dry the membranes.
14) Add 200uL pre-warmed 70C H20 to each well. Seal plate with new AirPore
tape. Incubate at RT for 2 min. Centrifuge at 6000 rpm for 2 min.
15) Repeat step 14 to obtain a total elution volume of 400 uL.
16) Seal plate with foil adhesive cover. Store at -20C.
Comments: Make sure that the plate centrifuge is well greased at the knuckles so that plates
don't get imbalanced. If running one plate at a time, make absolutely sure that the balance
plate has the exact same volumes as the sample plate.
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Appendix 12 - Quantitative Real-time Taqman PCR Protocol
This protocol allows for sensitive quantification of the gWiz P-Gal plasmid purified from
cell samples after gene delivery.
EXPERIMENT:
DNA Quantitation of gWiz P-Gal Plasmid
OBJECTIVE:
Determine plasmid quantity using MJR Chromo 4 System.
Samples:
METHOD:
1) Thaw frozen samples for 30 min. at room temperature. Thaw primers and probe
and keep on ice.
2) Mix samples well with a multichannel pipette.
3) Prepare Master mix and keep on ice (15uL per well, make for at least
rxns if using electronic multichannel):
10-15 extra
Final Volume (uL) Volume (uL)
Concentration
per 25uL per
2x Master Mix lx 12.5
Forward Primer 400nM 0.125
Reverse Primer 400nM 0.125
Probe 25nM 0.125
H20 2.125
Add 10 uL sample 10
4) Prepare standard curve by pipetting 90uL H20 to wells B1-H1 of first column
and A3-C3 in the third column in a new 96-well plate. Pipette 100uL gWiz B-
Gal plasmid stock (1E9 copies/uL) into first well using P200 pipette. Perform
10-fold dilutions down column (10uL) using Rainin 10 uL pipette. Scale up these
volume as needed if prepping multiple plates.
5) Pipette 15uL master mix per well into MJ White Optical plate using Biocontrol
Electronic pipette by setting pipette to 15uL 12x in Stepper Mode. Holding
trigger to second stop before aspirating, dispense by pulling trigger to first stop.
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6) Pipette 10uL standards or sample into appropriate well. Use PCR layout sheet to
note sample locations.
7) Cover and seal plate with caps and sealing tool. Centrifuge at 3000 rpm for 1
min in Qiagen Centrifuge. Perform PCR on MJR Chromo 4 (FAM dye, TAMRA
quencher, ROX reference):
a) Cycle Routine in Protocol File
1. Hold
2. Hold
3.Cycle
4. Hold
50C 2 Min
95C 10 Min
95C 15 Sec 40 times
60C 1 Min
Plate Read
50C 2 Min
Make sure rxn volume is 25 uL in upper entry window.
b) Plate File
1. Make sure plate type is selected as MJ White
2. Have every dye designation as sample except for standards wells
where FAM should be set to standards or blank with the appropriate
copy number added in.
c) Save Master File to link the Plate and Protocol Files
d) Click run and save Data File.
8) For data analysis, set cycle threshold level at .025 for these primers to be in the
log linear range for nearly all cases. Keep this threshold consistent between
plates for the most accurate comparison of copy numbers. Export data by
copying output sorted by dye and paste into an Excel sheet.
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This protocol allows for quantification of the endogenous rat GAPDH gene purified from
cell samples after gene delivery. Comparison to a standard curve generated from the same
DNA purification method allows determination of hepatocyte number to normalize samples
on a per cell basis.
EXPERIMENT:
DNA Quantitation of Rat Genomic DNA via GAPDH
OBJECTIVE:
Determine cell quantity using MJR Chromo 4 System.
Samples:
METHOD:
Thaw frozen samples for 30 min. at room temperature.
Mix samples well with a multichannel pipette.
Prepare Master mix (15uL per well):
Final Volume (uL) Volume (uL)
Concentration
per 25uL per
2x Master Mix 1x 12.5
Forward Primer 900nM 1.0
Reverse Primer 900nM 1.0
Probe 225nM 0.5
Add 10 uL sample 10
4) Pipette 15uL master mix per well into MJ White Optical plate using Biocontrol
Electronic pipette by setting pipette to 15uL 6x in Stepper Mode. Holding
trigger to second stop before aspirating, dispense by pulling trigger to first stop.
5) Pipette 10uL samples into appropriate well. Use PCR layout sheet to note sample
locations.
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6) Cover and seal plate with caps with sealing tool. Centrifuge at 3000 rpm for 1
min in Qiagen Centrifuge. Perform PCR on MJR Chromo 4 (FAM dye, TAMRA
quencher, ROX reference):
a) Cycle Routine in Protocol File
1. Hold 50C 2 Min
2. Hold 95C 10 Min
3.Cycle 95C 15 Sec 40 times
54C 1 Min
Plate Read
4. Hold 50C 2 Min
Make sure rxn volume is 25 uL in upper entry window.
b) Plate File
1. Make sure plate type is selected as MJ White
2. Have every dye designation as sample.
c) Save Master File to link the Plate and Protocol Files.
d) Click run and save Data File.
7) For data analysis, set cycle threshold level at .025 as well for these primers to be
in the log linear range for nearly all cases. Keep this threshold consistent
between plates for the most accurate comparison of cell numbers. Export data
by copying output sorted by dye and paste into an Excel sheet.
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Appendix 13 - Gene Expression Assays in 2-D and 3-D Culture Systems
For 2-D Adsorbed Collagen Monolayer Cultures:
1. Prepare fresh 1x reporter lysis buffer at room temp from the 5x stock and water.
2. Take plates out of the incubator and wash 1x with PBS.
3. Add 450 uL of 1x reporter lysis buffer to each plate. Rotate and tilt plates to ensure
even coverage.
4. Place plates on the rack in the hybridization oven and turn the tilt speed to
maximum to achieve good movement of the lysis buffer. Incubate for 15 minutes at
room temp.
5. Scrape each plate with a new hard white scraper. Collect scraped cells in the bottom
of the plate with a pipette and put in a pre-chilled 1.5 mL Eppendorf tube on ice.
6. Vortex each sample for 20-30 seconds, then centrifuge the tubes at top speed in a
microcentrifuge (at least greater than 12,000 RPM) for 2 minutes.
7. Return the tubes to ice, being very careful not to dislodge the pellet.
8. Transfer 400 uL of the supernatant to a new pre-chilled tube, keeping the pipette tip
as far away from the pellet as possible during the transfer.
9. Freeze samples at -80'C. Full P-Gal activity is retained for at least two months.
For 3-D Liver Bioreactor Cultures:
1. Prepare fresh 1x reporter lysis buffer at room temp from the 5x stock and water.
2. Warm up at least 3 mL of Dispase to 37oC per reactor to be taken down.
3. Disassemble reactor and carefully push the scaffold sandwich out of the reactor
pocket into a sterile Petri dish in the hood.
4. Carefully shear the top scaffold off of the filter in a direction perpendicular to the
scaffold/filter face to ensure that the tissue remains in the channels. Place the top
scaffold in a 10 cm Petri dish.
5. Add 3 mL of prewarmed Dispase on top of the channel array and place in the
incubator for 5 minutes.
6. After 5 minutes, hold the scaffold up with flat tweezers and gently pipette the cells
out of the channel.
7. Collect the cells with a pipette and pellet them at 50xg for 3 minutes at 4oC.
8. Carefully removed the supernatant with a pipette (not the vacuum aspirator) to
ensure that the pellet is not dislodged but that as much media as possible is removed.
9. Add 1.5 mL of lx reporter lysis buffer to the pellet. Resuspended the pellet by
pipetting, transfer lysate to a prechilled 1.5 mL Eppendorf tube on ice.
10. Vortex samples for at least 30 seconds to break up any remaining tissue chunks, then
centrifuge the tubes at top speed in a microcentrifuge (at least greater than 12,000
RPM) for 2 minutes.
11. Transfer 1400 uL of the supernatant to a new prechilled Eppendorf tube with a
pipette keeping the pipette tip as far away from the pellet as possible during the
transfer.
12. Freeze samples at -800 C. Full f-Gal activity is retained for at least two months.
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Note: If western blots are to be performed on the reactor samples, especially for any
membrane surface proteins, an alternative collection and lysis method is to directly pipette
1.5-2 mLs of 1x reporter lysis buffer over the cell array and use a large gauge syringe or
pipette to force the cells out of the channels and then proceed with the rest of the protocol.
It is more difficult to recover the cells using this technique, but it guarantees that epitope of
interest won't get cleaved by the Dispase, and there is little difference in the P-Gal/total
between the two methods.
Measuring [-Gal Activity:
I. Thaw the Promega Assay 2x Buffer on ice and the Promega 1 M Sodium Carbonate
Stop Buffer at room temp. Ensure that there is no precipitate in the Stop Buffer (if
so, place in the water bath and shake until).
2. Thaw lysate supernatants and keep on ice.
3. Prepare a standard curve in duplicate as described for the 96 well assay in the
Promega protocol.
4. Place 50 uL of each sample in triplicate into the appropriate sample wells of the
plate.
5. Add 50 uL of the Assay 2x buffer with a multiwell pipette, mixing well and using
new tips for each row.
6. Put the top on the plate and incubate for 30 min at 370C in the incubator.
7. Stop the reaction by adding 150 uL of the 1 M Sodium Carbonate to each well. Pop
any bubbles that are formed during this step with a syringe tip.
8. Read the absorbance of the samples at 420 nm in the plate reader.
In parallel, prep duplicate 50 uL replicates (triplicate for reactors where there is plenty of
supernatant) of the samples with 50 uL of water in another plate and perform the BCA total
protein assay as described in Appendix 4 in order to normalize the gene expression levels.
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Appendix 14 - Toxicity Assay Protocols
LDH Release Assay:
This assay is a close adaptation of the Promega CytoTox-ONE Homogeneous Membrane
Integrity Assay.
1. At the time point of interest, take the plates out of the incubator and let them
equilibrate to room temperature. Allow Substrate Mix and Assay Buffer to thaw and
equilibrate to room temperature at this time as well.
2. Add 11 mL of Assay Buffer to a vial of Substrate Mix. Mix with the pipette-aid to
fully resuspend. Keep the vial closed and protected from light. It is not
recommended to reuse reagent past very short term storage contrary to the
manufacturer's protocol.
3. Run a no treatment control and a max release control (add 1% NP-40 lysis buffer to
untreated cells) along with the samples. Media only blanks should also be used.
4. Remove 50 uL of the media in triplicate from each well and place in the appropriate
wells of a new 96 well plate.
5. Add 50 uL of the assay reagent prepared in step 2 to each well with a multichannel
pipette, mixing well after adding.
6. Incubate for at least 10 min at room temperature.
7. Add 25 uL of the stop solution.
8. Shake the plate (you can use the plate reader mixing function).
9. Read the fluorescence with Excitation = 560 and Emission = 590 in the plate reader.
10. Use the cells from this plate for the MTT or ATP assay in parallel with this assay.
ATP Assay:
This assay is an adaptation of the Promega CellTiter-Glo® Luminescent Cell Viability Assay.
1. Remove CellTiter-Glo* Luminescent Cell Viability Assay (Promega) buffer and
substrate bottles from the -200 C freezer to the 40 C refrigerator the day before
intended use. Purchase the buffer-substrate combo in the 10mL increments to avoid
reconstituting much more than needed at once.
2. Remove buffer and substrate from the 40 C refrigerator - 1 hour before intended use.
3. Add buffer to substrate -30 minutes prior to intended use. If the buffer is still not
thawed, slightly warmed water may be used to heat up the buffer solution.
4. Shake gently to reconstitute the substrate.
5. Remove tissue culture plate from incubator and allow it to equilibrate to room
temperature (- 15-20 minutes). Already done if coupled with LDH assay.
6. Remove media from the wells. Media can be used for the LDH assay.
7. For a 24-well plate with a nominal seeding density of 50,000 cells/cm2 , add 100 uL
of the reconstituted reagent to each well.
8. Shake gently for 15 seconds.
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9. Cover the plate with foil and place on a shaker.
10. Pipette 90 uL of media into a few wells in a white 96-well luminescence plate (no cell
control).
11. 30 minutes after adding the reagent to the plate, remove from the shaker.
12. Mix plate gently and pipette 90 uL from each well into a well in the white 96-well
luminescence plate.
13. Read luminescence.
Note: Reconstituted substrate should be stored at -200C if you do not plan on using it soon
(~a few days). Otherwise, store it at 40 C. Although the Promega tech bulletin for this assay
reports a substantial loss of activity if stored at 40C, using the amount given in the above
protocol will give you a great excess of the luciferin substrate and luciferase enzyme for the
luminescence reaction. Therefore, the reconstituted reagent can be stored at 40 C with
minimal loss in luminescence production in the collagen gel plates. This keeps day to day
readings more consistent in the short term.
MTT Assay:
This assay is adapted from the Promega CellTiter® Non-Radioactive Cell Proliferation Assay
for use in 24 well plate cultures.
1. Add 150 uL of the Promega Dye Solution to the media of each sample well.
2. Return the plate to the incubator and allow it to develop for 4 hours.
3. After 4 hours, add 1 mL of Solubilization/Stop Solution to each well.
4. Place the plates in a sealed plastic box with a wet Kimwipe to keep the box
humidified. Incubate overnight at 370 C to break up the formazan crystals.
5. The following day, mix the contents of each well with a pipette such that well
contents are completely homogeneous.
6. Transfer triplicate volumes (anywhere between 100 and 300 uL as long as you are
consistent) of the dissolved lysate to a 96 well plate, and read absorbance at 570 nm
in the plate reader.
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Appendix 15 - Matlab, Teranode, and Jacobian Models and Code
Matlab Code for Model Extensions
%Nathan Tedford
%Code to run the vector specific models
%Nov. 2006
time= [0:120]; %time vector in minutes
%time=[10 20 40 60 120];
ICPolymer=[5e5 0 0 0 0 0 0 00 0 00 0 0];
ICAd5=[20 0 00 0  0  0 0 0 0 0 0 0 0];
[t,y]=odel 5s(@C32_model,time,IC_Polymer);
plasmid_vesicularC32 = y(:,2) + y(:,3);
plasmid_cytoplasmic_C32 = y(:, 5) + y(:,6) + y(:,10) + y(:,12);
plasmid_nuclearC32 = y(:, 7) + y(:,8) + y(:,9) + y(:,13) + y(:,14) + y(:,15);
plasmidtotal_C32 = plasmid_cytoplasmic_C32 + plasmid_nuclear_C32 +
plasmidvesicular C32;
%Experimetal Data
C32Whole = 10 2.22E+04 4.70E+04 9.93E+04 2.34E+05 1.71E+05];
C32LateVes = [0 8.92E+02 1.56E+03 1.29E+03 4.37E+02 7.41E+02];
C32Cyto = [0 5.16E+03 5.18E+03 7.48E+03 7.01E+03 2.34E+03];
C32NucAssoc = [0 1.98E+04 2.24E+04 5.89E+04 1.10E+05 1.23E+05];
C32AllVes = [0 8.97E+02 1.57E+03 1.32E+03 4.45E+02 7.53E+02];
X = [0 10 20 40 60 120];
figure(1);
plot(t,plasmid_cytoplasmic_C32,'k')
hold on
plot(X,C32Cyto,'ko:')
plot(t,plasmid_vesicular_C32,'b')
plot(X,C32AllVes,'bo:)
plot(t,plasmid nuclearC32,'g')
plot(X,C32NucAssoc,'go:')
plot(t,plasmid_total_C32,'r)
plot(X,C32Whole,'ro:')
titleCInternalization, Trafficking and Nuclear Uptake Kinetics for C32')
225
xlabel(Time (min))
ylabel(Normalized Plasmid Number per Cell')
legend('Cytoplasmic','Vesicular','Nuclear-associated','Total Cellular')
%Now for the Ad5 Specific Model
[t,y] =ode15s(@Ad5_model,time,IC_Ad5);
plasmidvesicular_Ad5 = y(:, 2) + y(:,3);
plasmid_cytoplasmicAd5 = y(:,5) + y(:, 6) + y(:,10) + y(:,12);
plasmidnuclear_Ad5 = y(:, 7) + y(:,8) + y(:,9) + y(:,13) + y(:,1 4) + y(:,15);
plasmidtotal_Ad5 = plasmid_cytoplasmic_Ad5 + plasmid_nuclear_Ad5 +
plasmid vesicular_Ad5;
figure(2);
plot(t,plasmid_cytoplasmic_Ad5,'k')
hold on
plot(t,plasmid vesicular Ad5,'b')
plot(t,plasmid nuclearAd5,'g')
plot(t,plasmid_total_Ad5,'r')
title(Internalization, Trafficking and Nuclear Uptake Kinetics for Ad5')
xlabel(Time (min)')
ylabel(Normalized Plasmid Number per Cell')
legend(Cytoplasmic','Vesicular','Nuclear-associated','Total Cellular)
%Now for the X-link Specific Model
[t,y] =ode 15s(@Ad5_model,time,IC_Polymer);
plasmid_vesicular_Xlink = y(:, 2) + y(:,3);
plasmid_cytoplasmic_Xlink = y(:, 5) + y(:, 6) + y(:,10) + y(:,12);
plasmid_nuclear_Xlink = y(:, 7) + y(:,8) + y(:,9) + y(:,1 3) + y(:,1 4 ) + y(:,15);
plasmid_total_Xlink = plasmid_cytoplasmic_Xlink + plasmid_nuclear_Xlink +
plasmid_vesicular Xlink;
figure(3);
plot(t,plasmid_cytoplasmic_Xlink,'k)
hold on
plot(t,plasmid_vesicular_Xlink,'b')
plot(t,plasmid_nuclear_Xlink,'g')
plot(t,plasmid_total_Xlink,'r')
title(Internalization, Trafficking and Nuclear Uptake Kinetics for X-link')
xlabel(Time (min))
ylabelCNormalized Plasmid Number per Cell')
legend(Cytoplasmic','Vesicular','Nuclear-associated','Total Cellular')
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%The following are the function files that the main script calls.
function dydt=C32 model(t, x)
0/oAll rate constants are in min^-1.
%Inital conditon is: VectPlas_Ext=5e5, everything else is 0;
%These are the rate constant values from the Jacobian fit:
kbinduptake= 1.99e-2; %fit.
k_traffic= 1.07e2; %fit.
k_degvesicle=9.53e-1; %fit.
k_escape=9.51e-1; %fit.
kunpack=2.79e-1; %fit.
k_deg=5e-3;
k_bind_vector=2.99e-1; %fit.
k_bind_plasmid=2e-3;
k_NPC=le3;
k_in=3e-3;
k_dissociation= l e3; %/oWritten as k_dis in schematic so it would fit in there.
k_protein=l e2;
%Relevant species to put into the ODE function.
VectPlas_Ext=x(1);
VectPlas_Int=x(2);
VectPlas_LateVes=x(3);
X_PLas_Ves=x(4);
VectPlas_Cyt=x(5);
VectPlasBound_Cyt=x(6);
VectPlasBound_NPC=x(7);
VectPlasBound_Nuc=x(8);
VectPlas_Nuc=x(9);
Plas_Cyt=x(10);
Vect_Cyt=x(1 1);
PlasBound_Cyt=x(12);
PlasBound_NPC=x(13);
PlasBound_Nuc=x(14);
Plas_Nuc=x(15);
XPlasCyt=x(1 6);
Protein=x(l 7);
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oModel Equations
dydt(1,:)=-k bind_uptake*x(1); %VectPlas_Ext
dydt(2,:)=k_bind_uptake*x(1)-k_traffic*x(2); %VectPlas_Int
dydt(3,:)= k_traffic*x(2)-k_deg_vesicle*x(3)-kescape*x(3); %VectPlas_LateVes
dydt(4,:)=k_deg_vesicle*x(3); %X_PlasVes
dydt(5,:)= k_escape*x(3)-kbind vector*x(5)-k_unpack*x(5); %VectPLas_Cyt
dydt(6,:)= k_bind_vector*x(5)-kNPC*x(6); %VectPlasBound_Cyt
dydt(7,:)=k_NPC*x(6)-k_in*x(7); %VectPlasBound_NPC
dydt(8,:) =k_in*x(7)-k_dissociation*x(8); %VectPlasBound_Nuc
dydt(9,:) =k _dissociation*x(8)-k_unpack*x(9); %VectPlas_Nuc
dydt(10,:)= k_unpack*x(5)-k_deg*x(10)-k_bind_plasmid*x(10); %Plas_Cyt
dydt(l 1,:)=k_unpack*x(5); %VectCyt
dydt(12,:)= kbind_plasmid*x(10)-k NPC*x(12); %PlasBound_Cyt
dydt(13,:) =k_NPC*x(12)-k_in*x(13); %PlasBound_NPC
dydt(14,:) = k_in*x(13)-k_dissociation*x(14); %PlasBound_Nuc
dydt(15,:)= k_unpack*x(9)+k_dissociation*x(14); %Plas_Nuc
dydt(16,:)= k_deg*x(1 0); %X_Plas_Cyt
dydt(17,:) lk_protein*x(15); %Protein
%The Ad5 and Xlink Model Functions have the same variable assignments and model
equations, they just use different parameters, which are listed below for brevity.
function dydt=Ad5_model(t, x)
%All rate constants are in min^-1.
%Inital conditon is: VectPlas_Ext=20, everything else is 0;
%These are the rate constant values from the Jacobian fit:
k_bind_uptake=1.17e-2; %fit.
k_traffic= 1.17el; %fit.
k_deg_vesicle=3.84e-1; %fit.
kescape= 1.15; %fit.
k_unpack=3.48e-1; %fit.
k_deg=5e-3;
k_bind_vector=3.98e-1; %fit.
k_bind_plasmid=2e-3;
k_NPC= le3;
k_in=3e-3;
k_dissociation=le3; %Written as k_dis in schematic so it would fit in there.
kprotein= 1e2;
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function dydt=Xlinkmodel(t, x)
/oAll rate constants are in minA -1.
%Inital conditon is: VectPlas_Ext=20, everything else is 0;
%/These are the rate constant values from the Jacobian fit:
kbind_uptake=5.14e-3; %fit.
k_traffic=9.5el; %fit.
k_deg_vesicle=9.99e-1; %fit.
k_escape=9.50; %fit.
k_unpack=9.89e-1; %fit.
k_deg=5e-3;
k_bind_vector=9.46e-1; %fit.
k_bind_plasmid=2e-3;
k_NPC= le3;
k_in=3e-3;
k_dissociation= le3; %Written as k_dis in schematic so it would fit in there.
k_protein= le2;
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Graphical Model Structure Built in Teranode and Imported into Jacobian in SBML
V4*- L
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Jacobian Code: Parameter Fitting, Simulations, Sensitivity Analysis and Multi-Start
# JACOBIAN input file created from SBML file: "NatesModel 4.xml"#
#######################################################################
##############
DECLARE
TYPE
JAC_Default_Type = 0.0 : -1.0e20 : 1.0e20 unit = "none"
ENUMERATION
cellVARS IS {PlasBound Cyt, PlasBound NPC,
PlasBound_Nuc, Plas_Cyt, Plas_Nuc, Protein, ProteinSynthesis,
Rxnl0_Flux, Rxnll_Flux, Rxnl2_Flux, Rxnl3_Flux, Rxnl4_Flux, Rxnl5 Flux,
Rxnl_Flux, Rxn2_Flux, Rxn3_Flux, Rxn4_Flux, Rxn5 Flux, Rxn6 Flux,
Rxn7_Flux, Rxn8_Flux, Rxn9_Flux, Rxn_Flux, VectPlasBound_Cyt,
VectPlasBound_NPC, VectPlasBound_Nuc, VectPlas_Cyt, VectPlas Ext,
VectPlas_Int, VectPlas_LateVes, VectPlas_Nuc, Vect_Cyt, X PlasVes,
XPlasCyt }
cell_PARAM IS {Volume}
main_VARS IS {report_Cytosol, report CytosolX,
report_EarlyVesicles, report_LateVesicles, report_LateVesiclesX,
report_Nuclear, report_PNS, report_PNSX1, report_PNSX2, report_PNSX3,
report_Protein, reportTOTAL, report_TotalVesicles,
report_TotalVesiclesX, report_WholeCell, report_WholeCellXl,
report WholeCellX2, report_WholeCellX3}
main_PARAM IS (Pk NPC, P k bindplasmid,
P k bind_uptake, P k bind_vector, P k deg, P k_degvesicle,
P k dissociation, P_k_escape, P k in, P_kprotein, P k traffic,
P k_unpack, PlasBound_Cyt_cell_0, PlasBound NPC cell 0,
PlasBound_Nuc_cell_0, Plas_Cyt_cell_0, Plas_Nuc_cell_0, Protein_cell_0,
VectPlasBoundCyt_cell_0, VectPlasBound NPC cell 0,
VectPlasBound Nuc_cell_0, VectPlas Cyt_cell_0, VectPlas Ext cell 0,
VectPlas_Int_cell_0, VectPlas LateVes cell 0, VectPlas Nuc cell 0,
Vect_Cyt_cell_0, Volume, X_PlasVes_cell_0, X_Plas_Cytcell 0}TopPARAM IS {Volume}
END
#######################################################################
EXTERNAL PARAM_ASSIGN(STATUS,DEPENDENT,CONSTANT INTEGER,CONSTANT
INTEGER, CHARACTER)
OPTIONS
LIB_NAME := "ParameterAssign"
LIB_PATH := "C:\Program Files\Jacobian\Lib" ;
LANGUAGE := "C" ;
BLACK BOX := TRUE
END
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########################################################## ###########
MODEL cell
PARAMETER
P AS ARRAY(cell PARAM) OF REAL DEFAULT 0
L AS ARRAY(cell PARAM) OF REAL DEFAULT 0
U AS ARRAY(cell PARAM) OF REAL DEFAULT le8
PName AS ARRAY(cell_PARAM) OF STRING DEFAULT
XName AS ARRAY(cell VARS) OF STRING DEFAULT
UNIT
# empty UNIT section
VARIABLE
X AS ARRAY(cell_VARS) OF JACDefault_Type
SET
XName (PlasBoundCyt)
XName (PlasBound NPC)
XName (PlasBoundNuc)
XName (Plas_Cyt )
XName(Plas Nuc)
XName (Protein)
XName (ProteinSynthesis)
XName(RxnlO Flux)
XName (Rxnll Flux)
XName (Rxnl2_ Flux)
XName(Rxnl3_Flux)
XName(Rxnl4 Flux)
XName (Rxnl5_Flux)
XName(RxnlFlux)
XName(Rxn2 Flux)
XName(Rxn3_Flux)
XName(Rxn4 Flux)
XName(Rxn5 Flux)
XName(Rxn6_ Flux)
XName(Rxn7_Flux)
XName(Rxn8 Flux)
XName(Rxn9 Flux)
XName (Rxn Flux)
XName (VectPlasBound_Cyt )
XName (VectPlasBound_NPC)
XName (VectPlasBound_Nuc )
XName (VectPlas_Cyt)
XName (VectPlas Ext)
XName (VectPlas Int)
XName (VectPlas LateVes)
XName (VectPlas Nuc)
XName (Vect_Cyt)
XName(XPlasVes)
XName (X_Plas_Cyt)
# 34 variables
PName (Volume)
P(Volume)
L(Volume)
U(Volume)
EQUATION
# empt.y EQUATION section
END
"P iasBoend Cyti ;
1Rxn0 FBcux ;
"Rxnials3 NPFu ' ;
" .P.s'xn. iu x
"Rxni Flux',
"Rxn6 Flux "X
"Rxnil lx ;
"Vcr t P LuP '..1
"Veotla yth" ; ;
"VecLPl Fl xt" ;
"Vecxnt Fluxa ;
"R.cr!].tl Flavux'";
"V t .: . U " ;
"X •Plas~'s ;
"X . Plas C.t" ;
"R~i6 a >:
1 ;
1 ;
1 ;
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MODEL main
PARAMETER
P AS ARRAY(main PARAM) OF REAL DEFAULT 0
L AS ARRAY(mainPARAM) OF REAL DEFAULT 0
U AS ARRAY(main PARAM) OF REAL DEFAULT le8
PName AS ARRAY(main_PARAM) OF STRING DEFAULT ""
XName AS ARRAY(main_VARS) OF STRING DEFAULT ..
UNIT
cell AS cell
VARIABLE
X AS ARRAY(main_VARS) OF JAC_Default_Type
SET
XName (report_Cytosol)
XName (report_CytosolX)
XName (report EarlyVesicles)
XName (report LateVesicles)
XName (report LateVesiclesX)
XName (reportNuclear)
XName (reportPNS)
XName (reportPNSX1)
XName (reportPNSX2)
XName (report PNSX3)
XName (reportProtein)
XName (reportTOTAL)
XName (report TotalVesicles)
XName (report TotalVesiclesX)
XName (report WholeCell)
XName (report WholeCellXl)
XName (reportWholeCellX2)
XName (reportWholeCellX3)
# 18 variables
PName(P k NPC)
PName (P k bind_plasmid)
PName(P k bind uptake)
PName(P k bind vector)
PName (Pk deg)
PName(P k deg_vesicle)
PName(P k dissociation)
PName(P_k_escape)
PName(P k in)
PName (P_k_protein)
PName(P k traffic)
PName (P kunpack)
PName (PlasBound_Cyt _cell _0 )
PName(PlasBound NPC cell 0)
PName(PlasBound Nuc cell 0)
PName(Plas_Cyt_cell_0)
PName(Plas Nuc cell 0)
PName(Protein cell_0)
PName (VectPlasBound_Cyt_cell _0)
PName(VectPlasBound NPC cell 0)
PName(VectPlasBound Nuc cell 0)
PName (VectPlas_Cyt_cell_0)
PName(VectPlas Ext cell 0)
"report Cytosol" ;
"report CytosoiX" ;
"report._Ea rlyVesicles" ;
"report LateVesicl.es" ;
"report LateVesiclesX" ;
"report N-icl ear" ;
"report PNS" ;
"repo.r PNSX1" ;
"report PNSX2" ;
"report _PNSX3" ;
"report Protein" ;
"report TOTAL" ;
"report TotalVesicles" ;
"report TotalvesiclesX"
"report WholeCell" -
"report WholeCel.iXI" ;
"report IWholeCe 1X2 "
"report WholeCellX3" ;
"P k NPC" ;
"P k bind plasmid" ;
"P•k bind uptake" ;
"P k bind vector" ;
"P k_deg" ;
"P k _deg_vesicle" ;
"P k dissociation"
"P_ k__escape";
"P k .in" ;
"P kprotein"
"P k traffic" ;
"P k unpack" ;
"PlasBoundCyt 2cell." ;O
"PlasBound NPC cell "
"PlasBound Nuc cell 0" ;
"Pl.as Cyt cell 0" ;
"Plas Nuc cell. 0" ;
"Protein cell 0" ;
"VectPlasBoundCytce l_0" ;
"VectPliasBound NPC cell 0" ;
"VectPl.asBound Nuc cell 0" ;
"Vect Plas_ Cyte: 0"
"Vect;Plas Ext cell 0" ;
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PName(VectPlas Int cell 0)
PName(VectPlas LateVes cell 0)
PName(VectPlas Nuc cell 0)
PName(Vect_Cyt_cell_0)
PName(Volume)
PName(X PlasVes cell 0)
PName(X Plas Cyt cell 0)
P(P k NPC)
P(P k bindplasmid)
P(P k bind uptake)
P(P k bind vector)
P(P k deg)
P(P_k_deg vesicle)
P(P k dissociation)
P(P k escape)
P(P k in)
P(P_k_protein)
P(P k traffic)
P(P k unpack)
P(Volume)
L(P k NPC)
L(P k bind_plasmid)
L(P k bind uptake)
L(P k bind vector)
L(P k deg)
L(P k deg vesicle)
L(P k dissociation)
L(P k escape)
L(P k in)
L(P k_protein)
L(P k traffic)
L(P k unpack)
L(Volume)
U(P k NPC)
U(P k bind_plasmid)
U(P k binduptake)
U(P k bind vector)
U(P kdeg)
U(P k_degvesicle)
U(P k dissociation)
U(P k escape)
U(P k in)
U(P k protein)
U(P k traffic)
U(P k unpack)
U(Volume)
1000
0.002
0.077
le-5
0.005
le-4 ;
1000
le-4 ;
0.003
0.01 ;
le-4 ;
le-4 ;
1 ;
1000
0.002
0.077
lel ;
0.005
le0 ;
1000 ;
1e2 ;
0.003
0.01 ;
1e3
le0 ;
1 ;
le-2;
j• r ¢?
rr
* le2 ;
f# to be fitt edS:::o be fit:te
EQUATION
END
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1000
0.002 ;
0.077
0.07 ;
0.005
le-2
1000
0.05
0.003
0.01
0.05
0.03
1 ;
;zei.!
0" I
I~ Oil
CS
MODEL Top
PARAMETER
UNIT
main AS main
VARIABLE
SET
# 0 variables
# Zero initial conditions:
main. P(PlasBound_Cyt_cell _0)
main.P(PlasBound NPC cell 0)
main.P(PlasBound Nuc cell 0)
main.P(Plas_Cyt_cell 0)
main.P(Plas Nuc cell 0)
main.P(Protein cell 0)
main.P(VectPlasBound_Cyt_cell_0)
main.P(VectPlasBound NPC cell 0)
main.P(VectPlasBound Nuc cell 0)
main.P(VectPlas_Cyt cell_0)
main.P(VectPlas Int cell 0)
main.P(VectPlas LateVes cell 0)
main.P(VectPlas Nuc cell 0)
main.P(Vect_Cyt_cell 0)
main.P(X PlasVes cell 0)
main.P(X_Plas_Cyt_cell_0)
# Non-zero initial conditions:
main.P(VectPlas Ext cell 0)
# Initial condition LOWER bounds .
# Zero initial conditions:
main.L(PlasBound Cyt_cell _0)
main.L(PlasBound NPC cell 0)
main.L(PlasBound Nuc cell 0)
main.L (Plas_Cyt cell 0)
main.L(Plas Nuc cell 0)
main.L(Protein cell 0)
main.L(VectPlasBound_Cyt_cell_0)
main.L(VectPlasBound NPC cell 0)
main.L(VectPlasBound Nuc cell 0)
main.L(VectPlas_Cyt cell_0)
main.L(VectPlas Int cell_0)
main.L(VectPlas LateVes cell 0)
main.L(VectPlas Nuc cell 0)
main.L(Vect_Cyt cell 0)
main.L(X PlasVes cell_0)
main.L(X_PlasCyt_cell_0)
# Non-zero initial conditions:
main.L(VectPlas Ext cell 0)
Initial condition UPPER bounds
Zero in7itial conditions:
main.U(PlasBound_Cyt_cell_0) := 0 ;
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:= 500000 ;
:= 20;
main.U(PlasBound NPC cell 0)
main.U(PlasBound Nuc cell 0)
main.U(Plas_Cyt cell_0)
main.U(Plas Nuc cell 0)
main.U(Protein cell 0)
main.U(VectPlasBound Cyt cell _0)
main.U(VectPlasBound NPC cell 0)
main.U(VectPlasBound Nuc cell 0)
main.U(VectPlas_Cyt cell 0)
main.U(VectPlas Int cell 0)
main.U(VectPlas LateVes cell 0)
main.U(VectPlas Nuc cell 0)
main.U(VectCyt cell_0)
main.U(X PlasVes cell 0)
main.U(X_Plas_Cytcell_0)
main.U(VectPlas Extcell_0) := 20;
INTERMEDIATE
Rxn3 Kf := main.P(P k escape)
Rxn2 Kf := main.P(P k deg-vesicle)
Rxn4 Kf := main.P(P k bind vector)
Rxn Kf := main.P(P k binduptake)
Rxn8 Kf := main.P(P k dissociation)
RxnlO0 Kf := main.P(P k dissociation)
Rxnl Kf := main.P(P k traffic)
Rxn5 Kf := main.P(P_k unpack)
Rxnl2 Kf := main.P(P k bind_plasmid)
Rxnll Kf := main.P(P k deg)
Rxnl5 Kf
main.P(P k-protein)*main.cell.X(Plas_Nuc)
Rxn9 Kf := main.P(P_ kunpack)
Rxnl3 Kf := main.P(P k NPC)
Rxn7 Kf := main.P(P k in) ;
Rxnl4 Kf := main.P(P k in) ;
Rxn6 Kf := main.P(P k NPC)
EQUATION
# Fp ux Evua;ios:
main.cell.X(Rxn2 Flux)
Rxn2 Kf*main.cell.X(VectPlas LateVes)*main.cell.P(Volume)
main.cell.X(Rxn4 Flux)
Rxn4 Kf*main.cell.X(VectPlas Cyt)*main.cell.P(Volume) ;
main.cell.X(Rxn3 Flux)
Rxn3 Kf*main.cell.X(VectPlas LateVes)*main.cell.P(Volume)
main.cell.X(Rxnl Flux)
Rxnl Kf*main.cell.X(VectPlas Int)*main.cell.P(Volume)
main.cell.X(Rxn8 Flux)
Rxn8 Kf*main.cell.X(VectPlasBound Nuc)*main.cell.P(Volume) ;
main.cell.X(Rxnll Flux)
Rxnll Kf*main.cell.X(Plas_Cyt)*main.cell.P(Volume)
main.cell.X(Rxnl0 Flux)
Rxnl0 Kf*main.cell.X(PlasBound Nuc)*main.cell.P(Volume)
main.cell.X(Rxnl2 Flux)
Rxnl2 Kf*main.cell.X(Plas Cyt)*main.cell.P(Volume)
main.cell.X(Rxn Flux)
Rxn Kf*main.cell.X(VectPlas Ext)*main.cell.P(Volume)
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main.cell.X(Rxn5 Flux)
Rxn5_Kf*main.cell.X(VectPlas_Cyt) *main.cell.P(Volume) ;
main.cell.X(Rxnl5 Flux) = Rxnl5 Kf*main.cell.P(Volume)
main.cell.X(Rxnl4 Flux)
Rxnl4_Kf*main.cell.X(PlasBoundNPC) *main.cell.P (Volume) ;
main.cell.X(Rxn7 Flux)
Rxn7_Kf*main.cell.X(VectPlasBoundNPC) *main.cell.P(Volume) ;
main.cell.X(Rxn9 Flux)
Rxn9_Kf*main.cell.X(VectPlas_Nuc) *main.cell.P(Volume) ;
main.cell.X(Rxn6 Flux)
Rxn6_Kf*main.cell.X(VectPlasBoundCyt) *main. cell. P(Volume) ;
main.cell.X(Rxnl3 Flux)
Rxnl3 Kf*main.cell.X(PlasBoundCyt) *main. cell. P(Volume)
# Algebraic Equations:
main.X(report_EarlyVesicles) = main.cell.X(VectPlas_Int) ;
main.X(report_CytosolX)
main.cell.X(VectPlas_Cyt)+main.cell.X(PlasCyt)+main.cell. X (VectPlasBou
nd_Cyt)+main.cell.X(PlasBound Cyt)+main.cell.X(XPlasCyt)
main. X(report_Nuclear)
main.cell.X(VectPlasBound NPC)+main.cell.X(VectPlasBound Nuc)+main.cell
.X(VectPlas Nuc)+main.cell.X(PlasBoundNPC)+main.cell.X(PlasBoundNuc)+
main.cell.X(Plas Nuc) ;
main.X(report_Protein) = main.cell.X(Protein) ;
main.X(report_LateVesiclesX)
main.cell.X(VectPlas LateVes)+main.cell.X(X PlasVes) ;
main.X(report_WholeCellX3) =
main.X(report_CytosolX)+main.X(report Nuclear)+main.X(report_EarlyVesic
les)+main.X(report_LateVesiclesX) ;
main.X(report_TotalVesiclesX)
main.X(report_EarlyVesicles)+main.X(report_LateVesiclesX) ;
main. X (report_Cytosol)
main.cell.X(VectPlas_Cyt)+main.cell.X(PlasCyt)+main.cell. X (VectPlasBou
ndCyt)+main.cell.X(PlasBound Cyt) ;
main.X(reportLateVesicles) = main.cell.X(VectPlas_LateVes)
main.X(report_PNSX3)
main.X(reportEarlyVesicles)+main.X(report_LateVesiclesX)+main.X(report
_CytosolX) ;
main.X(report_WholeCellX2)
main.X(report_Cytosol)+main.X(report_Nuclear)+main.X(report_EarlyVesic1
es)+main.X(report_LateVesiclesX) ;
main.X(report_TOTAL) = main.X (reportWholeCellX3) ;
main.X(report_PNS)
main.X(reportEarlyVesicles)+main.X(reportLateVesicles)+main.X(report_
Cytosol) ;
main.X(report PNSX2)
main.X(report_EarlyVesicles)+main.X(report_LateVesiclesX)+main.X(report
_Cytosol) ;
main.X(report_PNSX1)
main.X(report_EarlyVesicles)+main.X(report_LateVesicles)+main.X(report
CytosolX) ;
main.X(report_WholeCell) =
main.X(report_Cytosol)+main.X(report_Nuclear)+main.X(report_EarlyVesicl
es)+main.X(report_LateVesicles) ;
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main.X(report WholeCellX1)
main.X(report CytosolX)+main.X(report_Nuclear)+main. X (reportEarlyVesic
les)+main.X(report_LateVesicles)
main.X (report_TotalVesicles)
main.X(report_EarlyVesicles) +main.X(report_LateVesicles)
main.cell.X(ProteinSynthesis) = 1
main.cell.$X(VectPlas Int)*main.cell.P(Volume) = +
(main.cell.X(Rxn Flux)) - (main.cell.X(Rxnl Flux));
main.cell. $X(VectPlas LateVes)*main.cell. P(Volume) = +
(main.cell.X(Rxnl Flux)) - (main.cell.X(Rxn2 Flux))
(main.cell.X(Rxn3 Flux));
main.cell.$X(X PlasVes)*main.cell.P(Volume) = +
(main.cell.X(Rxn2 Flux));
main.cell. $X(VectPlas Cyt)*main.cell.P(Volume) = +
(main.cell.X(Rxn3 Flux)) - (main.cell.X(Rxn4 Flux)) -
(main.cell.X(Rxn5 Flux));
main.cell.$X(VectPlasBoundCyt)*main.cell.P(Volume) = +
(main.cell.X(Rxn4 Flux)) - (main.cell.X(Rxn6 Flux));
m - .yt)*m$X(PlasCyt)*main.cell.P(Volume) = +
(main.cell.X(Rxn5 Flux)) - (main.cell.X(Rxnll Flux))
(main.cell.X(Rxnl2 Flux));
main.cell.$X(Vect_Cyt)*main.cell.P(Volume) = +
(main.cell.X(Rxn5 Flux));
main.cell.$X(PlasBound Cyt)*main.cell.P(Volume) = +
(main.cell.X(Rxnl2 Flux)) - (main.cell.X(Rxnl3 Flux));
main.cell.$X(X Plas Cyt)*main.cell.P(Volume) = +
(main.cell.X(Rxnll Flux));
main.cell.$X(Protein)*main.cell.P(Volume) = +
(main.cell.X(Rxnl5 Flux));
main.cell.$X(VectPlasBound NPC)*main.cell.P(Volume)
(main.cell.X(Rxn7 Flux)) + (main.cell.X(Rxn6 Flux));
main.cell.$X(VectPlasBound Nuc)*main.cell.P(Volume) = +
(main.cell.X(Rxn7 Flux)) - (main.cell.X(Rxn8 Flux));
main.cell.$X(VectPlas Nuc)*main.cell.P(Volume) = +
(main.cell.X(Rxn8 Flux)) - (main.cell.X(Rxn9 Flux));
main.cell.$X(PlasBound NPC)*main.cell.P(Volume)
(main.cell.X(Rxnl4 Flux)) + (main.cell.X(Rxnl3 Flux));
main.cell.$X(PlasBound Nuc)*main.cell.P(Volume)
(main.cell.X(Rxnl0 Flux)) + (main.cell.X(Rxnl4 Flux));
main.cell.$X(Plas Nuc)*main.cell.P(Volume) = +
(main.cell.X(Rxn9 Flux)) + (main.cell.X(Rxnl0 Flux));
main.cell.$X(VectPlas Ext)*main.cell.P(Volume)
(main.cell.X(Rxn Flux));
END
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SIMULATION Sim
OPTIONS
INITRELATIVETOLERANCE := 1.0e-12 ; # Tolerances may need to be
adjusted .-. as high as le-8, le-8, le-4, le-8
INIT ABSOLUTE TOLERANCE := 1.0e-12 ;
DYNAMIC RELATIVETOLERANCE := 1.0e-7
DYNAMIC ABSOLUTE TOLERANCE := 1.0e-12 ;
DYNAMIC REPORTINGINTERVAL := 1
NORMALIZED SENS := TRUE
COMPUTEMETRICS := TRUE ; # compute integrals and
such
CSVOUTPUT := TRUE ; # write output files in csv
format
DYNAMIC_PRINT_LEVEL := 0 ; # suppress screen output
DYNAMIC_MAXIMUMSTEPS := 50000 ; # limit max steps
PARAMETER
SimulationTime AS REAL DEFAULT 120
UNIT
Top AS Top
REPORT
Top.main.X(report_Cytosol)
Top.main.X(report_CytosolX)
Top.main.X(report EarlyVesicles)
Top.main.X(report LateVesicles)
Top.main.X(report LateVesiclesX)
Top.main.X(report Nuclear)
Top.main.X(report_PNS)
Top.main.X(report_PNSX1)
Top.main.X(report_PNSX2)
Top.main.X(report_PNSX3)
Top.main.X(reportProtein)
Top.main.X(report_TOTAL)
Top.main.X (report TotalVesicles)
Top.main.X (report TotalVesiclesX)
Top.main.X(report WholeCell)
Top.main.X(reportWholeCellX1)
Top.main.X(report WholeCellX2)
Top.main.X(report WholeCellX3)
SENSITIVITY
## initial conditions (only non-zero initial conditions are listed):
(uncomment desired lines to activate)
# Top.main. P(Ve ctPlas Ext cell 0)
## parameters: (uncomment desired lines to activate)
# Top.main.P(P k NPC)
# Top. main.P(P k bind plasrmid)
# Top.main.P(P k bind uptake)
# Top.main.P(P k bind vector,)
# Top.main.P(P k deg)
# Top.main.P(P k degvesicle)
# Top.main.P(P k dissociation)
# Top. main. P (P k escape)
# Top.main.P(P k in)
# Top.mai n.P(P k protein)
# Top.main. P(P k traffic)
# Top. ma in.PP k unpack)
SET
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EQUATION
# empty equat.ion section
INPUT
# empty input section
PRESET
# empty preset section
SELECTOR
# empty selector sect ion
INITIAL
Top.main.cell.X(PlasBound_Cyt)
Top.main.P(PlasBound_Cyt_cell_0) ;
Top.main.cell.X(PlasBoundNPC)
Top.main.P(PlasBoundNPC_cell 0) ;
Top.main.cell.X(PlasBoundNuc)
Top.main.P(PlasBoundNuc_cell_0)
Top.main.cell.X(Plas_Cyt)
Top.main.P(Plas_Cyt_cell_0) ;
Top.main.cell.X(Plas_Nuc)
Top.main.P(Plas Nuc_cell_0)
Top.main.cell.X(Protein)
Top.main.P(Protein cell_0) ;
Top.main.cell.X(VectPlasBoundCyt)
Top.main.P(VectPlasBound_Cyt_cell_0) ;
Top.main.cell.X(VectPlasBound_NPC)
Top.main.P(VectPlasBound_NPC cell_0) ;
Top.main.cell.X(VectPlasBound_Nuc)
Top.main.P(VectPlasBound_Nuc_cell_0) ;
Top.main.cell.X(VectPlasCyt)
Top.main.P(VectPlasCyt_cell_0) ;
Top.main.cell.X(VectPlas Ext) = 20;
#Top.nmain. P(VectPlas Ext cell );
Top.main.cell.X(VectPlas_Int)
Top.main.P(VectPlas_Int_cell_0) ;
Top.main.cell.X(VectPlas LateVes)
Top.main.P(VectPlasLateVes_cell_0) ;
Top.main.cell.X(VectPlasNuc)
Top.main.P(VectPlas_Nuc_cell_0)
Top.main.cell.X(Vect_Cyt)
Top.main.P(Vect_Cyt_cell_0) ;
Top.main.cell.X(X_PlasVes)
Top.main.P(X_PlasVes_cell_0) ;
Top.main.cell.X(X_Plas_Cyt)
Top.main.P(X_Plas_Cyt_cell_0)
SCHEDULE
CONTINUE FOR SimulationTime
END
###############################################t#######################
##############
############# #######,##########..########,############ #######t#
############f#
SIMULATION SimSensitivity
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OPTIONS
INIT_RELATIVE_TOLERANCE := 1.0e-12 ; # Tolerances may need to be
adjusted ... as high as le-8, le-8, le-4, le--8
INITABSOLUTE TOLERANCE := 1.0e-12
DYNAMIC RELATIVE TOLERANCE := 1.0e-7
DYNAMIC ABSOLUTE TOLERANCE := 1.0e-12
DYNAMIC REPORTING INTERVAL := 1
NORMALIZED SENS := TRUE
COMPUTE_METRICS := TRUE ; # compute integrals and
such
CSVOUTPUT := TRUE ; # write output files in csv
format
DYNAMIC_PRINT_LEVEL := 0 ; # suppress screen output
DYNAMIC_MAXIMUM_STEPS := 50000 ; # limit max steps
PARAMETER
SimulationTime AS REAL DEFAULT 120
UNIT
Top AS Top
REPORT
Top.main.X(report_Cytosol)
Top.main.X(report_CytosolX)
Top.main.X(report EarlyVesicles)
Top.main.X(report LateVesicles)
Top.main.X(report_LateVesiclesX)
Top.main.X(reportNuclear)
Top.main.X(report_PNS)
Top.main.X(report_PNSX1)
Top.main.X(report_PNSX2)
Top.main.X(report_PNSX3)
Top.main.X(report_Protein)
Top.main.X(report_TOTAL)
Top.main.X(report_TotalVesicles)
Top.main.X(report TotalVesiclesX)
Top.main.X(report_WholeCell)
Top.main.X(report WholeCellX1)
Top.main.X(reportWholeCellX2)
Top.main.X(reportWholeCellX3)
SENSITIVITY
## initial conditions (only non--zero initial conditions are listed):
(uncomment desired lines to activate)
Top.main.P(VectPlas Ext cell 0)
## parameters: (uncomment desired lines to activate)
Top.main.P(P k NPC)
Top.main.P(P k bind_plasmid)
Top.main.P(P k binduptake)
Top.main.P(P k bindvector)
Top.main.P(P k deg)
Top.main.P(P_kdeg_vesicle)
Top.main.P(P k dissociation)
Top.main.P(P k escape)
Top.main.P(P k in)
Top.main.P(P_k protein)
Top.main.P(P k traffic)
Top.main.P(P k unpack)
SET
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EQUATION
# empty equation section
INPUT
# empty input section
PRESET
# empty preset section
SELECTOR
# empt-y selector section
INITIAL
Top.main.cell.X(PlasBound Cyt)
Top.main.P(PlasBound_Cyt_cell_0) ;
Top.main.cell.X(PlasBound NPC)
Top.main.P(PlasBound NPC cell 0) ;
Top.main.cell.X(PlasBoundNuc)
Top.main.P(PlasBound_Nuc_cell_0)
Top.main.cell.X(Plas_Cyt)
Top.main.P(Plas_Cyt_cell_0) ;
Top.main.cell.X(PlasNuc)
Top.main.P(Plas Nuc_cell_0) ;
Top.main.cell.X(Protein)
Top.main.P(Protein_cell_0) ;
Top.main.cell.X(VectPlasBound_Cyt)
Top.main.P(VectPlasBound_Cyt_cell_0) ;
Top.main.cell. X (VectPlasBound NPC)
Top.main.P(VectPlasBound NPC cell 0) ;
Top.main.cell.X(VectPlasBoundNuc)
Top.main.P(VectPlasBound Nuc cell 0)
Top.main.cell.X(VectPlasCyt)
Top.main.P(VectPlas_Cyt_cell_0) ;
Top.main.cell.X(VectPlasExt) = 20;
#Top.main. P(Vect . as Ext cel 1 0)
Top.main.cell.X(VectPlasInt)
Top.main.P(VectPlas_Int_cell_0) ;
Top.main.cell.X(VectPlasLateVes) =
Top.main.P(VectPlas_LateVes_cell_0) ;
Top.main.cell.X(VectPlas Nuc)
Top.main.P(VectPlas_Nuc_cell_0) ;
Top.main.cell.X(Vect_Cyt)
Top.main.P(Vect_Cyt_cell_0) ;
Top.main.cell.X(X_PlasVes)
Top.main.P(X_PlasVes_cell_0) ;
Top.main.cell.X(X_Plas_Cyt)
Top.main.P(X_Plas_Cyt_cell_0)
SCHEDULE
CONTINUE FOR SimulationTime
END
####f###ff#####################################
##############
#################################################4
###########
ESTIMATION Est Ad5
OPTIONS
INIT RELATIVE TOLERANCE := 1.0e-8 ;
INIT ABSOLUTETOLERANCE := 1.0e-8 ;
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DYNAMICRELATIVE TOLERANCE := 1.0e-6
DYNAMIC ABSOLUTE TOLERANCE := 1.0e-8
INITPRINT LEVEL := 0 ;
DYNAMIC PRINT LEVEL := 0
ESTIMATION PRINTLEVEL := 0
ESTIMATION TOLERANCE := le-6 ;
DYNAMIC MAXIMUM STEPS := 50000
PARAMETER
path AS STRING DEFAULT "
SimulationTime AS REAL DEFAULT 120
UNIT
Top AS Top
VARIABLE
UNCERTAIN
## Parameter := [value] : [lower bound] : [upper bound] ; # (uncomment
desired lines to actitvate)
## Initial Conditions:
# Top. main. P(VectPlas Ext cell_ ) -
Top.main. P'VectPlas Ext_cell 0) - Top.main.L (VectPlas_Extcell 0)
: Top. main. U(VectPlas Ext cell. 0)
# Parameters:
# Top.main.P(P RelNucVol)
Top.main. P(P RelNucVol) : Top.main.L(P RelNucVol)
: Top.main. U(PRelNucVol ;
# Top. main.P(P k NPC)
Top.main. P(P k NPC) : Top.main.L(P k NPC)
Top. ma in. U (P k NPC)
# Top. main.P(P_k bind plasmid)
Top.main.P(P k bind plasmid) : Top.main. L(P k bindplasmid)
: Top. main. U(P_ kbindplasmid)
Top.main.P(P k bind_uptake)
Top.main.P(P k bind uptake) : Top.main.L(P k bind uptake)
: Top.main.U(P k bind uptake)
Top.main.P(P k bind vector) :=
Top.main.P(P k bindvector) : Top.main.L(P k bindvector)
: Top.main.U(P k bind vector)
# Top. main.P(P k deg)
Top.main.P(P k deg) : Top.main.L(P k deg)
Top. main.U( P .kdeg)
Top.main.P(P_ kdeg_vesicle) :=
Top.main.P(P_k_deg vesicle) : Top.main.L(Pk deg_vesicle)
: Top.main.U(P k deg_vesicle)
# Top. main. P (P k dissociat.ion)
Top..main.P(P k dissociation) : Top.main.L(P k dissociation)
: Top.main.U(P k dissociation)
Top.main.P(P_k escape) :=
Top.main.P(P k escape) : Top.main.L(P_kescape)
: Top.main.U(P_ kescape)
# Top.main.P(P k in) :
Top.main.P(P k in) : Top.main.L(P k in)
Top.main.U(P k in)
# Top. ma in. P (Pk protein)
Top.main.P(Pk protein) : Top .main.L(Pk protein)
: Top. main. U(P k_protein)
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Top.main.P(P k traffic)
Top.main.P(P_k_traffic) : Top.main.L(Pktraffic)
: Top.main.U(P k traffic)
Top.main.P(P_k unpack)
Top.main.P(P_k unpack) : Top.main.L(Pk_unpack)
: Top.main.U(P k unpack)
SET
path := "C:\Documents and Settings\Nate Tedford\Desktop\Model\";
SimulationTime := 120;
INTERMEDIATE
EQUATION
OBJECTIVE WEIGHTED LEAST SQUARES
EXPERIMENT Exptl
DATA
Top.main.X(report_Cytosol) :=
IMPORT DATA(path+"Ad5 Cybsol 2 :sv", 6)
SOr,. op ia. in.. (report Latei- c -V •e .us ce :sX
TJ PO T D' (path+ "sJ.5 s 3 .• -. ,
Top.main.X(report_Nuclear) :=
IMPORT DATA (path+" ýAd• •!5 : e•-: , 6)
Top.main.X(report_TotalVesicles)
IMPORT DATA(path+ Ad5 t. i . i es. csv " , 5)
Top.main.X(report_WholeCell)
IMPORT DATA(path+"Ad5 h• l; eCe i. c:v", 6)
INPUT
PRESET
S·-ari -abl • a!e I defaVl I U va i 4. e : 0owebo
SELECTOR
# selecto-r nae :T seectov
INITIAL
Top.main.cell.X(PlasBound_Cyt)
Top.main.P(PlasBound Cyt_cell_0) ;
Top.main.cell.X(PlasBound_NPC)
Top.main.P(PlasBoundNPCcell_0) ;
Top.main.cell.X(PlasBound_Nuc)
Top.main.P(PlasBoundNuccell 0)
Top.main.cell.X(PlasCyt)
Top.main.P(PlasCyt cell_0) ;
Top.main.cell.X(Plas_Nuc)
Top.main.P(Plas_Nuc_cell_0) ;
Top.main.cell.X(Protein)
Top.main.P(Protein_cell_0) ;
Top.main.cell.X(VectPlasBound_Cyt)
Top.main.P(VectPlasBound_Cyt_cell_0)
Top.main.cell.X(VectPlasBound_NPC)
Top.main.P(VectPlasBound_NPC_cell_0) ;
Top.main.cell.X(VectPlasBoundNuc)
Top.main.P(VectPlasBound_Nuc cell_0)
Top.main.cell.X(VectPlasCyt)
Top.main.P(VectPlas_Cyt_cell 0) ;
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Top.main.cell.X(VectPlasExt) = 20
#Top. main. P(VectPlas _Ext cell 0)
Top.main.cell.X(VectPlasInt)
Top.main.P(VectPlas Int_cell_0) ;
Top.main.cell.X(VectPlasLateVes)
Top.main.P(VectPlas LateVes_cell_0) ;
Top.main.cell.X(VectPlas_Nuc)
Top.main.P(VectPlas Nuc cell 0) ;
Top.main.cell.X(VectCyt)
Top.main.P(Vect_Cyt cell_0)
Top.main.cell.X(X PlasVes)
Top.main.P(X_PlasVes_cell_0) ;
Top.main.cell.X(X_Plas_Cyt)
Top.main.P(X_PlasCyt_cell_0)
SCHEDULE
SEQUENCE
CONTINUE FOR SimulationTime
END
END # ESTIMATION Est Ad5
#######################################
#################
######################.## ## ###########################
##############
ESTIMATION Est C32
OPTIONS
INIT RELATIVE TOLERANCE := 1.0e-6 ;
INITABSOLUTE TOLERANCE := 1.0e-6 ;
DYNAMIC RELATIVE TOLERANCE := 1.0e-6
DYNAMICABSOLUTE TOLERANCE := 1.0e-6 ;
INIT PRINT LEVEL := 0 ;
DYNAMICPRINT LEVEL := 0 ;
ESTIMATION PRINT LEVEL := 0
ESTIMATION TOLERANCE := le-6
DYNAMICMAXIMUM STEPS := 50000
PARAMETER
path AS STRING DEFAULT ".
SimulationTime AS REAL DEFAULT 120
UNIT
Top AS Top
VARIABLE
UNCERTAIN
## Parameter := [value] : [lower bound] : [upper bound] ; # (uncomment
desired lines to activate)
## Initial Condit:ions:
# Top. main. P(VectPlas Ext cell 0)
Top. main. P(VectPlas Ext cell_0) : Top. main. L(VectPlas Ext cell 0)
: Top.main. U(VectPlas Ext cell 0)
# Parameters:
# Top. main.P(P RelNucVol)
Top.,main.P(P_RelNucVol) : Top.main.L (P RelNucVol)
: Top.main.U(P RelNucVol);
# Top.main. P(P k NPC)
Top.main. P(P k NPC) : Top.main.L(P k NPC)
Top. main.U(P k NPC)
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# TIop. main. P (P U ind p I J lsml d.
Top.ma-na.P( .,F k bind plasmni d) : Top.m!nai•n .L,(P k bind p'.slasmid)P ', , U -b d 7 r
o *i.main. U P  k f in ! -lasmi )
Top.main.P(P k bind_uptake)
Top.main.P(P_ kbind uptake) : Top.main.L(P k bind uptake)
: Top.main.U(P k bind uptake)
Top.main.P(P k bind vector)
Top.main.P(P_k bind_vector) : Top.main.L(P_k_bind_vector)
: Top.main.U(P_kbind_vector)
..o .. m in P(P k dleqlg
Top.,in. (P. .k deg) : 'T'o'p. m•a!.n.L P_ k_ deg;
o.m[jaiRin.U( P k d I)0 •: I I Q
Top.main.P(P_kdegvesicle)
Top.main.P(P_k_degvesicle) : Top.main.L(P k deg_vesicle)
: Top.main.U(P_ kdegvesicle)
1 o. i P (P a dissia t on)
Top.main.P(P k escape)
Top.main.P(P_k_escape) : Top.main.L(P_k_escape)
: Top.main.U(Pkescape)
j L;<.la . I? i .
bp, M71~i -, r11 "j t< ] F
Top.main.P(P k traffic)
Top.main.P(P_k traffic) : Top.main.L(Pktraffic)
Top.main.U(P k traffic)
Top.main.P(P_kunpack)
Top.main.P(P k unpack) : Top.main.L(P_k_unpack)
: Top.main.U(P_ kunpack)
SET
path := "C:\Documents and Settings\Nate Tedford\Desktop\Model\" ;
direct:oz._ containi n... :the :t fi-s
SimulationTime := 120;
INTERMEDIATE
EQUATION
OBJECTIVE WEIGHTED LEAST SQUARES
EXPERIMENT Expt_l
DATA
Top.main.X(report_Cytosol) :=
IMPORT DATA(path+"C32 C•tos... 2cs, , 6)
Sop.•main X r•epo-r La t i 4 cl esX
IMlPORT' ,;: ,c ( D, th .. 's"C32 La teVes i-les•.csv",
Top.main.X(report_Nuclear) :=
IMPORT DATA(path+'C32 1< clea.csv , 6)
Top.main.X(report_TotalVesicles) :=
IMPORT DATA(path+"C3! Total.V si--.es.cs, 5)
Top.main.X(reportWholeCell) :
IMPORT DATA(path+C3,2 iholeC .cs", 6) ;
INPUT
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PRESET
# va-~riable_ name := d• 3:1tvalue : lower bound : upper_ b.ound ;
SELECTOR
# selector n:a!-e : selector value
INITIAL
Top.main.cell. X(PlasBound Cyt)
Top.main. P(PlasBound Cyt cell 0) ;
Top. main.cell.X(PlasBound NPC)
Top.main.P(PlasBound NPC cell 0) ;
Top.main.cell.X(PlasBound Nuc)
Top.main.P(PlasBound Nuc cell 0)
Top.main.cell.X(PlasCyt)
Top.main.P(Plas_Cyt_cell 0) ;
Top.main.cell.X(Plas Nuc)
Top.main.P(PlasNuc cell_0) ;
Top.main.cell.X(Protein)
Top.main.P(Protein cell 0) ;
Top.main.cell.X(VectPlasBoundCyt)
Top.main.P(VectPlasBoundCyt_cell_0) ;
Top.main.cell.X(VectPlasBound NPC)
Top.main.P(VectPlasBound NPC cell 0) ;
Top.main.cell.X(VectPlasBound Nuc)
Top.main.P(VectPlasBound Nuc cell 0)
Top .main. cell. X(VectPlas_Cyt)
Top.main.P(VectPlas_Cyt_cell_0) ;
Top.main.cell.X(VectPlas Ext) = 5e5;
# Topma •( Ve/ F Plas . .cell. ..
Top. main.cell.X(VectPlas Int)
Top.main.P(VectPlas Int cell 0) ;
Top.main.cell.X(VectPlas LateVes)
Top.main.P(VectPlas LateVes cell 0) ;
Top.main.cell.X(VectPlas Nuc)
Top.main.P(VectPlas Nuc cell_0) ;
Top.main.cell.X(Vect_Cyt)
Top.main.P(VectCyt_cell 0) ;
Top.main.cell.X(X PlasVes)
Top.main.P(X PlasVes cell 0) ;
Top,. main. cell. X (XPlas Cyt)
Top.main.P(X_Plas_Cyt cell_0)
SCHEDULE
SEQUENCE
CONTINUE FOR SimulationTime
END
END # ES.TAION Estr C3
#t sf### # # ## A ft # #J # # #t#K# # ##f## ## # # 7114## # i
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ESTIMATION Est XPEI
OPTIONS
INIT RELATIVE TOLERANCE := 1.0e-6 ;
INITABSOLUTE TOLERANCE := 1.0e-6 ;
DYNAMICRELATIVETOLERANCE := 1.0e-6
DYNAMIC ABSOLUTETOLERANCE := 1.0e-6 ;
INIT PRINT LEVEL := 0 ;
DYNAMIC PRINTLEVEL := 0
ESTIMATION PRINT LEVEL := 0
ESTIMATION TOLERANCE := le-6
DYNAMIC MAXIMUM STEPS := 50000 ;
PARAMETER
path AS STRING DEFAULT ".
SimulationTime AS REAL DEFAULT 120
UNIT
Top AS Top
VARIABLE
UNCERTAIN
## Parameter := [value] : [lower bound] : rupper bound] ; # (uncomment
desired lines to activate)
## Initial Conditions:
S Top. main.P(VectPlas Ext cell 0) :
Top.main.P(-VectPlas_Ext cell_ ) : Top.main.L(Vec:tPlas Ext cell 0)
: Top. main.U(VectPlas Ext cell 0)
# Parameters:
# Top.main. P(P RelNucVol) :1
Top. main. P(P RelNucVol) : Top. main. L(P ReJNucVoi)
Top. main. UP Re.l ucP Vol)
# Top. ma in.P(cP Ick _NPC)
Top.main. PP k NPC) : Top.mainr.L'(P k NPC)
Top.main. U(P k NPC)
f Top. main. P P_k bind _plasmid)
Top.(main.P(P k bindplasmid) : Top.main.L(P k bind plasmid)
: Top. main. U (P. k _bindplasmid)
Top.main.P(Pk binduptake) :=
Top.main.P(P_k_bind_uptake) : Top.main.L(P k bind_uptake)
: Top.main.U(P k binduptake)
Top.main.P(Pk bindvector) :=
Top.main.P(P k bind_vector) : Top.main.L(P k bind_vector)
: Top.main.U(P k bindvector)
# Top.main. P(P k deg)
Top.main. P(P k deg) : Top.main. L (P k deg)
Top.main. U(P k deg)
Top.main.P(P_k deg_vesicle)
Top.main.P(P k_degvesicle) : Top.main.L(P_k_degvesicle)
: Top.main.U(P_k deg_vesicle)
# Top.main.P(P k dissociation)
Top. ain.,(P kdissociation) : Top.mai n. L(P kddissociaiaion)
: Top.main. U(P k dissociatnion)
Top.main.P(Pk escape) :=
Top.main.P(P k escape) : Top.main.L(P kescape)
: Top.main.U(Pk escape)
# Top.main. P(P in)
Top. main. (P k in) : Top.main.L._(P k in)
Top.main. U(P k in)
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# Toe.m-in.P(P k protein)
Top.main P(P k proteinA : To.mainL
: Top. main .. U (P ---k prot ke ein)
Top.main.P(Pk traffic)
Top.main.P(P_k_traffic) : Top.main.L(P k traffic)
: Top.main.U(P k_traffic)
Top .main. P(P k unpack)
Top.main.P(P_k_unpack) : Top.main.L(P k unpack)
: Top.main..U(P k unpack)
SET
path := "C:\Documents and Settings\Nate Tedford\Desktop\Model\"
dizrector:y c~ntaining the data files
SimulationTime := 120;
INTERMEDIATE
EQUATION
# output = data scalefactu b*[variable name]
OBJECTIVE WEIGHTED_LEAST_SQUARES
EXPERIMENT Expt 1
DATA
Top.main.X(report_Cytosol)
IMPORT_DATA(path+X'ECYt iPP _2 -`v, 6)
Top.. Ta in .X/ report L at:.Vesi cl es
IMPORT DATA a -"XPEI La ...iCles. oCAe, ;
Top.main.X(reportNuclear) : =
IMPORT_DATA (path+ "• XPE N~ l.r..C.., 6)
Top.main.X (reportTotalVesicles) :=
IMPORT_DATA(path+'"XPElTot: Vsil es.csv , 5)
Top.main.X(report WholeCell) :=
IMPORT_DATA(path+" .XPEWh.- ClWcsv , 6)
INPUT
PRESET
S<var-,able 3nam := de;ui I-value : l.ower bound : Iupeor bound
SELECTOR
INITIAL
Top.main.cell. X(PlasBound Cyt)
Top.main. P (PlasBound Cyt cell_0) ;
Top.main.cell.X(PlasBound NPC)
Top.main.P(PlasBound NPC cell 0) ;
Top.main.cell.X(PlasBound Nuc)
Top.main.P(PlasBound Nuc cell 0)
Top.main.cell.X(Plas Cyt)
Top.main.P(Plas_Cyt_cell 0) ;
Top.main.cell.X(Plas Nuc)
Top.main.P(Plas Nuc cell 0) ;
Top.main.cell.X(Protein)
Top.main.P(Protein cell 0) ;
Top.main.cell.X (VectPlasBound Cyt)
Top.main.P (VectPlasBound Cyt_cell_0)
Top.main.cell.X(VectPlasBound NPC)
Top.main.P(VectPlasBound NPC cell 0) ;
Top.main.cell.X(VectPlasBound Nuc)
Top.main.P(VectPlasBound Nuccell_0) ;
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Top.main.cell.X(VectPlas_Cyt)
Top.main.P(VectPlasCyt_cell_0)
Top.main.cell.X(VectPlas Ext) = 5e5 ;
#Top.main. P(VectPias Ext cell 0) ;
Top.main.cell.X(VectPlas Int)
Top.main.P(VectPlas_Int_cell 0) ;
Top.main.cell.X(VectPlas LateVes)
Top.main.P(VectPlas LateVes cell 0) ;
Top.main.cell.X(VectPlasNuc)
Top.main.P(VectPlas_Nuc_cell_0) ;
Top.main.cell.X(Vect Cyt)
Top.main.P(Vect_Cytcell_0) ;
Top.main.cell.X(X PlasVes)
Top.main.P(X PlasVes cell 0) ;
Top.main.cell.X(X_Plas_Cyt)
Top.main.P(X_Plas Cytcell_0)
SCHEDULE
SEQUENCE
CONTINUE FOR SimulationTime
END
END # ESTIMATTION Est XPEI
#######################################I######## ############• #####
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SCRIPT MultiStartEstimation
# tar1tin poitn ts at equaliy spaced on a log scaled between lower- and
upper bourndis.
PARAMETER
i, j, k, m, n, p, q, steps, count, nParameters AS INTEGER DEFAULT 0
EstName, OutputFileName, filepath, OutputFileID AS STRING DEFAULT
ObjectiveResult AS REAL DEFAULT 0
k_traffic_0, k_deg_vesicle_0, k_escape_0, k_unpack_0,
k bind_vector_0 AS ARRAY(steps) OF REAL DEFAULT 0
SET
EstName := "11-st- C32"; na• f EstiLma ion ro utine you want: to run
nParameters := 30;
filepath := adC Dom:e•, a:n Set tings ~ hendrbDes••.! oN"..Mo...
OutputFileName := "061e29 Mlitistarth: C32,csv"; # File with
parameter results
OutputFileID := "fid";
steps := 4; # this must equal the number of elements in the
paramet-er vector's!
RUN
INSTANTIATE EstName
FDIR filepath
FOPEN ({ID=OutputFileID,FILE=OutputFileName, ftype="o:i u )
FWRITE (ID=OutputFileID, FMT="%s")
"•ARAMIE''iH ~; S•tiSB • E C~~TIVE" " END
q := 1;
WHILE (q < nParameters) DO
FWRITE (ID=OutputFileID, FMT="%s, ") Top.main.PName(q) END
q := q+1;
END
FWRITE (ID=OutputFileID, FMT="%sn"') Top.main.PName(q) END
count := 0;
i :=1;
WHILE (i <= steps) DO
k traffic 0(i)
10 (logl0 (Top.main.L(P k traffic))+(logl0(Top.main.U (P k traffic))-
logl0(Top.main.L(P k traffic)))/(steps-1)*(i-1));
j := 1;
WHILE (j <= steps) DO
k_deg_vesicle_0(j) :=
10^ (logl0 (Top.main.L(Pk_deg_vesicle))+(loglO(Top.main.U(P k degvesicl
e))-loglO(Top.main.L(P_kdegvesicle)))/(steps-1)*(j-1));
k := 1;
WHILE (k <= steps) DO
k_escape 0(k) :=
10^ (logl0(Top.main.L(P k_escape))+(loglO(Top.main.U(Pkescape))-
loglO(Top.main.L(Pk_escape)))/(steps-l)*(k-1));
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m := 1;
WHILE (m <= steps) DO
k_unpack_0(m) :=
I0 ^ (logl 0 (Top.main.L( P k unpack))+(loglO(Top.main.U(Pkunpack))-
loglO(Top.main.L(Pkunpack)))/(steps-1)*(m-1));
n := 1;
WHILE (n <= steps) DO
k bind vector _0(n) :=
10^(logl0 (Top.main.L(P k bind_vector))+(loglO(Top.main.U(P_k bind_vecto
r))-logl0(Top.main.L(P k bindvector)))/(steps-l)*(n-l));
p := i; # addit s ct i u wan
WHILE (p <= 1) DO
W3ITE "k traf1ic
kk deg _ ves.ic.le 0 i 7 , "- k ..
ia.rnpack 0 ;m) , "; k bind ve
END
k deg vesicle = ,j
"; k u_•npack - ", k
k bind vecto• O ,)
kdeg vesicleN0(j)
FMT= •"~; %s,% n") Str(count)
pk rafi 0- 1
ape = ":, kI esca~pe 0(k)
k Jnpack - ir• • ' i:e s- • - o '
count := count+l;
WRITE "Iterati:o: , count END
Top.main.P(P k traffic) := k traffic 0(i);
Top.main.P(P k degvesicle) :=
Top.main.P(Pk escape) := k_escape_0(k);
Top.main.P(Pk unpack) := k_unpack 0(m);
Top.main.P(Pkbind vector) :=
SOLVE EstName
IF (STATUS <> ":!
WRITE 'Es iT
CCESS) THEN
FWRITE (ID=OutputFileID,
STATUS, -1 END
n := n+l;
CONTINUE
END
ObjectiveResult := GetObjective(STATUS,
EstName) ;
WRITE 'Ob-i , ObjectiveResult END
# W1rie ortoima parmeters to fiCle:
FWRITE (ID=OutputFileID, FMT=" % s , -% s
Str(count), STATUS, ObjectiveResult END
q := 1;
WHILE (q < nParameters) DO
FWRITE (ID=OutputFileID, FMT= " i
Top.main.P(q) END
q := q+l;
END
'2/,,
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FWRITE (ID=OutputFilelD, FMT= "% g ,,n ")
Top.main.P(q) END
FCLOSE (ID=OutputFileID) # close and open
ile to sae  resuls as it calcuiates
FOPEN (ID=OutputFileID,FILE=OutputFileName,
ftype= apped ; )
p := p+1;
END # WHILE p
n := n+l;
END # WHITLE n
m := m+l;
END # WFILE m
k := k+l;
END # WHILE k
j : j+1;
END # WHILE J
i := i+1;
END # WHILE i
FCLOSE (ID=OutputFileID)
WRITE "SCRIlPT? utiStasti tion C<mplete! " END
END # SCRIPT" Mu tiStarEstimatiron
##r#;######z ##;#4t#t4## ###tif#f#####4 4;4##44### 444441t44###
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SCRIPT SensitivityOutput
# This just runs the sensitivity analysis with the default parameters
in 'Sim Sensitivity"
# and outputs the integral to the screen.
PARAMETER
j, k, nParameters, nVariables AS INTEGER DEFAULT 0
timepoint AS REAL DEFAULT 0
ModelName, SimName AS STRING DEFAULT
value AS ARRAY(nVariables) OF REAL DEFAULT 0
integral AS ARRAY(nVariables, nParameters) OF REAL DEFAULT 0
SET
ModelName := "Sir Sensitivity" ;
nParameters := 30;
nVariables := 18;
timepoint := 30;
RUN
INSTANTIATE ModelName
SOLVE ModelName
IF (STATUS <> "SUCCESS") THEN WRITE "Solve failed." END END
SimName := "temp'";
MOVE ModelName TO SimName # this gets rid of all the info that is
solved for, but not reported.
k := 1;
WHILE (k <= nVariables) DO
j := 1;
WHILE (j <= nParameters) DO
integral(k,j) :=
GetlntegralAbs(STATUS,SimName,Top.main.X(k)/Top.main.P(j)) ; # I am
using this function to figure out if an ourput exists .
IF (STATUS <> '"SUCCbESS") THEN
j := j+l;
CONTINUE
END
# Putting GetFirst Value after the Getntegrais (and
contingent on its success makes sure
#:that we only track the repoit ed, va.riables an-d not ali of
them. This is a dirty trick.
IF (j = 1) THEN
value(k) := GetFirstValue(STATUS, SimName,
Top.main.X(k), TIME, timepoint);
END
j := j+l;
END # while j
k := k+l;
END # while k
# WRiITE results to screen:
WRITE "Inttegqrals of Sensit•jvitty :" END
k := 1;
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WHILE (k <= nVariables) DO
j := 1;
WHILE (j <= nParameters) DO
IF integral(k,j) <> -1 THEN
WRITE "Integral of ", Top.main.XName(k), "/",
Top.main.PName(j), " = ", integral(k,j), ":'" END
END
j := j+1;
END # while j
k := k+1;
END # while k
WRITE " " END
WRITE "Value at t = ", timepoint, ":" END
k := 1;
WHILE (k <= nVariables) DO
IF value(k) <> -1 THEN
WRITE Top.main.XName(k), " = ", value(k) END
END
k := k+1;
END # while k
WRITE "" END
END # SCRIPT Sensitivity Output
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